(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 December 2001 (13.12.2001)

PCT

(10) International Publication Number
WO 01/94627 A2

(51) International Patent Classification[7]: C12Q 1/68

(21) International Application Number: PCT/IB01/01213

(22) International Filing Date: 8 June 2001 (08.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0014009.5   8 June 2000 (08.06.2000)   GB

(71) Applicant (for all designated States except US): DEV-GEN NV [BE/BE]; Technologiepark 9, B-9052 Zwijnaarde (BE).

(72) Inventors; and
(75) Inventors/Applicants (for US only): VERWAERDE, Philippe [FR/FR]; 72, résidence Du Château D'Eau, F-59960 Neuville En Ferrain (FR). BOGAERT, Thierry [BE/BE]; Wolvendreef 26g, B-8500 Kortrijk (BE).

(74) Agents: BALDOCK, Sharon, Claire et al.; Boult Wade Tennant, Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)
— of inventorship (Rule 4.17(iv)) for US only

Published:
— without international search report and to be republished upon receipt of that report
— with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ASSAY TECHNIQUES BASED ON GROWTH STAGE DEPENDENT EXPRESSION IN C. ELEGANS

(57) Abstract: This invention is directed to new methods to perform assays with nematodes, and more particularly with microscopic nematodes such as C. elegans. In particular, the invention provides methods based on the use of growth-stage specific promoters to drive growth-stage specific gene expression.

BEST AVAILABLE COPY

Assay techniques based on growth stage dependent expression in *C. elegans*.

This invention is directed to new methods to perform assays with nematodes, and more particularly with microscopic nematodes such as *C. elegans*.

5   The assay techniques described herein may *inter alia* be used for a variety of purposes, such as the discovery and development of compounds for pharmaceutical, veterinary and/or agrochemical use, the selection and isolation of mutant nematode strains, and may also be used for the specific expression of desired amino acid sequences, such as polypeptides and/or proteins, at various growth stages of the

10   nematodes, among others.

Other aspects, embodiments, applications and advantages of the present invention will become clear from the further description hereinbelow.

General techniques and methodology for performing *in vivo* assays using the nematode worm *Caenorhabditis elegans* (*C.elegans*) - i.e. as a model organism for

15   higher multicellular animals - have been described in the art, most notably in the following applications by applicant: PCT/EP99/09710 (published on 15 June 2000 as WO 00/34438); PCT/EP99/04718 (published on January 15, 2000 as WO/00/01846); PCT/IB00/00575 (published on October 26, 2000 as WO 00/63427); PCT/IB00/00557 (published on October 26, 2000 as WO 00/63425); PCT/IB00/00558 (published on

20   October 26, 2000 as WO 00/63426); as well as for instance PCT/US98/10080 (published on 19-11-1998 as WO 98/51351), PCT/US99/13650, PCT/US99/01361 (published on 29-07-1999 as WO99/37770), and PCT/EP00/05102.

As described in these applications, one of the main advantages of assays involving the use of *C.elegans* is that such assays can be carried out in multi-well plate

25   format (with each well usually containing a sample of between 2 and 100 worms) and - also because of this - may also be carried out in an automated fashion, i.e. using suitable robotics (as are described in the aforementioned applications and/or as may be commercially available). This makes assays involving the use of *C.elegans* ideally suited for the screening of libraries of chemical compounds, in particular at medium to high

30   throughput. Such automated screens may for instance be used in the discovery and/or development of new compounds (e.g. small molecules and/or small peptides) for pharmaceutical, veterinary or agrochemical/pesticidal (e.g. insecticidal and/or nematocidal) use.

Some other advantages associated with the use of *C.elegans* as a model
organism (e.g. in the assay techniques referred to above) include, but are not limited to:
-   *C. elegans* has a short life-cycle of about 3 to 4 days.
    This not only means that these nematodes (and suitable mutants, transgenics and/or
5   stable lines thereof) can be cultivated/generated quickly and in high numbers, but
    also allows assays using *C.elegans* to test, in a relatively short period of time and at
    high throughput, the nematode worms over one or more, and up to all, stages of
    life/development, and even over one or more generations. Also, because of this short
    life span, in *C.elegans* based-assays, compounds may be tested over one or more,
10 and up to essentially all, stages of development, without any problems associated
    with compound stability and/or (bio)availability;
-   *C. elegans* is transparent, allowing -with advantage- for visual or non-visual
    inspection of internal organs and internal processes, and also the use of markers
    such as fluorescent reporter proteins, even while the worms are still alive. Also, as
15 further mentioned below, such inspection may be carried out in automated fashion
    using suitable equipment such as plate readers;
-   *C.elegans* is a well-established and well-characterized model organism. For
    example, the genome of *C.elegans* has been fully sequenced, and also the complete
    lineage and cell interactions (for example of synapses) are known. In addition,
20 *C.elegans* has full diploid genetics, and is capable of both sexual reproduction (e.g.
    for crossing) as well as reproduction as a self-fertilizing hermaphrodite. All this may
    provide many advantages, not only for the use of *C.elegans* in genetic and/or
    biological studies, but also for the use of *C.elegans* in the discovery, development
    and/or pharmacology of (candidate) drugs for human or animal use.
25 -   Techniques for transforming, handling, cultivating, maintaining and storing (e.g. as
    frozen samples, which offers great practical advantages) *C. elegans* are well
    established in the art, for instance from the handbooks referred to below. For
    example, *C.elegans* may be used as a one or more samples with essentially fully
    isogenic genotype(s).
30   Generally, in the assays described above, the nematodes are incubated in
    suitable vessel or container - such as a compartment or well of a multi-well plate - on a
    suitable medium (which may be a solid, semi-solid, viscous or liquid medium, with liquid
    and viscous media usually being preferred for assays in multi-well plate format). The
    nematodes are then contacted with the compound(s) to be tested, e.g. by adding the

compound to the medium containing the worms. After a suitable incubation time (i.e. sufficient for the compound to have its effect - if any - on the nematodes), the worms are subjected to a suitable detection technique, i.e. to measure/determine a signal that is representative for the influence of the compound(s) to be tested on the nematode

5   worms, which may then be used as a measure for the activity of the compound(s) in the in vivo assay. Often, such a signal will be based on and/or derived from (changes in) at least one biological, phenotypical, behavioural and/or biochemical property of the worm, such as drinking, pharynx pumping, movement, egg laying, mating or defecation (vide for instance PCT/IB00/00575). These properties are also generally referred to as

10   *(biological) read outs* of or for the assay.

        Often, in particular for automated assays, such a detection technique involves a non-visual detection method (as further described in the applications mentioned above), such as measurement of fluorescence or another optical method, measurement of a particular marker (either associated with worms or associated with the medium) such as

15   an autonomous fluorescent proteins (AFP) for example green fluorescent protein (GFP), aequorin, alkaline phosphatase, luciferase, Beta-glucoronidase, Beta- lactamase, Beta-galactosidase, acetohydroxyacid, chloramphenicol acetyl transferase, horse radish peroxidase, nopaline synthase, or octapine synthase. For example, for automated assays carried out in multi-well plates, so called (multi-well) "plate readers" may be used

20   for detecting/measuring such a signal.

        For a further description of the above and other assay techniques involving the use of nematodes as a model organism, reference is made to the prior art, such as the applications by applicant referred to above.

        For general information on *C.elegans* and techniques for handling this nematode

25   worm, reference is made to the standard handbooks, such as W.B. Wood et al., *"The nematode Caenorhabditis elegans"*, Cold Spring Harbor Laboratory Press (1988) and D.L. Riddle et al., *"C. ELEGANS II"*, Cold Spring Harbor Laboratory Press (1997), and Caenorhabditis elegans, Modern Biological analysis of an organism: ed. by H. Epstein and D. Shakes, Methods in Cell Biology, Vol 48, 1995

30   Although the assay techniques described in the prior art mentioned above demonstrate the usefulness of *C. elegans* in a range variety of *in vivo* assays and for a variety of different purposes, there is an ever continuing need to develop further *C.elegans* based assays, in order to further broaden and expand the applicability of this model organism in drug discovery, development, testing and pharmacology.

The present invention provides such assay techniques, which, in addition to the advantages described hereinbelow, again have all the general advantages associated with the use of C.elegans as already described above.

In particular, the invention provides such assays, which are based on (changes in) growth and/or development of the nematode as the biological read out.

The invention is *inter alia* based on the fact that the nematodes used show a number of very distinct stages of development, e.g. from egg to the subsequent development stages referred to as embryonic (early, mid, late), L1, L2, L3 and L4, respectively, to adult . In addition, and mainly depending on environmental factors such as the absence of food, temperature, population and/or certain pheromones, the nematodes may optionally go into a specific and very distinctive stage called the "dauer-state" (which, although an optional stage of development, for the purposes of the present application is also considered a stage of life/development of the nematode).

Thus, more in particular, the present invention provides assay techniques which have been specifically designed to make use of such transition(s) by C.elegans from a first stage of development to another (i.e. second, and usually subsequent) stage of development as a biological read out.

The invention is also based on the fact that certain genes within the genome of the nematodes are expressed only during some of these stages of development of the nematodes, but not during some other stages. This is essentially because the promoters associated with these genes drive the expression of these genes in a manner that is dependent on the stage of development.

Some non-limiting examples of such "*development-dependent*" promoters, as well as the specific stage(s) of development in which they drive expression of their associated gene(s), are mentioned in Table 1 below. Others may be found in the handbooks referred to above.

Table 1: Promoters with growth stage dependent expression in C. elegans		
glp-1	Very early embryonic stage	WBG* 13(2):22 (1feb, 1994)
unc-54	Mid-late embryonic stage	WBG 13(2):22 (1feb, 1994)
myo-2	Mid-late embryonic stage- adult	WBG 13(2):22 (1feb, 1994)
vit-2	Adult	WBG 13(2):22 (1feb, 1994)
lin-28	Embryonic-late L2	WBG 14(5):56 (1feb, 1997)
lin-4	Late L1-adult	C.elegans II :501-518
lin-14	Late embryonic- mid L1	WBG 11(3):46
col-7	L4-early adult	WBG (11)4:61
col-19	L4-early adult	WBG (11)4:61
col-17	Late embryonic-L3	WBG (11)4:61
ctl-1	Dauer	Nature 399:162-166
sod-3	Dauer	FASEB 13: 1385-1393

WBG*: worm breeders gazette

5   One promoter of particular interest for the purposes of the present invention is
the vit-2 promoter, which specifically induces expression in the adult stage of the worm,
and does so in a very stringent manner. The regulation and gene expression of the
vitellogenin gene of C. elegans designated vit-2 promoter is well known, and the
promoter region has been analyzed in detail. (MacMorris et al., Mol. Cell. Biol., 1992,
10   12:1652-1662; MacMorris et al., Mol. Cell. Biol., 1994, 14:484-491; Greenspoon et al.,
worm breeder's gazette, 1988, 10:25).

In the present invention, the "development-dependent" promoters referred to
above are used to provide transgenic (strains of) nematode worms, which strains can be
used in the assay techniques of the invention.

15   Thus, although promoters that may provide for development-dependant
expression in C.elegans, as well as transgenic C.elegans lines that use such promoters
for development-dependant expression in C.elegans have been described in the art, so
far, such promoters and transgenes have not yet been used in the art in (the design of)

assay techniques, in particular in (the design of) automated, high-throughput assay techniques.

Generally, to accomplish the present invention, the inventors have constructed transgenic nematodes which contain a growth stage dependent promoter operationally linked to a marker gene, and have used this transgenic nematode to develop assays which can be configured for a high throughput setting. The speed of growth or the passage in one of the growth stages which is monitored by the expression of the marker gene which is only expressed in a specific growth stage is then the criteria for selection. Mutant nematodes, and chemically treated nematodes are known to show growth delay, or even growth stage growth arrest. So this method allows for the selection of nematodes which growth faster or slower than the reference nematode. Particular descriptions and examples below are included to clarify this new method.

Thus, in a first aspect, the invention relates to a method for determining the influence of at least one exogenous factor on the development and/or growth of a sample of nematode worms, said method comprising:

a) providing a sample of nematode worms,

which nematode worms contain a marker gene operably linked to a promoter,

which promoter is capable of driving the expression of the marker gene in the nematode worms such that the marker gene is not expressed in at least a first development stage of the nematodes, but is expressed in at least a second development stage of the nematodes (different from the first life stage);

b) exposing said sample of nematode worms to at least one exogenous factor;

c) maintaining/cultivating said sample of nematode worms in a suitable medium, optionally over one or more life stages and/or generations;

d) subjecting the sample of nematode worms to at least one detection technique that is capable of detecting the signal generated by the marker gene (if expressed).

The nematodes used are preferably from the genus *Caenorhabditis*, such as *Caenorhabditis briggsae* or *Caenorhabditis elegans*.

The sample of nematodes may comprise any suitable number of worms, depending on the size of the container/vessel used. Usually, the sample will comprise between 2 and 500, in preferably between 3 and 300, more preferably between 5 and 200, even more preferably between 10 and 100 nematodes. When the assay is carried out in multi-well plate format, each well usually contains between 15 and 75 worms, such

as 20 to 50 worms. Although not preferred, it is not excluded that a sample may consist of a single worm.

Usually, each such individual sample of worms will consist of worms that - at least at the start of the assay - are essentially the same, in that they are of the same strain, in that they contain the same mutation(s), in that they are essentially of an isogenic genotype, in that they show essentially the same phenotype(s), in that they are essentially "synchronised" (i.e. at essentially the same stage of development; it should however be noted that this stage of development may - and usually will - change during the course of the assay), in that they have been grown/cultivated in essentially the same way, and/or in that they have been grown under and/or exposed to essentially the same conditions, factors or compounds, including but not limited to pheromones, gene suppression (such as by RNAi), gene- or pathway-inducing factors or (small) molecules, and/or gene- or pathway-inhibiting factors or (small) molecules, and/or mutagenesis. However, in its broadest sense, the invention is not limited thereto.

In step a), when the sample of nematodes is initially provided, it is preferably such that the nematodes are essentially all in the first development stage.

Preferably said first development stage is such that it precedes the second development stage, in which said first development stage and said second development stage may or may not be separated (i.e. in time) by one or more further, intermediate development stages. For example, the first development stage may be L1, and the second development stage may be adult, with L2, L3, and L4 being intermediate development stages.

Preferably, the first development stage is chosen from eggs, an embryonal stage, L1, L2, L3, L4, or dauer; with eggs, embryonal stages, L1, L2 and dauer being particularly preferred, and L1 being the most preferred.

The second development stage is preferably a development stage subsequent to the first development stage (which may also be, if the first stage is dauer, any stage following escape from dauer) and is preferably chosen from L4, adult or dauer, and more preferably from adult or dauer, dependant on the choice of the first development stage. However, as can also be seen from Table 2 below, which lists some preferred combinations of first development stage, second development stage and promoter, the invention is not limited strictly thereto.

8

Table 2: some preferred combinations of first development stage, second development stage and promoter.

Promoter	First stage	Second stage
glp-1	L1, L2, L3, L4, dauer, (adults)	very early embryonic stage (eggs)
unc-54	L1, L2, L3, L47 dauers,(adults)	mid-late embryonic stage (eggs)
myo-2	Very early eggs	mid-late embryonic stage-adult
vit-2	Eggs, L1, L2, L3, (L4, dauer)	Adult
lin-28	L4, dauer, adult (L3)	Embryonic-late L2
lin-4	Eggs	late L1-adult
lin-14	L3,L4, adult, dauer, (L2)	late embryonic- mid L1
col-7	Eggs, L1, L2, dauer, (L3)	L4-early adult
col-19	Eggs,L1, L2, dauer, (L3)	L4-early adult
col-17	Adult, dauer, (L4)	Late embryonic-L3
ctl-1	Eggs,L1, (L2, L3, L4, adult)	Dauer
sod-3	Eggs, L1,(L2, L3, L4, adult)	Dauer

5

In the assays of the invention, the nematodes may be kept in or on any suitable medium, including but not limited to solid and semi-solid media - but are preferably kept in a suitable liquid or viscous medium (e.g. with a viscosity at the temperature of the assay that is equal to a greater than the viscosity of M9 medium, as measured by a suitable technique, such as an Ubbelohde, Ostwald and/or Brookfield viscosimeter).

Generally, suitable media for growing/maintaining nematode worms will be clear to the skilled person, and include for example the media generally used in the art, such

as M9 (10 X M9 buffer: 30 g KH_2PO_4, 75.212 g Na_2HPO_4. $2H_2O$, 50 g NaCl, 10 ml 1M $MgSO_4$, add up to 1 L), S-buffer (5.9 g NaCl, 50 ml 1M KH_2PO_4, 1ml 5g/L cholesterol, add up to 1 L), and the further media described in the applications and handbooks mentioned hereinabove.

5   The medium may further contain all factors, compounds and/or nutrients as may be required for the survival, maintenance and/or growth of the worms. For this, reference is again made to the prior art, such as the applications and handbooks referred to above. The medium may also contain a suitable source of food for the worms such as bacteria, for example a suitable strain of E.coli in a suitable amount, e.g. between 0.001 and 10

10   % (w/v), preferably between 0.01 and 1%, more preferably between 0.1 and 0.2 %, such as about 0.125 % w/v. In one specific embodiment, further described below, said bacteria may also contain or express a double stranded RNA (construct), intended for specific gene down regulation in the nematode worm, e.g. by means of RNA-interference (vide PCT/EP99/04718)

15   The assay may be carried out at a suitable temperature, which may for example be a temperature of between 10°C and 30 °C, preferably between 20°C and 27 °C, such as 21, 22, 23, 24, 25 or 26°C, depending on the specific strain used. The temperature may be kept essentially constant during the course of the assay, and/or may be varied, e.g. within the ranges indicated above.

20   In the method of the invention, the sample of nematodes can be kept - e.g. maintained, grown or incubated - in any suitable vessel or container, but is preferably kept in a well of a multi-well plate, such as a standard 6, 24, 48, 96, 384, 1536, or 3072 well-plate (in which each well of the multi-well plate may contain a separate sample of worms, which may be the same or different). Such plates and general techniques and

25   apparatus for maintaining/ handling nematode worms in such multi-well plate format are well known in the art, for instance from the applications mentioned hereinabove.

         The method/assay of the invention is preferably carried out in an automated fashion, e.g. using the equipment and techniques described in the applications mentioned above.

30   In the invention, a nematode strain is used that contains a marker gene that is operably linked to a promoter, which promoter is capable of driving the expression of the marker gene in the nematode worm(s) such that the marker gene is not expressed in at least a first development stage of the nematodes, but is expressed in at least a second development stage of the nematodes (different from the first development stage).

As already indicated hereinabove, such promoters are also referred to herein as "development-dependent" promoters, and some preferred examples have been given above.

A particularly preferred development-dependent promoter is the vit-2 promoter. An operational fusion of a DNA sequence (gene, cDNA) with the vit-2 promoter allows for the expression of this DNA sequence in the adult stage of C. elegans, and not in the other life stages of C. elegans such as the L1, L2, L3, and L4 larvae stages and the dauer stages.

In the present disclosure, two or more nucleotide sequences, such as a promoter and a marker gene, are considered "operably linked" when they are in a functional relationship with each other. For instance, the development-dependent promoter is considered "operably linked" to the marker gene if said promoter is able to initiate or otherwise control/regulate the transcription and/or the expression of said marker gene, in particular in a development-dependent manner (and in which said marker gene should be understood as being "under the control of" said promoter). Generally, when two nucleotide sequences are operably linked, they will be in the same orientation and usually also in the same reading frame. They will usually also be essentially contiguous, although this may also not be required.

The marker gene may be any gene which, upon expression in C. elegans - i.e. under the control of the development-dependent promoter - provides a signal that can be detected, e.g. visually or preferably by the automated, non-visual detection techniques referred to above.

For example, the marker gene may be chosen from green fluorescent protein, beta-galactosidase, beta-lactamase, luciferase, acetohydroxyacid synthase, alkaline phosphatase, beta-glucuronidse, chloramphenicol acetyltransferase, horseradish peroxidase, nopaline synthase and/or octapine synthase. Other suitable marker genes will be clear to the skilled person, and are for instance described in the applications referred to above.

In a specific embodiment, the gene may be a toxic gene, e.g. a gene that encodes a gene product that is toxic (e.g. lethal) to the nematode. Thus, another application of the invention consists in the conditional expression of putative toxic genes, and in the conditional expression genes, to be expressed in specific growth stage in nematodes such as C. elegans. When toxic genes are expressed in nematode at any growth stage, and surely in the early development of the nematode, this will have

dramatic influences on the further development and vitality of the nematode. It may be opportune to express such genes in a particular growth phase of the worm, such as the L1, L2, L3, L4, adult or dauer stages. Such transgenic nematodes have more change to survive the expression of the toxic gene and may be used for further analysis, for

5   instance in a HTS assay, screening for compounds, mutants, etc. Some preferred, but non-limiting examples of such toxic genes are ataxin, alpha-synuclein, ubiquitin, the tau gene, the huntington gene, the best macular dystrophy gene product, unc-53; others are mentioned in the applications referred to above.

The nematode strain used in the invention may generally be provided by

10 transforming a suitable nematode strain with a nucleotide sequence that comprises the marker gene under the control of the development-dependent promoter. Preferably, said nucleic acid sequence is in the form of a genetic construct, which may be DNA or RNA (and are preferably double-stranded DNA) and which is preferably in a form suitable for transformation of the nematode strain used. For example, it may be in the form of a

15 construct that, upon transformation, is integrated in the genomic DNA of the nematode, and/or may be in a form suitable for independent replication, maintenance and/or inheritance in the nematode. Preferably, the construct is also such that it is capable of independent replication, maintenance and/or inheritance in the (micro-) organism used for cloning, such as E. coli. For instance, said genetic construct may be in the form of a

20 plasmid, vector, viron or transposon.

The genetic construct(s) used in the invention may further contain - i.e. besides the nucleotide sequences encoding the development-dependent promoter and the marker gene -   one or more further suitable elements of genetic constructs known per se, including but not limited to selection markers and/or elements that may facilitate or

25 increase (the rate of) transformation or integration. These and other suitable elements for such genetic constructs will be clear to the skilled person, also from the applications referred to above.

The constructs of the invention can be provided in a manner known per se, which will generally involve techniques such as restricting and linking nucleic acids/nucleic acid

30 sequences, as will be clear to the skilled person. Reference is made to the standard handbooks, such as Sambrook et al, "Molecular Cloning: A Laboratory Manual" (2nd.ed.), Vols. 1-3, Cold Spring Harbor Laboratory Press (1989) and F. Ausubel et al, eds., "Current protocols in molecular biology", Green Publishing and Wiley Interscience, New York (1987). The nucleic acids encoding the development-dependent promoters

12

and marker genes used in the invention have been described in the art and can be provided in the manner described therein.

The nematodes may be transformed with the constructs in any suitable manner, such as micro-injection or ballistic transformation, for which reference is made to the
5   handbooks referred to above, as well as for instance in PCT/EP99/01903 (published as WO 99/49066)

The nematode strain that is transformed with the nucleotide sequence encoding the marker gene/development-dependent promoter - i.e. to provide a nematode strain useful in the assay of the invention - is not particularly limited, and may for instance be
10   any nematode strain known per se, such as wildtype, N2 or hawaiian (CB4856, Hodgkin et al., Genetics146:149-164, 1997). Also, specific mutant nematode strains or lines and transgenic strains or lines may be used which are particularly suited/adapted for transformation and/or the specific transformation technique used, or if they are desired in the assay.

15   In one embodiment, before use in the present assays, the nematodes are subjected to random or specific mutagenesis. Thereupon, the different strains resulting from the mutagenesis may be tested in the assay(s) of the invention, and optionally may be compared to the original strain and/or to a(nother) reference strain. This may be done with and/or without exposure to the exogenous factor(s) and may for instance be used to
20   identify genes and/or mutations that influence the development and/or growth of the nematodes, and/or to identify genes and/or mutations which alter or influence the response of the nematodes (i.e. with respect to development and growth) to the exogenous factors. For example, when a mutation in a gene leads to a marked change in development and/or growth (as determined using the assay(s) of the invention), or
25   leads to a markedly different response to the exogenous compound(s), it may be concluded that said gene is involved in development or growth and/or in the response of the nematode to the exogenous factor(s). In this way, the assays of the invention may for instance be used to determine the function of (known or unknown) genes (for instance as part of a functional genomics program) and/or to determine the mode of
30   action of the exogenous factor(s).

In step b), a sample of nematodes containing the marker gene under the control of the development-dependent promoter is exposed to the exogenous factor(s) to be tested. This may be carried out while the nematodes in the sample are (still) in the first stage of development, and/or in any subsequent stage(s) of development. Preferably,

however, the sample of nematodes is exposed to the at least one exogenous factor in at least one stage of development which precedes the second stage of development (however, it should be noted that the invention does not exclude that the sample of nematodes is still in contact with the exogenous factor(s) while the nematodes transit into and/or are in the second stage of development).

For example, the nematodes may be exposed to the exogenous factor(s) in only a single stage of development (such as only in the first stage or only in a subsequent stage that precedes the second development stage), in two or more stages (which may include the first stage, any subsequent stage(s) and/or the second stage), or essentially continuously throughout the duration of the assay.

Thus, generally, the nematodes may be exposed to the exogenous factor(s) during a time of 1 minute up to the entire life (cycle) of the nematodes, and/or to the duration of the assay. Usually, a contact time of between 5 minute and 110 hours, preferably between 10 minutes and 80 hours will be preferred.

The total time for the assay will preferably be such that it is sufficient to allow at least one of the nematodes in the sample to transit from the first development stage into a subsequent development stage, and more preferably sufficient to allow at least one of the nematode worms in the sample to enter from the development stage into the second development stage, optionally via any (further) intermittent stages of development

For example, in step c), the sample of nematode worms may be maintained/cultivated for a time such that at least 1%, preferably at least 5%, of the nematode worms present in the sample enter from the first development stage into at least one other/further development stage.

Also, for example, in step c), the sample of nematode worms may be maintained/cultivated for a time such that at least 1%, preferably at least 5%, of the nematode worms present in the sample enter from the first development stage into the second development stage.

Often, the total time for the assay will be at least such that it would allow at least one of the nematode worms present in a reference sample - i.e. a sample not containing any exogenous factor(s) - to enter from the first development stage into the second development stage, optionally via any (further) intermittent stages of development.

For example, for assays from the following first development stage to the following second development stage, the total time of the assay can be as follows: from eggs to adults: 45 to 110 hours; from L1 to adults: 30 to 80 hours; from eggs to L1: 13 to

30 hours; from L1 to L2: 13 to 25 hours; from L2 to L3: 8 to 20 hours; from L3 to L4: 8 to 15 hours; from L4 to adult: 8 to 25 hours; for assays involving dauer as the first or second stage: between 8 and 72 hours (depending on the strain used, temperature and food quality, nematodes will generally enter the L1 growth stage between 13 and 30 hours, the L2 growth stage between 24 and 55 hours, the L3 growth stage between 30 and 70 hours, the L4 growth stage between 38 and 85 hours, and the adult stage between 45 and 110 hours, starting from eggs).

During the duration of the assay, the sample may be subjected to the - preferably non-visual - detection method for determining/measuring the expression of the marker gene essentially continuously during the entire duration of the assay, essentially continuously during one part of the duration of the assay (usually the latter part, when the nematodes are considered likely to enter the second stage of development, e.g. during the last 24, 12, or even 6 hours of the duration of the assay), at regular intervals, or any combination thereof.

In the assays of the invention, each individual sample of nematode worms will generally be exposed to a single exogenous factor to be tested, at a single amount or concentration; with different samples (e.g. as present in the different wells of the multi-well plate used) being exposed either to different concentrations of the same factor (e.g. to establish a dose response curve for said factor), to one or more different factors (e.g. in the case of compounds for instance are part of a chemical library and/or of a chemical class or series, such as a series of closely related structural analogues; or in case of a library or series of dsRNA constructs for RNAi), or both (e.g. to the same and/or different factors at different concentrations).

It is also within the scope of the invention to expose the (sample of) nematodes to two or more factors - at essentially the same time or sequentially (e.g. with an intermediate washing step) - for example to determine whether the two factors have an effect which is the same or different from both the factors separately (e.g. to provide a synergistic effect or an inhibitory or competitive effect).

Furthermore, it is within the scope of the invention to use one or more reference samples, e.g. samples without any factor(s) present, and/or with a predetermined amount of a reference factor. The invention also includes the use, in an assay, of two or more samples of nematode worms of different strains (e.g. each containing a marker gene under the control of a (different) development-dependent promoter), e.g. to compare (the effect of the factors(s) to be tested on) said different strains.

In one specific embodiment, which is referred to herein as an "FPTP-type assay", each sample of a series of two or more essentially similar samples of nematode worms (e.g. containing the same development-dependant promoter, preferably the same marker gene - although this is not strictly required - and preferably comprised of worms in the same stage of development) is exposed, in essentially the same manner (e.g. time and conditions, but optionally at different concentrations), to (a) different exogenous factor(s), and optionally to one or more reference factors. Thereupon, the order in which the nematodes present in each of these samples enter the second development stage is determined, i.e. by determining the order in which the samples of the series show expression of the marker gene (i.e. which sample shows the expression of the marker gene first, second, third, etc.). Inter alia, this allows the different factors present in each of the samples to be compared and/or ranked according to their influence on the development/growth of the nematode, and also compared to the reference factor(s). This for instance allows the identification of factors with an influence on the nematodes comparable to, or even improved compared to, the influence of the reference factors. Generally, such FPTP-assays will involve determining the (possible) expression of the marker gene in the series of samples essentially continuously, at least during the last 36, 24, 12, or 6 hours of the assay.

Thus, in a specific embodiment, the invention relates to a method for determining the influence of at least a first exogenous factor on the development and/or growth of a sample of nematode worms, said method comprising:

a) providing at least a first and a second sample of nematode worms,

in which the nematode worms in each sample contain a marker gene operably linked to a promoter,

which promoter is capable of driving the expression of the marker gene in the nematode worms such that the marker gene is not expressed in at least a first development stage of the nematodes, but is expressed in at least a second development stage of the nematodes (different from the first life stage);

b) exposing at least said first sample of nematode worms to said first one exogenous factor;

c) maintaining/cultivating said samples of nematode worms in a suitable medium, optionally over one or more life stages and/or generations;

16

d) subjecting the samples of nematode worms to at least one detection technique that is capable of detecting the signal generated by the marker gene (if expressed);

e) determining the time required for the first sample of nematode worms to show expression of the marker gene (as determined by the signal detected for the first sample in step b)), and preferably also determining the time required for the second sample of nematode worms to show expression of the marker gene (as determined by the signal detected for the second sample in step b)); and/or comparing the time required for the first sample of nematode worms to show expression of the marker gene with the time required for the second sample of nematode worms to show expression of the marker gene.

In one aspect, the second sample of nematode worms will be a reference sample, e.g. a sample of worms that is not exposed to any exogenous factor, or to a known reference factor. The second sample may also be exposed to a second exogenous factor, e.g. to compare the first and the second factor.

Generally, as already indicated above, the assay according to this aspect of the invention will involve the use/testing of a series of samples, e.g. more than 5, preferably more than 10, such as about 6, 24, 48, 96, 384, 1536, or 3072 (i.e. essentially the number of wells of a multi-well plate), each sample being exposed to a different factor and/or to a different concentration of factor (including any reference samples), and the samples than being ranked as described above.

Usually, to allow for a good comparison between the samples/factors, all samples will be essentially similar (as described above) and cultivated/maintained in an essentially similar manner. These FPTP-assays may further be carried out in essentially the manner described herein.

In all the assays described above, the exogenous factor may be any factor the influence of which on the growth/development of nematode worms is to be tested. The exogenous factors may for instance be chosen from small compounds (as defined below), small peptides (as defined below), factors which induce or suppress specific pathways in the worm, factors which induce or suppress (the expression of) specific genes in the worm (such as dsRNAi for RNA-interference), polypeptide and/or proteins, or extracts from natural products(such as plants, animals, fungi, bacteria), amino acids and derivatives, hormones and derivatives, nucleic acids and derivatives.

For the purposes of the present disclosure, a "small molecule" generally means a molecular entity with a molecular weight of less than 1500, preferably less than 1000.

This may for example be an organic, inorganic or organometallic molecule, which may also be in the form or a suitable salt, such as a water-soluble salt.

The term "small molecule" also covers complexes, chelates and similar molecular entities, as long as their (total) molecular weight is in the range indicated above.

In a preferred embodiment, such a "small molecule" has been designed according, and/or meets the criteria of, at least one, preferably at least any two, more preferably at least any three, and up to all of the so-called Lipinski rules for drug likeness prediction (vide Lipinksi et al., Advanced Drug Delivery Reviews 23 (1997), pages 3-25). As is known in the art, small molecules which meet these criteria are particularly suited (as starting points) for the (design and/or) development of drugs (e.g) for human use, e.g. for use in (the design and/or compiling of) chemical libraries for (high throughput screening), (as starting points for) hits-to-leads chemistry, and/or (as starting points for) lead development.

In a preferred embodiment, such a "small molecule" has been designed according, and/or meets the criteria of, at least one, preferably at least any two, more preferably at least any three, and up to all of the so-called Lipinski rules for rational drug design (vide Lipinksi *et al.*, Advanced Drug Delivery Reviews 23 (1997), pages 3-25). As is known in the art, small molecules which meet these criteria are particularly suited (as starting points for) the design and/or development of drugs (e.g) for human use

Also, for these purposes, the design of such small molecules (as well as the design of libraries consisting of such small molecules) preferably also takes into account the presence of pharmacophore points, for example according to the methods described by I. Muegge et al., J. Med. Chem. 44, 12 (2001), pages 1-6 and the documents cited herein.

The term "small peptide " generally covers (oligo)peptides that contain a total of between 2 and 35, such as for example between 3 and 25, amino acids (e.g. in one or more connected chains, and preferably a single chain). It will be clear that some of these small peptides will also be included in the term small molecule as used herein, depending on their molecular weight.

Thus, the methods of the invention may in particular be used to test and/or screen (libraries of) such small molecules and/or peptides, in the manner as further outlined herein.

According to another embodiment, the exogenous factor is a factor that suppresses or enhances the expression of one or more genes in the nematodes used. In

18

one preferred example, this factor may be a dsRNA, which may be used for gene suppression in accordance with well-known RNA-interference techniques. Such dsRNA may for instance be provided to the nematode worms in the manner described in PCT/EP99/04718 (published as WO 00/01846) or PCT/US98/27233 (published as WO 99/32619), e.g. by injection of dsRNA or by feeding of bacteria containing/expressing the dsRNA to the nematode. In this latter embodiment, for example, the effect(s) of the suppression of one or more gene(s) on the growth or development of the nematode worms and/or on the response of other exogenous factors, may be determined.

5

The nematodes may be exposed to the exogenous factor in any suitable manner, such as by incorporating the exogenous factor in the medium in which the nematode worms are grown/maintained or by incorporating the nematode worms in the food of the nematodes (e.g. in the case of dsRNA for RNAi purposes).

10

The nematode worms may take up the exogenous factor in any suitable manner, such as by drinking, feeding, soaking, pharynx pumping, or in any other suitable way, e.g. either through (a part of) the gastrointestinal tract, the cuticle and/or through openings in the cuticle, and either through an active or passive uptake mechanism, or any combination thereof.

15

When the exogenous factor is a compound, it will usually be used in step b) at a concentration of between 0.1 nanomolar and 100 milimolar, preferably between between 1 nanomolar and 50 milimolar, more preferably between 10 nanomolar and 10 milimolar, even more preferably between 100 nanomolar and 5 milimolar, in particular between 1 micromolar and 1 milimolar, even more particular between 10 micromolar and 600 micromolar, most particular between 20 micromolar and 500 micromolar, such as about 30 micromolar for compound selection screens and about 300 micromolar for compound resistance screens.

20

25

For dsRNA, suitable amounts will be as described in the PCT/EP99/04718 (published as WO 00/01846) or PCT/US98/27233 (published as WO 99/32619).

The assay techniques of the invention may be used for several different applications, some non-limiting examples of which will now be further described.

A first application is to identify and select chemical entities that may be used in the development of pharmaceutical products, veterinary products, and pesticides. In this respect, it should also be noted that the invention may not just be used to identify exogenous factors (such as compounds) which directly influence development and/or growth, but also compounds which influence other behavioural, biological, phenotypical

30

and/or biochemical processes which in turn influence growth and/or development, such as metabolic processes, feeding/drinking behaviour and/or (other) processes which are controlled by the central nervous system or other nerve cells.

Thus, the invention may also be used to identify compounds which may influence metabolic processes and neuron-controlled processes, not just in nematodes, but also in higher animals including humans and other mammals, for which the nematode is used as a model organism. Thus, the assays of the invention may be used in the discovery and/or development of pharmaceuticals and/or veterinary products.

Also, exogenous factors such as compounds which, in the assays of the invention, retard growth and/or development may find use in the development of novel insecticides or other pesticides (including but not limited to nematocides).

Another application is to identify and select new mutants, and further on isolating the genes which are mutated. This genes and the proteins they encode for are then considered as putative target genes and/or members of biochemical pathways. In a specific variant of this objective, mutants are selected that show resistance to a chemical compound, and once again the final objective is to isolate the mutated gene.

A third possible application is related to the isolation of genes, and the proteins they encode for by dsRNA inhibition (RNAi). The isolated genes and the proteins they encode for are considered as putative target genes, members of biochemical pathways, resistance.

In the development and performance of HTS assays with nematodes, the synchronicity of the animals is of major importance, i.e. nematodes used in the assay need to be at the same growth stage. Although several methods have been developed to grow a culture of nematodes at the same speed, while they are in the same growth stage, aberrations are usual. The present invention also offers a solution to this problem. As the nematodes described in this invention express marker genes at a certain growth stage, the nematodes in a culture at the same growth stage can easily be detected and isolated prior to the HTS assay. Moreover several machines are presently available that allow to select automatically nematodes which have common features (such as expressing a green fluorescent proteins). An example of such machine, generally designated as a worm dispensers or FANS (Fluorescence Activated Nematode Sorter), is provided by UBI (Union, Biometrica, USA). The methods allows the inventors to select nematodes which are in a specific growth stage, such growth stage may for example be, eggs, L1, L2, L3,L4, Adult or dauer growth stage.

In another aspect, the invention relates to the use of a (sample of at least one) nematode worm, which nematode worm contains a marker gene operably linked to a promoter, which promoter is capable of driving the expression of the marker gene in the nematode worms such that the marker gene is not expressed in at least a first

5   development stage of the nematodes, but is expressed in at least a second development stage of the nematodes (different from the first life stage), in a method or assay for determining the influence of at least one exogenous factor on the development and/or growth on a nematode worm.

In a particular aspect, the invention relates to the use of a (sample of at least

10   one) nematode worm in an FPTP assay as described above.

The invention will now be further illustrated by means of the following non-limiting Figures and Examples. The Figures show:

- Figure 1: Nucleotide sequence of pGQ1
- Figure 2: Nucleotide sequence of PCLUC6

15   - Figure 3: Nucleotide sequence of pGQ2
- Figure 4: Nucleotide sequence of pGN156
- Figure 5: Nucleotide sequence of pGQ3
- Figure 6: Nucleotide sequence of pGQ4
- Figure 7: Nucleotide sequence of the vit-2 promoter/NLS as present plasmid

20   pPM143
- Figure 8: Schematic drawing of pGN156
- Figure 9: Schematic drawing of pGQ1
- Figure 10: Schematic drawing of pGQ2
- Figure 11: Schematic drawing of pCLUC6

25   - Figure 12: Schematic drawing of pGQ3
- Figure 13: Schematic drawing of pGQ4
- Figure 14 : Stage specific expression of LacZ (C. elegans harboring pGN156) after one hour of probe addition.
- Figure 15 : Stage specific expression of LacZ (C. elegans harboring pGN156) after

30   two hours of probe addition.
- Figure 16: Stage specific expression of LacZ (C. elegans harboring pGN156) after three hours of probe addition.
- Figure 17: Expression of Lacz in function of the number of nematodes (C. elegans harboring pGN156).

- Figure 18: Fluorescence activity of adult nematodes (*C. elegans* UG1513) in flat bottom wells in function of the number of wells

- Figure 19 : Fluorescence activity of adult nematodes (*C. elegans* UG1513) in U-Shaped wells in function of the number of wells

5

Strain *C. elegans* UG1353 (pGN156) is deposited under accession number: "LMBP 5719CB" , at the Belgian Coordinated Collection of Microorganisms (BCCM), Laboratorium voor molecular Biology-plasmidencollectie (LMBP) University of Ghent, K.L. Ledeganckstaat 35, 9000 Ghent, Belgium, according to the Budapest treaty of 28

10 April 1977 on the international recognition of the deposit of microorganisms for the purpose of patent procedures.

Examples:

15 <u>Example 1: Construction of plasmids which allow for the expression of markers in a specific growth stage.</u>

<u>1) Construction of pGQ1 (ctl-1::GFP vector) (Figure 1, 9)</u>

20 PCR was performed on genomic DNA isolated from *C. elegans* wild-type strain N2 under standard conditions with following primers:

oGQ1:

5'AAAACTGCAGCCAATGCATTGGAAGAGATATTTTGCGCGTCAAATATGTTTTGTGT CC3'

25 oGQ2:

5'CGCGGATCCGGCCGATTCTCCAGCGACCG3'

The PCR fragment was isolated and cloned as a PstI/BamHI fragment in pDW2020, resulting in pGQ1.

30 <u>2) Construction of pGQ2 (ctl-2::luciferase vector) (Figure 3, 10)</u>

PCR was performed on genomic DNA isolated from *C. elegans* wild-type strain N2 under standard conditions with following primers:

oGQ3:

5'CCAGGCCTGAGATATTTTGCGCGTCAAATATGTTTTGTGTCC3'

oGQ4:

5'CGGAGCTCCGATTGGATGTGGTGAGCAGG3'

The PCR fragment was isolated and cloned as a StuI/SacI fragment in pCluc6, resulting

5 in pGQ2.

3) Construction of pGQ3 (sod-3::GFP vector) (figure 5, 12)

PCR was performed on genomic DNA isolated from C. elegans wild-type strain N2 under

10 standard conditions with following primers:

oGQ7: 5'GCAGAATTTGCAAAACGAGCAGGAAAGTC3'

oGQ6: 5'TTGGCGCGCCAAGCCTTAATAGTGTCCATCAGC3'

The PCR fragment was isolated and cloned as a PstI/AscI fragment in pDW2020,

resulting in pGQ3.

15

4) Construction of pGQ4 (sod-3::luciferase vector) (Figure 6, 13)

PCR was performed on genomic DNA isolated from C. elegans wild-type strain N2 under

standard conditions with following primers:

20 oGQ7: 5'GCAGAATTTGCAAAACGAGCAGGAAAGTC3'

oGQ8: 5'CTGAGCTCGGCTTAATAGTGTCCATCAGC3'

The PCR fragment was isolated and cloned as a PstI/CacIII fragment in pCluc6,

resulting in pGQ4.

25

5) Construction of pCluc6 (vit-2::Luciferase vector) (Figure 2, 11)

PCR was performed on genomic DNA isolated from C. elegans wild-type strain N2 under

standard conditions with following primers:

30 vit-2F: 5'CCCCCAAGCTTCCATGTGCTAGCTGAGTTTCATCATGTCC3'

vit-2R: 5'CCCCCCAAGCTTGGCTGAACCGTGATTGG3'

The PCR fragment was isolated and cloned as a HindIII fragment in pCluc2, resulting in

pCluc6.

23

6) Construction pGN156 (vit-2::lacZ vector) (Figure 4, 8)

The LacZ fragment of pPD95.4 (Fire et al, Gene Gene. 1990 Sep 14;93(2):189-98) was
5   isolated as a SfuI/SpeI fragment and cloned in pPM143 (MacMorris et al., Gene
expression vol. 3 no. p27, 1993) digested with the same enzymes, resulting in vector
pGN156.

Example 2: Construction of C. elegans nematodes harboring the plasmids described
10   above, and construction of stable integrated lines.

Each of the vectors was injected into C. elegans nematode worms using standard
techniques as described in one of the references above. All the constructed transgenic
strains showed the desired marker gene expression pattern, in a heritable way. Stable
15   integrated line were constructed, an example is given for the integration of pGN156 (vit-
2::lacZ):

1) C. elegans wild-type N2 nematodes have been injected with various concentrations
of pGN156, reference and selection plasmid pGR6 (myo2::GFP), and carrier DNA
20   (pUC18)
2) A good heritable strain was selected from the injection with 25ng pGN156, 5ng
pGR6, 80 ng pUC18. Approximately 60 animals were gamm-irradiated (3000rad;
$16 \times 16 \ cm^2$, 50 cm, 82.2 min) after which each worm was placed on a single plate
and allowed to growth for offspring growth. Approximately 560 F1 offspring worms
25   expressing GFP were placed each on a single plate, and allowed to grow. From The
F2 generation, worms were again placed on single plates, and finally the F3
generation was checked for its GFP expression. The strains were then out-crossed
with wild-type strain N2 to eliminate undesirable mutations, and checked for LacZ
expression.
30   3) 6 selected nematodes, wherein pGN156 is integrated, were grown. From each
culture, 10 nematodes were placed in the well of a 96 well plate, 25 µl M9 buffer
(see above), 25 µl 60% ice cold Methanol, and 50 µl 20mM C12FDG probe(
molecular probes) was added, the wells were further incubated for 2h at 37°C and

24

fluorescence was measured in a plate reader with following settings: ex/em: 485nm/535nm

4) One of the six strains showed high viability, strong GFP expression and relatively high LacZ expression and was selected for further analysis

5

This strain, designated *C. elegans* UG1353 (pGN156) is deposited under accession number: "LMBP 5719CB" , at the Belgian Coordinated Collection of Microorganisms (BCCM), Laboratorium voor molecular Biology-plasmidencollectie (LMBP) University of Ghent, K.L. Ledeganckstaat 35, 9000 Ghent, Belgium, according to the Budapest treaty

10   of 28 April 1977 on the international recognition of the deposit of microorganisms for the purpose of patent procedures.

Example 3: LacZ-staining of an increasing number of *C. elegans* UG1353 (pGN156)

15   Transgenic nematodes, in various quantities per well, were dispensed using a worm dispenser: Copas 250NF (UBI), and the volume was added up to 35µL with M9 buffer. 35 µL C12FDG (molecular probes) and 35 µL 45% methanol was added. The wells were further incubated for at least 1h at 37°C. Fluorescence was measured with a Wallac Victor2 plate reader at ex/em: 485 nm/535 nm.

20   As shown in figure 18 and figure 19, the expression pattern of the transgenic nematodes is stable, which is clear from the linear increase of fluorescence versus a linear increase of nematodes in the wells.

Example 4: LacZ staining of *C. elegans* harboring pGN156 at various growth stages.

25   The expression pattern in function of the growth stage was measured. *C. elegans* harboring pGN156 was grown at various growth stages. Approximately 35 nematodes at various growth stages were placed in the wells of a microtiter plate. Each well contains only nematodes at a defined growth stage, being L1, L2-L3, L4, young adults, adults and older adults. M9 medium is added to a final volume of 35 µL.

30   35 µL 45% methanol and 35 µL 60 µM probe is added. Two probes have been tested:

1) Fluorescein di-beta-D-galactopyranoside (FDG) (Molecular Probes)

2) ImaGene green TM C12FDG (FDG) (Molecular Probes)

The probe was incubated for different time intervals (1 to 5 hours) at 37°C, after which the plates are cooled down to 30°C prior to measurement.

Measurement of fluorescence was performed described above. The results are shown in figures 14, 15, and 16, and clearly show that the marker gene under the control of the

5   vit-2 promoter is only expressed at the adult growth stage.

Further more linear relationship has also been tested between the number of worms added to the well and the fluorescence measured. Essential this has been performed in the same way as described above. Figure 17 shows the results, and the clear linearity

10   between the number of nematodes and the fluorescence.

Example 5: Constructing mutant strains harboring the integrates pGN156

The integrated pGN156 in C. elegans UG1353 can be crossed in any desired mutant

15   available (as provided by the references above, or by the CGC, university of Minnesota, St.-Paul) , or in any mutant newly created. As an example the integrated line has been crossed in a Daf-2 mutant line.

Strain UG1353 was crosses with a Wild-type male (N2) resulting in heterozygote males

20   and hermaphrodites. A daf-2 (m41) strain was crossed with the herterozygote strain isolated above. From the offspring, the GFP expressing nematodes were isolated, and allowed self-fertilization, once again, L4 stage nematodes were isolated which express GFP, and the nematodes were placed at 25°C to allow o form dauers. Dauers were isolated and further incubated at 15°C. The offspring was analysed and nematodes

25   which have a 100% GFP expressing offspring are isolated for further analysis. These analysed nematodes are homozygote for both the integration of PGN156 and for daf-2 (mp41)

Example 6: Screening for compounds that affect dauer formation using the daf-2

30   (PNZ156) nematodes of the example above.

The C. elegans daf-2 (pNZ156) nematodes were synchronized, and approximately 50 nematodes at the L1 stage were placed in each well of a 96 well plate. S medium was added as well as E. coli as described above to a final volume of 50 µL. Compound was

added at a final concentration of 30 µL and th enematoçdes were allowed to grow
between 22°C and 25°C for approximately 4 days, dependent on the temperature
chosen.

Methanol and probe was than added as described in the examples above to allow the
5   detection of the expression of the LacZ marker, and the wells were further incubated for
1 hour to overnight as described above, after which the fluorescence was measured, as
described above.

At a temperature higher than 22°C this strains enters the dauer stage, at which stage no
vit-2 expression, and hence no LacZ expression can be observed. Compounds which
10   allow the nematode to bypass the dauer stage, and hence allows the nematodes to
growth till the adult stage, will result in the expression of lacZ. Hence, fluorescence in
detected in the wells where nematodes have been grown till at least the adult stage,
hereby selecting a compound that affect dauer formation.

15   <u>Example 7: selection of synchronized worms</u>

<u>Example 8: selection of mutants</u>
Chemical mutagenesis has been described extensively in C. elegans , Modern biological
20   analysis of an organism, Methods in Cell Biology, Vol 48. Transposon mutagenesis has
been described in WO 00/73510 (PCT/US00/40091). In general, the desired mutated
nematodes are selected which have a desired phenotype by microscopy. When these
mutagenesis techniques are performed with transgenic strains harboring a marker gene
such as GFP under the control of a growth stage specific promoter, this allows for a
25   faster and automated selection.

In Short:

Approximately 1000000 eggs of a strain harboring a marker gene under the regulation of
a growth stage dependent promoter (such as vit-2::GFP) are grown till L4-young adult
stage after which they are treated with the mutagen. They are allowed to growth further
30   on plates (approximately 25.000 worms per plate). The nematodes are washed off the
plates with M9 buffer, while the eggs (harboring the mutants) are allowed to grow further.
The L1 offspring is then washed off and filtered using a 20µM nylon membrane
(millipore).

The L1 nematodes (F1) contain the desired dominant mutants. Depending on the desired phenotype, between 2 and 50 worms are then placed in the wells of a 96 well plate, and allowed to grow further. The plates are place into a plate reader at various time intervals (approximately every 12 hours) to check the growth speed. As mutants are

5   known to have a slower growth speed, selection can be made automatically the mutants that grow slower or selected for further analysis.

To select for recessive mutants, the L1 nematodes (F1) are allowed to grow further, and the resulting young adults are placed (approximately 500 per plate) on plates.

The eggs are isolated as above and allow to grow further till L1 stage (F2) prior to the

10   dispensing of the nematodes into the wells, as described above. The selection occurs as described for the F1 generation.

Example 9: Selection in resistance genetics

A particular kind of mutants to be selected, are those mutants who show resistance to a

15   compound. The addition of an active compound to a nematode result mainly in growth delay, growth arrest, lethality, and/or paralysis. Analogous as in the assay described above, mutant nematodes can be isolated that are resistant to the compound. Such mutant can be selected as the mutants will overcome the induction of the phenotype induced by the compound, and hence growth faster that the none mutated nematodes.

20   The mutagenesis is performed as described above, while the assay and the outcome is different. In the well plates, were the L1 nematodes are allowed to grow, the compound is added. The concentration is dependent on the compound and may be between 10 µM and 350 µM, preferably 100 µM. As such compound resistance mutants will grow faster than the non-mutated nematodes, selection of the desired mutants occurs by selecting

25   the nematodes that show firstly expression, which also has been done automatically.

Example 10: Growth monitoring in RNAi screens

Analogous to the mutatagenesis methods above, dsRNA inhibition can be performed. The principle of HTS RNAi has bee described in WO 00/01846, Nematodes can be feed

30   by bacteria that express high amounts of dsRNA. Such RNA crossed the gut barrier, and enters the cells of C. elegans performing is RNA inhibitory action.

In short:

Approximately 3 to 5 L1 synchronized nematodes (harboring a marker gene under the regulation of stage specific promoter) are placed in the wells of a microtiter plate, in

which also E. coli bacteria are present that express high levels of dsRNA. The nematodes are allowed to grow, and those are selected that show lethality, growth delay, growth arrest, etc, which can automatically be measured as these nematodes will not enter the growth stage that allows the expression of the marker gene. The assay to

5   select for the desired E. coli (harboring dsRNA expression of the gene of interest) is essential the same as the assu described above for mutagenesis.

In addition, a compound that induced growth delay, growth arrest, paralysis, or lethality can be added to the wells, at appropriate concentrations as described above. RNAi action on the nematode can induce resistance to such compound, analogous as has

10   been described above for compound resistance selection. Also in this case, the nematodes are selected that overcome the phenotype induced by the compound, as they will grow faster than the nematodes that have not acquired resistance by the RNAi. As the nematodes harbor a functional promoter marker fusion, such as vit-2::GFP, only the nematodes that grow (fast), will express the marker, and hence can be selected.

15

CLAIMS

1. Method for determining the influence of at least one exogenous factor on the development and/or growth of a sample of nematode worms, said method comprising:

5   a)   providing a sample of nematode worms,

in which said nematode worms contain a marker gene operably linked to a promoter,

which promoter is capable of driving the expression of the marker gene in the nematode worms such that the marker gene is not expressed in at

10   least a first development stage of the nematodes, but is expressed in at least a second development stage of the nematodes (different from the first life stage);

b)   exposing said sample of nematode worms to at least one exogenous factor;

c)   maintaining/cultivating said sample of nematode worms in a suitable medium,

15   optionally over one or more life stages and/or generations;

d)   subjecting the sample of nematode worms to at least one detection technique that is capable of detecting the signal generated by the marker gene (if expressed).

2. Method for determining the influence of at least a first exogenous factor on the

20   development and/or growth of a sample of nematode worms, said method comprising:

a)   providing at least a first and a second sample of nematode worms,

in which the nematode worms in each sample contain a marker gene operably linked to a promoter,

which promoter is capable of driving the expression of the marker gene in

25   the nematode worms such that the marker gene is not expressed in at least a first development stage of the nematodes, but is expressed in at least a second development stage of the nematodes (different from the first life stage);

b)   exposing at least said first sample of nematode worms to said first one exogenous

30   factor;

c)   maintaining/cultivating said samples of nematode worms in a suitable medium, optionally over one or more life stages and/or generations;

d)   subjecting the samples of nematode worms to at least one detection technique that is capable of detecting the signal generated by the marker gene (if expressed);

e) determining the time required for the first sample of nematode worms to show expression of the marker gene (as determined by the signal detected for the first sample in step b)), and preferably also determining the time required for the second sample of nematode worms to show expression of the marker gene (as determined by the signal detected for the second sample in step b)); and/or comparing the time required for the first sample of nematode worms to show expression of the marker gene with the time required for the second sample of nematode worms to show expression of the marker gene.

3. Method according to claim 2, in which the second sample of nematode worms is not exposed to any exogenous factor.

4. Method according to claim 2, in which the second sample of nematode worms is exposed to a second exogenous factor.

5. Method according to any of the preceding claims, in which nematodes used are preferably from the genus *Caenorhabditis*, such as from *Caenorhabditis briggsae* or *Caenorhabditis elegans*.

6. Method according to claim any of the preceding claims, in which the first development stage is chosen from eggs, an embryonal stage, L1, L2 and dauer.

7. Method according to claim any of the preceding claims, in which the first development stage is L1.

8. Method according to claim any of the preceding claims, in which the first development stage is chosen from L4, adult or dauer.

9. Method according to any of the preceding claims, in which the promoter chosen from any one of the following promoters: gpl-1, unc-54, myo-2, lin-28, lin-4, lin-14, col-7, col-19, col-17, ctl-1, sod-3, vit-2.

10. Method according to any of the preceding claims, in which the promoter is the vit-2 promoter.

11. Method according to any of the preceding claims, in which marker gene is chosen from green fluorescent protein, beta-galactosidase, beta-lactamase, luciferase, acetohydroxyacid synthase, alkaline phosphatase, beta-glucuronidse, chloramphenicol acetyltransferase, horseradish peroxidase, nopaline synthase and/or octapine synthase.

12. Method according to any of the preceding claims, in which marker gene encodes a gene product that is toxic (e.g. lethal) to the nematode.

13. Method according to any of the preceding claims, in which step d) is carried out using a non-visual detection technique.

14. Method according to any of the preceding claims, which is carried out in multi-well plate format.

15. Method according to any of the preceding claims, which is carried out in an automated fashion.

16. Method according to any of the preceding claims, in which the at least one exogenous factor is at least one small compound or at least one small peptide.

17. Method according to any of the preceding claims, in which the at least one exogenous factor is a double stranded RNA sequence, suitable or intended for suppression the expression of at least one nucleotide sequence in the nematode worm by means of RNA interference.

18. Method according to any of the preceding claims, in which the nematode worms have been subjected to mutagenesis prior to use in step a).

19. Use of a (sample of at least one) nematode worm, which nematode worm contains a marker gene operably linked to a promoter, which promoter is capable of driving the expression of the marker gene in the nematode worms such that the marker gene is not expressed in at least a first development stage of the nematodes, but is expressed in at least a second development stage of the nematodes (different from the

first life stage), in a method or assay for determining the influence of at least one exogenous factor on the development and/or growth on a nematode worm.

5   20. Use according to claim 19, in which nematodes used are preferably from the genus *Caenorhabditis*, such as from *Caenorhabditis briggsae* or *Caenorhabditis elegans*.

21. Use according to claim 19 or 20, in which the promoter chosen from any one of the following promoters: gpl-1, unc-54, myo-2, lin-28, lin-4, lin-14, col-7, col-19, col-17,
10   ctl-1, sod-3, vit-2.

22. Use according to any of claims 19-21, in which the promoter is the vit-2 promoter.

15   23. Use according to any of claims 19-22, in which the marker gene is chosen from green fluorescent protein, beta-galactosidase, beta-lactamase, luciferase, acetohydroxyacid synthase, alkaline phosphatase, beta-glucuronidse, chloramphenicol acetyltransferase, horseradish peroxidase, nopaline synthase and/or octapine synthase.

20   24. Use according to any of claims 19-22, in which the marker gene encodes a gene product that is toxic (e.g. lethal) to the nematode.

FIG. 1. Nucleotide sequence of pGQ1

```
ATGACCATGA TTACGCCAAG CTTGCATGCC TGCAGCCAAT GCATTGGAAG
AGATATTTTG CGCGTCAAAT ATGTTTTGTG TCCCCGTAAT ATTTTTTTAA
ATCAAATTTC ACATTTTAAC CATAAAAAAC TCTTTCAAAA GTGTAATTTT
CTACGCAAAA ATGCCGTTCG GATGAAAAAT TACTTTTGAA AAACAAACTC
GAAACTACGG TACGCAAAAA AGTACATCGG TGTTTGCACA TAAGTGAAAA
CAATGTTGTT TTTTTGTAAT TAAAATCGAT TAATTTTTTT TCCCGGAAAA
CAAAAACGTT TTCAGCGTGG ATTTCTATTG TTTCTTGCGT AAAAAAAAAT
TATTTACCAA TTTTAAACGA TAATTTCCAC GAATTTTCGC CATTAATCTC
TCGATTTTGT TGATTCTTGA CTCCGAGCAA TCTCTCCGGT TTTCGCAAAC
GATTATATTA TTTATTTGTT TTCCTTTTCA GTGCCGATTC TCGGAAATTC
AACAGTAAAT CTTCAAAATG CCAATGCTTC CCCACATGGT CAATCTAAGT
GAGTTTCTTT GTTACAAAAT ACACGTGATG TCAGATTGTC TCATTTCGGT
TTGATCTACG TAGATCTACA AAAAATGCGG GAATTGAGCC GCAGAGTTCT
CAACTGCTTT CGCATGGTTA AGAACGTGCG GACGTCAAAT TGTTTTGGGC
AAAAATTCCC GCATTTTTTG TAGATCAAAC CGTAATGGGA CAGTCTGGCA
CCACGTGACT ATATATTTTT AGCGGTCAAC GACACAAAAC CCGGACCAAT
GGCTGAGGAT CAGCTGAAAG CTTATAGAGA TAGAAATCAG GTGAGAAAAA
TCAATTTCAG CGATTTTCTT CGCAATTTAT ATAAAAACTG ATTTTTCCAG
GAACCCCACC TGCTCACCAC ATCCAATGGA GCTCCGATCT ACTCGAAGAC
CGCCGTGCTC ACCGCCGGAC GACGTGGTCC AATGCTAATG CAGGACATCG
TTTATATGGA CGAGATGGCT CATTTCGATC GTGAACGCAT CCCGGAGCGT
GTCGTCCATG CCAAAGGTGG TGGTGCTCAT GGATACTTCG AGGTCACCCA
TGACATCACC AAGTACTGTA AGGCCGATAT GTTCAACAAG GTCGGAAAAC
AGACACCACT TCTCGTTCGT TTTTCAACGG TCGCTGGAGA ATCGGCCGGA
TCCCCGGGAT TGGCCAAAGG ACCCAAAGGT ATGTTTCGAA TGATACTAAC
ATAACATAGA ACATTTTCAG GAGGACCCTT GGCTAGCGTC GACGGTACCA
TGGGGCGCGC CATGAGTAAA GGAGAAGAAC TTTTCACTGG AGTTGTCCCA
ATTCTTGTTG AATTAGATGG TGATGTTAAT GGGCACAAAT TTTCTGTCAG
TGGAGAGGGT GAAGGTGATG CAACATACGG AAAACTTACC CTTAAATTTA
TTTGCACTAC TGGAAAACTA CCTGTTCCAT GGGTAAGTTT AAACATATAT
ATACTAACTA ACCCTGATTA TTTAAATTTT CAGCCAACAC TTGTCACTAC
TTTCTGTTAT GGTGTTCAAT GCTTCTCGAG ATACCCAGAT CATATGAAAC
GGCATGACTT TTTCAAGAGT GCCATGCCCG AAGGTTATGT ACAGGAAAGA
ACTATATTTT TCAAAGATGA CGGGAACTAC AAGACACGTA AGTTTAAACA
GTTCGGTACT AACTAACCAT ACATATTTAA ATTTTCAGGT GCTGAAGTCA
AGTTTGAAGG TGATACCCTT GTTAATAGAA TCGAGTTAAA AGGTATTGAT
TTTAAAGAAG ATGGAAACAT TCTTGGACAC AAAATTGGAAT ACAACTATAA
CTCACACAAT GTATACATCA TGGCAGACAA ACAAAGAAT GGAATCAAAG
TTGTAAGTTT AAACTTGGAC TTACTAACTA ACGGATTATA TTTAAATTTT
CAGAACTTCA AAATTAGACA CAACATTGAA GATGGAAGCG TTCAACTAGC
AGACCATTAT CAACAAAATA CTCCAATTGG CGATGGCCCT GTCCTTTTAC
CAGACAACCA TTACCTGTCC ACACAATCTG CCCTTTCGAA AGATCCCAAC
GAAAAGAGAG ACCACATGGT CCTTCTTGAG TTTGTAACAG CTGCTGGGAT
TACACATGGC ATGGATGAAC TATACAAATA GGGCCGGCCG AGCTCCGCAT
CGGCCGCTGT CATCAGATCG CCATCTCGCG CCCGTGCCTC TGACTTCTAA
GTCCAATTAC TCTTCAACAT CCCTACATGC TCTTTCTCCC TGTGCTCCCA
CCCCCTATTT TTGTTATTAT CAAAAAAACT TCTTCTTAAT TTCTTTGTTT
TTTAGCTTCT TTTAAGTCAC CTCTAACAAT GAAATTGTGT AGATTCAAAA
ATAGAATTAA TTCGTAATAA AAAGTCGAAA AAAATTGTGC TCCCTCCCCC
```

FIG. 1 (CONTINUED 1).

```
CATTAATAAT AATTCTATCC CAAAATCTAC ACAATGTTCT GTGTACACTT
CTTATGTTTT TTTTACTTCT GATAAATTTT TTTTGAAACA TCATAGAAAA
AACCGCACAC AAAATACCTT ATCATATGTT ACGTTTCAGT TTATGACCGC
AATTTTTATT TCTTCGCACG TCTGGGCCTC TCATGACGTC AAATCATGCT
CATCGTGAAA AAGTTTTGGA GTATTTTTGG AATTTTTCAA TCAAGTGAAA
GTTTATGAAA TTAATTTTCC TGCTTTTGCT TTTTGGGGGT TTCCCCTATT
GTTTGTCAAG AGTTTCGAGG ACGGCGTTTT TCTTGCTAAA ATCACAAGTA
TTGATGAGCA CGATGCAAGA AAGATCGGAA GAAGGTTTGG GTTTGAGGCT
CAGTGGAAGG TGAGTAGAAG TTGATAATTT GAAAGTGGAG TAGTGTCTAT
GGGGTTTTTG CCTTAAATGA CAGAATACAT TCCCAATATA CCAAACATAA
CTGTTTCCTA CTAGTCGGCC GTACGGGCCC TTTCGTCTCG CGCGTTTCGG
TGATGACGGT GAAAACCTCT GACACATGCA GCTCCCGGAG ACGGTCACAG
CTTGTCTGTA AGCGGATGCC GGGAGCAGAC AAGCCCGTCA GGGCGCGTCA
GCGGGTGTTG GCGGGTGTCG GGGCTGGCTT AACTATGCGG CATCAGAGCA
GATTGTACTG AGAGTGCACC ATATGCGGTG TGAAATACCG CACAGATGCG
TAAGGAGAAA ATACCGCATC AGGCGGCCTT AAGGGCCTCG TGATACGCCT
ATTTTTATAG GTTAATGTCA TGATAATAAT GGTTTCTTAG ACGTCAGGTG
GCACTTTTCG GGGAAATGTG CGCGGAACCC CTATTTGTTT ATTTTTCTAA
ATACATTCAA ATATGTATCC GCTCATGAGA CAATAACCCT GATAAATGCT
TCAATAATAT TGAAAAAGGA AGAGTATGAG TATTCAACAT TTCCGTGTCG
CCCTTATTCC CTTTTTTGCG GCATTTTGCC TTCCTGTTTT TGCTCACCCA
GAAACGCTGG TGAAAGTAAA AGATGCTGAA GATCAGTTGG GTGCACGAGT
GGGTTACATC GAACTGGATC TCAACAGCGG TAAGATCCTT GAGAGTTTTC
GCCCCGAAGA ACGTTTTCCA ATGATGAGCA CTTTTAAAGT TCTGCTATGT
GGCGCGGTAT TATCCCGTAT TGACGCCGGG CAAGAGCAAC TCGGTCGCCG
CATACACTAT TCTCAGAATG ACTTGGTTGA GTACTCACCA GTCACAGAAA
AGCATCTTAC GGATGGCATG ACAGTAAGAG AATTATGCAG TGCTGCCATA
ACCATGAGTG ATAACACTGC GGCCAACTTA CTTCTGACAA CGATCGGAGG
ACCGAAGGAG CTAACCGCTT TTTTGCACAA CATGGGGGAT CATGTAACTC
GCCTTGATCG TTGGGAACCG GAGCTGAATG AAGCCATACC AAACGACGAG
CGTGACACCA CGATGCCTGT AGCAATGGCA ACAACGTTGC GCAAACTATT
AACTGGCGAA CTACTTACTC TAGCTTCCCG GCAACAATTA ATAGACTGGA
TGGAGGCGGA TAAAGTTGCA GGACCACTTC TGCGCTCGGC CCTTCCGGCT
GGCTGGTTTA TTGCTGATAA ATCTGGAGCC GGTGAGCGTG GGTCTCGCGG
TATCATTGCA GCACTGGGGC CAGATGGTAA GCCCTCCCGT ATCGTAGTTA
TCTACACGAC GGGGAGTCAG GCAACTATGG ATGAACGAAA TAGACAGATC
GCTGAGATAG GTGCCTCACT GATTAAGCAT TGGTAACTGT CAGACCAAGT
TTACTCATAT ATACTTTAGA TTGATTTAAA ACTTCATTTT TAATTTAAAA
GGATCTAGGT GAAGATCCTT TTTGATAATC TCATGACCAA AATCCCTTAA
CGTGAGTTTT CGTTCCACTG AGCGTCAGAC CCCGTAGAAA AGATCAAAGG
ATCTTCTTGA GATCCTTTTT TTCTGCGCGT AATCTGCTGC TTGCAAACAA
AAAAACCACC GCTACCAGCG GTGGTTTGTT TGCCGGATCA AGAGCTACCA
ACTCTTTTTC CGAAGGTAAC TGGCTTCAGC AGAGCGCAGA TACCAAATAC
TGTCCTTCTA GTGTAGCCGT AGTTAGGCCA CCACTTCAAG AACTCTGTAG
CACCGCCTAC ATACCTCGCT CTGCTAATCC TGTTACCAGT GGCTGCTGCC
AGTGGCGATA AGTCGTGTCT TACCGGGTTG GACTCAAGAC GATAGTTACC
GGATAAGGCG CAGCGGTCGG GCTGAACGGG GGGTTCGTGC ACACAGCCCA
GCTTGGAGCG AACGACCTAC ACCGAACTGA GATACCTACA GCGTGAGCAT
TGAGAAAGCG CCACGCTTCC CGAAGGGAGA AAGGCGGACA GGTATCCGGT
AAGCGGCAGG GTCGGAACAG GAGAGCGCAC GAGGGAGCTT CCAGGGGGAA
ACGCCTGGTA TCTTTATAGT CCTGTCGGGT TTCGCCACCT CTGACTTGAG
```

FIG. 1(CONTINUED 2).

```
CGTCGATTTT TGTGATGCTC GTCAGGGGGG CGGAGCCTAT GGAAAAACGC
CAGCAACGCG GCCTTTTTAC GGTTCCTGGC CTTTTGCTGG CCTTTTGCTC
ACATGTTCTT TCCTGCGTTA TCCCCTGATT CTGTGGATAA CCGTATTACC
GCCTTTGAGT GAGCTGATAC CGCTCGCCGC AGCCGAACGA CCGAGCGCAG
CGAGTCAGTG AGCGAGGAAG CGGAAGAGCG CCCAATACGC AAACCGCCTC
TCCCCGCGCG TTGGCCGATT CATTAATGCA GCTGGCACGA CAGGTTTCCC
GACTGGAAAG CGGGCAGTGA GCGCAACGCA ATTAATGTGA GTTAGCTCAC
TCATTAGGCA CCCCAGGCTT TACACTTTAT GCTTCCGGCT CGTATGTTGT
GTGGAATTGT GAGCGGATAA CAATTTCACA CAGGAAACAG CT
```

4/27

FIG. 2. Nucleotide sequence of PCLUC6

```
ATGACTGCTC CAAAGAAGAA GCGTAAGGTA CCGGTAGAAA AAATGGAAGA
CGCCAAAAAC ATAAAGAAAG GCCCGGCGCC ATTCTATCCG CTGGAAGATG
GAACCGCTGG AGAGCAACTG CATAAGGCTA TGAAGAGATA CGCCCTGGTT
CCTGGAACAA TTGCTTTTAC AGATGCACAT ATCGAGGTGG ACATCACTTA
CGCTGAGTAC TTCGAAATGT CCGTTCGGTT GGCAGAAGCT ATGAAACGAT
ATGGGCTGAA TACAAATCAC AGAATCGTCG TATGCAGTGA AAACTCTCTT
CAATTCTTTA TGCCGGTGTT GGGCGCGTTA TTTATCGGAG TTGCAGTTGC
GCCCGCGAAC GACATTTATA ATGAACGTGA ATTGCTCAAC AGTATGGGCA
TTTCGCAGCC TACCGTGGTG TTCGTTTCCA AAAAGGGGTT GCAAAAAATT
TTGAACGTGC AAAAAAAGCT CCCAATCATC CAAAAAATTA TTATCATGGA
TTCTAAAACG GATTACCAGG GATTTCAGTC GATGTACACG TTCGTCACAT
CTCATCTACC TCCCGGTTTT AATGAATACG ATTTTGTGCC AGAGTCCTTC
GATAGGGACA AGACAATTGC ACTGATCATG AACTCCTCTG GATCTACTGG
TCTGCCTAAA GGTGTCGCTC TGCCTCATAG AACTGCCTGC GTGAGATTCT
CGCATGCCAG AGATCCTATT TTTGGCAATC AAATCATTCC GGATACTGCG
ATTTTAAGTG TTGTTCCATT CCATCACGGT TTTGGAATGT TTACTACACT
CGGATATTTG ATATGTGGAT TTCGAGTCGT CTTAATGTAT AGATTTGAAG
AAGAGCTGTT TCTGAGGAGC CTTCAGGATT ACAAGATTCA AAGTGCGCTG
CTGGTGCCAA CCCTATTCTC CTTCTTCGCC AAAAGCACTC TGATTGACAA
ATACGATTTA TCTAATTTAC ACGAAATTGC TTCTGGTGGC GCTCCCCTCT
CTAAGGAAGT CGGGGAAGCG GTTGCCAAGA GGTTCCATCT GCCAGGTATC
AGGCAAGGAT ATGGGCTCAC TGAGACTACA TCAGCTATTC TGATTACACC
CGAGGGGGAT GATAAACCGG GCGCGGTCGG TAAAGTTGTT CCATTTTTTG
AAGCGAAGGT TGTGGATCTG GATACCGGGA AAACGCTGGG CGTTAATCAA
AGAGGCGAAC TGTGTGTGAG AGGTCCTATG ATTATGTCCG GTTATGTAAA
CAATCCGGAA GCGACCAACG CCTTGATTGA CAAGGATGGA TGGCTACATT
CTGGAGACAT AGCTTACTGG GACGAAGACG AACACTTCTT CATCGTTGAC
CGCCTGAAGT CTCTGATTAA GTACAAAGGC TATCAGGTGG CTCCCGCTGA
ATTGGAATCC ATCTTGCTCC AACACCCCAA CATCTTCGAC GCAGGTGTCG
CAGGTCTTCC CGACGATGAC GCCGGTGAAC TTCCCGCCGC CGTTGTTGTT
TTGGAGCACG GAAAGACGAT GACGGAAAAA GAGATCGTGG ATTACGTCGC
CAGTCAAGTA ACAACCGCGA AAAAGTTGCG CGGAGGAGTT GTGTTTGTGG
ACGAAGTACC GAAAGGTCTT ACCGGAAAAC TCGACGCAAG AAAAATCAGA
GAGATCCTCA TAAAGGCCAA GAAGGGCGGA AAGATCGCCG TGTAATTCTA
GGAATTCCAA CTGAGCGCCG GTCGCTACCA TTACCAACTT GTCTGGTGTC
AAAAATAATA GGGGCCGCTG TCATCAGAGT AAGTTTAAAC TGAGTTCTAC
TAACTAACGA GTAATATTTA AATTTTCAGC ATCTCGCGCC CGTGCCTCTG
ACTTCTAAGT CCAATTACTC TTCAACATCC CTACATGCTC TTTCTCCCTG
TGCTCCCACC CCCTATTTTT GTTATTATCA AAAAAACTTC TTCTTAATTT
CTTTGTTTTT TAGCTTCTTT TAAGTCACCT CTAACAATGA AATTGTGTAG
ATTCAAAAAT AGAATTAATT CGTAATAAAA AGTCGAAAAA AATTGTGCTC
CCTCCCCCCA TTAATAATAA TTCTATCCCA AAATCTACAC AATGTTCTGT
GTACACTTCT TATGTTTTTT TTACTTCTGA TAAATTTTTT TTGAAACATC
ATAGAAAAAA CCGCACACAA AATACCTTAT CATATGTTAC GTTTCAGTTT
ATGACCGCAA TTTTTATTTC TTCGCACGTC TGGGCCTCTC ATGACGTCAA
ATCATGCTCA TCGTGAAAAA GTTTTGGAGT ATTTTTGGAA TTTTTCAATC
AAGTGAAAGT TTATGAAATT AATTTTCCTG CTTTTGCTTT TTGGGGGTTT
CCCCTATTGT TTGTCAAGAG TTTCGAGGAC GGCGTTTTTC TTGCTAAAAT
CACAAGTATT GATGAGCACG ATGCAAGAAA GATCGGAAGA AGGTTTGGGT
```

FIG. 2 (CONTINUED 1).

```
TTGAGGCTCA GTGGAAGGTG AGTAGAAGTT GATAATTTGA AAGTGGAGTA
GTGTCTATGG GGTTTTTGCC TTAAATGACA GAATACATTC CCAATATACC
AAACATAACT GTTTCCTACT AGTCGGCCGT ACGGGCCCTT TCGTCTCGCG
CGTTTCGGTG ATGACGGTGA AAACCTCTGA CACATGCAGC TCCCGGAGAC
GGTCACAGCT TGTCTGTAAG CGGATGCCGG GAGCAGACAA GCCCGTCAGG
GCGCGTCAGC GGGTGTTGGC GGGTGTCGGG CTGGCTTAA CTATGCGGCA
TCAGAGCAGA TTGTACTGAG AGTGCACCAT ATGCGGTGTG AAATACCGCA
CAGATGCGTA AGGAGAAAAT ACCGCATCAG GCGGCCTTAA GGGCCTCGTG
ATACGCCTAT TTTTATAGGT TAATGTCATG ATAATAATGG TTTCTTAGAC
GTCAGGTGGC ACTTTTCGGG GAAATGTGCG CGGAACCCCT ATTTGTTTAT
TTTTCTAAAT ACATTCAAAT ATGTATCCGC TCATGAGACA ATAACCCTGA
TAAATGCTTC AATAATATTG AAAAAGGAAG AGTATGAGTA TTCAACATTT
CCGTGTCGCC CTTATTCCCT TTTTTGCGGC ATTTTGCCTT CCTGTTTTTG
CTCACCCAGA AACGCTGGTG AAAGTAAAAG ATGCTGAAGA TCAGTTGGGT
GCACGAGTGG GTTACATCGA ACTGGATCTC AACAGCGGTA AGATCCTTGA
GAGTTTTCGC CCCGAAGAAC GTTTTCCAAT GATGAGCACT TTTAAAGTTC
TGCTATGTGG CGCGGTATTA TCCCGTATTG ACGCCGGGCA AGAGCAACTC
GGTCGCCGCA TACACTATTC TCAGAATGAC TTGGTTGAGT ACTCACCAGT
CACAGAAAAG CATCTTACGG ATGGCATGAC AGTAAGAGAA TTATGCAGTG
CTGCCATAAC CATGAGTGAT AACACTGCGG CCAACTTACT TCTGACAACG
ATCGGAGGAC CGAAGGAGCT AACCGCTTTT TTGCACAACA TGGGGGATCA
TGTAACTCGC CTTGATCGTT GGGAACCGGA GCTGAATGAA GCCATACCAA
ACGACGAGCG TGACACCACG ATGCCTGTAG CAATGGCAAC AACGTTGCGC
AAACTATTAA CTGGCGAACT ACTTACTCTA GCTTCCCGGC AACAATTAAT
AGACTGGATG GAGGCGGATA AAGTTGCAGG ACCACTTCTG CGCTCGGCCC
TTCCGGCTGG CTGGTTTATT GCTGATAAAT CTGGAGCCGG TGAGCGTGGG
TCTCGCGGTA TCATTGCAGC ACTGGGGCCA GATGGTAAGC CCTCCCGTAT
CGTAGTTATC TACACGACGG GGAGTCAGGC AACTATGGAT GAACGAAATA
GACAGATCGC TGAGATAGGT GCCTCACTGA TTAAGCATTG GTAACTGTCA
GACCAAGTTT ACTCATATAT ACTTTAGATT GATTTAAAAC TTCATTTTTA
ATTTAAAAGG ATCTAGGTGA AGATCCTTTT TGATAATCTC ATGACCAAAA
TCCCTTAACG TGAGTTTTCG TTCCACTGAG CGTCAGACCC CGTAGAAAAG
ATCAAAGGAT CTTCTTGAGA TCCTTTTTTT CTGCGCGTAA TCTGCTGCTT
GCAAACAAAA AAACCACCGC TACCAGCGGT GGTTTGTTTG CCGGATCAAG
AGCTACCAAC TCTTTTTCCG AAGGTAACTG GCTTCAGCAG AGCGCAGATA
CCAAATACTG TCCTTCTAGT GTAGCCGTAG TTAGGCCACC ACTTCAAGAA
CTCTGTAGCA CCGCCTACAT ACCTCGCTCT GCTAATCCTG TTACCAGTGG
CTGCTGCCAG TGGCGATAAG TCGTGTCTTA CCGGGTTGGA CTCAAGACGA
TAGTTACCGG ATAAGGCGCA GCGGTCGGGC TGAACGGGGG GTTCGTGCAC
ACAGCCCAGC TTGGAGCGAA CGACCTACAC CGAACTGAGA TACCTACAGC
GTGAGCATTG AGAAAGCGCC ACGCTTCCCG AAGGGAGAAA GGCGGACAGG
TATCCGGTAA GCGGCAGGGT CGGAACAGGA GAGCGCACGA GGGAGCTTCC
AGGGGGAAAC GCCTGGTATC TTTATAGTCC TGTCGGGTTT CGCCACCTCT
GACTTGAGCG TCGATTTTTG TGATGCTCGT CAGGGGGGCG GAGCCTATGG
AAAAACGCCA GCAACGCGGC CTTTTTACGG TTCCTGGCCT TTTGCTGGCC
TTTTGCTCAC ATGTTCTTTC CTGCGTTATC CCCTGATTCT GTGGATAACC
GTATTACCGC CTTTGAGTGA GCTGATACCG CTCGCCGCAG CCGAACGACC
GAGCGCAGCG AGTCAGTGAG CGAGGAAGCG GAAGAGCGCC CAATACGCAA
ACCGCCTCTC CCCGCGCGTT GGCCGATTCA TTAATGCAGC TGGCACGACA
GGTTTCCCGA CTGGAAAGCG GGCAGTGAGC GCAACGCAAT TAATGTGAGT
TAGCTCACTC ATTAGGCACC CCAGGCTTTA CACTTTATGC TTCCGGCTCG
```

FIG. 2(CONTINUED 2).

```
TATGTTGTGT GGAATTGTGA GCGGATAACA ATTTCACACA GGAAACAGCT
ATGACCATGA TTACGCCAAG CTGTAAGTTT AAACATGATC TTACTAACTA
ACTATTCTCA TTTAAATTTT CAGAGCTTAA AAATGGCTGA AATCACTCAC
AACGATGGAT ACGCTAACAA CTTGGAAATG AAATAAGCTT GCATGCCTGC
AGGCCTTGGT CGACTCTAGA GGATCAAACT GTATTACTTG AAACAATTTA
GTTATATGTT TAGAACCCCT CATTCAAAAT TAATAGACAG GGCTCTCACC
GAATGTTGCA ATTTGTTTCT GATAAGGGTC ACAAAGCGGA GCGAATGCTT
GAATGTGTCC ATCAATGAGC TTATCAATGC GCTAAAACGC TATAACTTCC
ATATGAAGTC AATCGAACAT ATGTCAATCT TTAGCCGTAT ATAAAGGTGC
ACTGAAAACA GTCCAATCAC GGTTCAGCCA TGAGGTCGAT CCCCGGCCGG
GATTGGCCAA AGGACCCAAA GGTATGTTTC GAATGATACT AACATAACAT
AGAACATTTT CAGGAGGACC CTTGGAGGGT ACCGGGGATT GGCCAAAGGA
CCCAAAGGTA TGTTTCGAAT GATACTAACA TAACATAGAA CATTTTCAGG
AGGACCCTTG CTTGGAGGGT ACCGAGCTCA GAAAAA
```

FIG. 3. Nucleotide sequence of pGQ2

```
ATGACTGCTC CAAAGAAGAA GCGTAAGGTA CCGGTAGAAA AAATGGAAGA
CGCCAAAAAC ATAAAGAAAG GCCCGGCGCC ATTCTATCCG CTGGAAGATG
GAACCGCTGG AGAGCAACTG CATAAGGCTA TGAAGAGATA CGCCCTGGTT
CCTGGAACAA TTGCTTTTAC AGATGCACAT ATCGAGGTGG ACATCACTTA
CGCTGAGTAC TTCGAAATGT CCGTTCGGTT GGCAGAAGCT ATGAAACGAT
ATGGGCTGAA TACAAATCAC AGAATCGTCG TATGCAGTGA AAACTCTCTT
CAATTCTTTA TGCCGGTGTT GGGCGCGTTA TTTATCGGAG TTGCAGTTGC
GCCCGCGAAC GACATTTATA ATGAACGTGA ATTGCTCAAC AGTATGGGCA
TTTCGCAGCC TACCGTGGTG TTCGTTTCCA AAAAGGGGTT GCAAAAAATT
TTGAACGTGC AAAAAAAGCT CCCAATCATC CAAAAAATTA TTATCATGGA
TTCTAAAACG GATTACCAGG GATTTCAGTC GATGTACACG TTCGTCACAT
TTCATCTACC TCCCGGTTTT AATGAATACG ATTTTGTGCC AGAGTCCTTC
GATAGGGACA AGACAATTGC ACTGATCATG AACTCCTCTG GATCTACTGG
TCTGCCTAAA GGTGTCGCTC TGCCTCATAG AACTGCCTGC GTGAGATTCT
CGCATGCCAG AGATCCTATT TTTGGCAATC AAATCATTCC GGATACTGCG
ATTTTAAGTG TTGTTCCATT CCATCACGGT TTTGGAATGT TTACTACACT
CGGATATTTG ATATGTGGAT TTCGAGTCGT CTTAATGTAT AGATTTGAAG
AAGAGCTGTT TCTGAGGAGC CTTCAGGATT ACAAGATTCA AAGTGCGCTG
CTGGTGCCAA CCCTATTCTC CTTCTTCGCC AAAAGCACTC TGATTGACAA
ATACGATTTA TCTAATTTAC ACGAAATTGC TTCTGGTGGC GCTCCCCTCT
CTAAGGAAGT CGGGGAAGCG GTTGCCAAGA GGTTCCATCT GCCAGGTATC
AGGCAAGGAT ATGGGCTCAC TGAGACTACA TCAGCTATTC TGATTACACC
CGAGGGGGAT GATAAACCGG GCGCGGTCGG TAAAGTTGTT CCATTTTTTG
AAGCGAAGGT TGTGGATCTG GATACCGGGA AAACGCTGGG CGTTAATCAA
AGAGGCGAAC TGTGTGTGAG AGGTCCTATG ATTATGTCCG GTTATGTAAA
CAATCCGGAA GCGACCAACG CCTTGATTGA CAAGGATGGA TGGCTACATT
CTGGAGACAT AGCTTACTGG GACGAAGACG AACACTTCTT CATCGTTGAC
CGCCTGAAGT CTCTGATTAA GTACAAAGGC TATCAGGTGG CTCCCGCTGA
ATTGGAATCC ATCTTGCTCC AACACCCCAA CATCTTCGAC GCAGGTGTCG
CAGGTCTTCC CGACGATGAC GCCGGTGAAC TTCCCGCCGC CGTTGTTGTT
TTGGAGCACG GAAAGACGAT GACGGAAAAA GAGATCGTGG ATTACGTCGC
CAGTCAAGTA ACAACCGCGA AAAAGTTGCG CGGAGGAGTT GTGTTTGTGG
ACGAAGTACC GAAAGGTCTT ACCGGAAAAC TCGACGCAAG AAAAATCAGA
GAGATCCTCA TAAAGGCCAA GAAGGGCGGA AAGATCGCCG TGTAATTCTA
GGAATTCCAA CTGAGCGCCG GTCGCTACCA TTACCAACTT GTCTGGTGTC
AAAAATAATA GGGGCCGCTG TCATCAGAGT AAGTTTAAAC TGAGTTCTAC
TAACTAACGA GTAATATTTA AATTTTCAGC ATCTCGCGCC CGTGCCTCTG
ACTTCTAAGT CCAATTACTC TTCAACATCC CTACATGCTC TTTCTCCCTG
TGCTCCCACC CCCTATTTTT GTTATTATCA AAAAAACTTC TTCTTAATTT
CTTTGTTTTT TAGCTTCTTT TAAGTCACCT CTAACAATGA AATTGTGTAG
ATTCAAAAAT AGAATTAATT CGTAATAAAA AGTCGAAAAA AATTGTGCTC
CCTCCCCCCA TTAATAATAA TTCTATCCCA AAATCTACAC AATGTTCTGT
GTACACTTCT TATGTTTTTT TTACTTCTGA TAAATTTTTT TTGAAACATC
ATAGAAAAAA CCGCACACAA AATACCTTAT CATATGTTAC GTTTCAGTTT
ATGACCGCAA TTTTTATTTC TTCGCACGTC TGGGCCTCTC ATGACGTCAA
ATCATGCTCA TCGTGAAAAA GTTTTGGAGT ATTTTTGGAA TTTTTCAATC
AAGTGAAAGT TTATGAAATT AATTTTCCTG CTTTTGCTTT TTGGGGGTTT
CCCCTATTGT TTGTCAAGAG TTTCGAGGAC GGCGTTTTTC TTGCTAAAAT
CACAAGTATT GATGAGCACG ATGCAAGAAA GATCGGAAGA AGGTTTGGGT
```

8/27

FIG. 3 (CONTINUED 1).

```
TTGAGGCTCA GTGGAAGGTG AGTAGAAGTT GATAATTTGA AAGTGGAGTA
GTGTCTATGG GGTTTTTGCC TTAAATGACA GAATACATTC CCAATATACC
AAACATAACT GTTTCCTACT AGTCGGCCGT ACGGGCCCTT TCGTCTCGCG
CGTTTCGGTG ATGACGGTGA AAACCTCTGA CACATGCAGC TCCCGGAGAC
GGTCACAGCT TGTCTGTAAG CGGATGCCGG GAGCAGACAA GCCCGTCAGG
GCGCGTCAGC GGGTGTTGGC GGGTGTCGGG GCTGGCTTAA CTATGCGGCA
TCAGAGCAGA TTGTACTGAG AGTGCACCAT ATGCGGTGTG AAATACCGCA
CAGATGCGTA AGGAGAAAAT ACCGCATCAG GCGGCCTTAA GGGCCTCGTG
ATACGCCTAT TTTTATAGGT TAATGTCATG ATAATAATGG TTTCTTAGAC
GTCAGGTGGC ACTTTTCGGG GAAATGTGCG CGGAACCCCT ATTTGTTTAT
TTTTCTAAAT ACATTCAAAT ATGTATCCGC TCATGAGACA ATAACCCTGA
TAAATGCTTC AATAATATTG AAAAAGGAAG AGTATGAGTA TTCAACATTT
CCGTGTCGCC CTTATTCCCT TTTTTGCGGC ATTTTGCCTT CCTGTTTTTG
CTCACCCAGA AACGCTGGTG AAAGTAAAAG ATGCTGAAGA TCAGTTGGGT
GCACGAGTGG GTTACATCGA ACTGGATCTC AACAGCGGTA AGATCCTTGA
GAGTTTTCGC CCCGAAGAAC GTTTTCCAAT GATGAGCACT TTTAAAGTTC
TGCTATGTGG CGCGGTATTA TCCCGTATTG ACGCCGGGCA AGAGCAACTC
GGTCGCCGCA TACACTATTC TCAGAATGAC TTGGTTGAGT ACTCACCAGT
CACAGAAAAG CATCTTACGG ATGGCATGAC AGTAAGAGAA TTATGCAGTG
CTGCCATAAC CATGAGTGAT AACACTGCGG CCAACTTACT TCTGACAACG
ATCGGAGGAC CGAAGGAGCT AACCGCTTTT TTGCACAACA TGGGGGATCA
TGTAACTCGC CTTGATCGTT GGGAACCGGA GCTGAATGAA GCCATACCAA
ACGACGAGCG TGACACCACG ATGCCTGTAG CAATGGCAAC AACGTTGCGC
AAACTATTAA CTGGCGAACT ACTTACTCTA GCTTCCCGGC AACAATTAAT
AGACTGGATG GAGGCGGATA AAGTTGCAGG ACCACTTCTG CGCTCGGCCC
TTCCGGCTGG CTGGTTTATT GCTGATAAAT CTGGAGCCGG TGAGCGTGGG
TCTCGCGGTA TCATTGCAGC ACTGGGGCCA GATGGTAAGC CCTCCCGTAT
CGTAGTTATC TACACGACGG GGAGTCAGGC AACTATGGAT GAACGAAATA
GACAGATCGC TGAGATAGGT GCCTCACTGA TTAAGCATTG GTAACTGTCA
GACCAAGTTT ACTCATATAT ACTTTAGATT GATTTAAAAC TTCATTTTTA
ATTTAAAAGG ATCTAGGTGA AGATCCTTTT TGATAATCTC ATGACCAAAA
TCCCTTAACG TGAGTTTTCG TTCCACTGAG CGTCAGACCC CGTAGAAAAG
ATCAAAGGAT CTTCTTGAGA TCCTTTTTTT CTGCGCGTAA TCTGCTGCTT
GCAAACAAAA AAACCACCGC TACCAGCGGT GGTTTGTTTG CCGGATCAAG
AGCTACCAAC TCTTTTTCCG AAGGTAACTG GCTTCAGCAG AGCGCAGATA
CCAAATACTG TCCTTCTAGT GTAGCCGTAG TTAGGCCACC ACTTCAAGAA
CTCTGTAGCA CCGCCTACAT ACCTCGCTCT GCTAATCCTG TTACCAGTGG
CTGCTGCCAG TGGCGATAAG TCGTGTCTTA CCGGGTTGGA CTCAAGACGA
TAGTTACCGG ATAAGGCGCA GCGGTCGGGC TGAACGGGGG GTTCGTGCAC
ACAGCCCAGC TTGGAGCGAA CGACCTACAC CGAACTGAGA TACCTACAGC
GTGAGCATTG AGAAAGCGCC ACGCTTCCCG AAGGGAGAAA GGCGGACAGG
TATCCGGTAA GCGGCAGGGT CGGAACAGGA GAGCGCACGA GGGAGCTTCC
AGGGGGAAAC GCCTGGTATC TTTATAGTCC TGTCGGGTTT CGCCACCTCT
GACTTGAGCG TCGATTTTTG TGATGCTCGT CAGGGGGGCG GAGCCTATGG
AAAAACGCCA GCAACGCGGC CTTTTTACGG TTCCTGGCCT TTTGCTGGCC
TTTTGCTCAC ATGTTCTTTC CTGCGTTATC CCCTGATTCT GTGGATAACC
GTATTACCGC CTTTGAGTGA GCTGATACCG CTCGCCGCAG CCGAACGACC
GAGCGCAGCG AGTCAGTGAG CGAGGAAGCG GAAGAGCGCC CAATACGCAA
ACCGCCTCTC CCCGCGCGTT GGCCGATTCA TTAATGCAGC TGGCACGACA
GGTTTCCCGA CTGGAAAGCG GGCAGTGAGC GCAACGCAAT TAATGTGAGT
TAGCTCACTC ATTAGGCACC CCAGGCTTTA CACTTTATGC TTCCGGCTCG
```

FIG. 3 (CONTINUED 2).

```
TATGTTGTGT GGAATTGTGA GCGGATAACA ATTTCACACA GGAAACAGCT
ATGACCATGA TTACGCCAAG CTGTAAGTTT AAACATGATC TTACTAACTA
ACTATTCTCA TTTAAATTTT CAGAGCTTAA AAATGGCTGA AATCACTCAC
AACGATGGAT ACGCTAACAA CTTGGAAATG AAATAAGCTT GCATGCCTGC
AGGCCTGAGA TATTTTGCGC GTCAAATATG TTTTGTGTCC CCGTAATATT
TTTTTAAATC AAATTTCACA TTTTAACCAT AAAAAACTCT TTCAAAAGTG
TAATTTTCTA CGCAAAAATG CCGTTCGGAT GAAAAATTAC TTTTGAAAAA
CAAACTCGAA ACTACGGTAC GCAAAAAAGT ACATCGGTGT TTGCACATAA
GTGAAAACAA TGTTGTTTTT TTGTAATTAA AATCGATTAA TTTTTTTTCC
CGGAAAACAA AAACGTTTTC AGCGTGGATT TCTATTGTTT CTTGCGTAAA
AAAAAATTAT TTACCAATTT TAAACGATAA TTTCCACGAA TTTTCGCCAT
TAATCTCTCG ATTTTGTTGA TTCTTGACTC CGAGCAATCT CTCCGGTTTT
CGCAAACGAT TATATTATTT ATTTGTTTTC CTTTTCAGTG CCGATTCTCG
GAAATTCAAC AGTAAATCTT CAAAATGCCA ATGCTTCCCC ACATGGTCAA
TCTAAGTGAG TTTCTTTGTT ACAAATACA CGTGATGTCA GATTGTCTCA
TTTCGGTTTG ATCTACGTAG ATCTACAAAA AATGCGGGAA TTGAGCCGCA
GAGTTCTCAA CTGCTTTCGC ATGGTTAAGA ACGTGCGGAC GTCAAATTGT
TTTGGGCAAA AATTCCCGCA TTTTTTGTAG ATCAAACGT AATGGGACAG
TCTGGCACCA CGTGACTATA TATTTTTAGC GGTCAACGAC ACAAAACCCG
GACCAATGGC TGAGGATCAG CTGAAAGCTT ATAGAGATAG AAATCAGGTG
AGAAAAATCA ATTTCAGCGA TTTTCTTCGC AATTTATATA AAAACTGATT
TTTCCAGGAA CCCCACCTGC TCACCACATC CAATCGGAGC TCAGAAAAA
```

FIG. 4. Nucleotide sequence of pGN156

```
agcttgcatgcctgcagggtcgactctagaggatcaaactgtattacttgaaacaatttagttatatgttta
gaacccctcattcaaaattaatagacagggctctcaccgaatgttgcaatttgtttctgataagggtcacaa
agcggagcgaatgcttgaatgtgtccatcaatgagcttatcaatgcgctaaaacgctataacttccatatga
agtcaatcgaacatatgtcaatctttagccgtatataaaggtgcactgaaaacagtccaatcacggttcagc
catgaggtcgatccccggccgggattggccaaaggacccaaaggtatgtttcgaatgatactaacataacat
agaacattttcaggaggacccttggagggtaccggtgggtgaagaccagaaacagcacctcgaactgagccg
cgatattgcccagcgtttcaacgcgctgtatggcgagatcgatcccgtcgttttacaacgtcgtgactggga
aaaccctggcgttacccaacttaatcgccttgcagcacatccccctttcgccagctggcgtaatagcgaaga
ggcccgcaccgatcgcccttcccaacagttgcgaaggtaagtttaaacagatccatactaactaacttgttc
tgacataattttcagcttgaatggcgaatggcgctttgcctggtttccggcaccagaagcggtgccggaaag
ctggctggagtgcgatcttcctgaggccgatactgtcgtcgtcccctcaaactggcagatgcacggttacga
tgcgcccatctacaccaacgtaacctatcccattacggtcaatccgccgtttgttcccacggagaatccgac
gggttgttactcgctcacatttaatgttgatgaaagctggctacaggaaggccagacgcgaattattttttga
tggcgttaactcggcgtttcatctgtggtgcaacgggcgctgggtcggttacggccaggtaagtttaattaa
gttgatactaactaacaaagatctgattaattttcaggacagtcgtttgccgtctgaatttgacctgagcgc
atttttacgcgccggagaaaaccgcctcgcggtgatggtgctgcgttggagtgacggcagttatctggaaga
tcaggatatgtggcggatgagcggcattttccgtgacgtctcgttgctgcataaaccgactacacaaatcag
cgatttccatgttgccactcgctttaatgatgatttctcccgcgctgtactggaggctgaagtccaggtaag
tttaaacaggatcttactaactaacatgctaacactgaattttcagatgtgcggcgagttgcgtgactacct
acgggtaacagtttctttatggcagggtgaaacgcaggtcgccagcggcaccgcgcctttcggcggtgaaat
tatcgatgagcgtggtggttatgccgatcgcgtcacactacgtctgaacgtcgaaaacccgaaactgtggag
cgccgaaatcccgaatctctatcgtgcggtggttgaactgcacaccgccgacggcacgctgattgaagcaga
agcctgcgatgtcggtttccgcgaggtgcggattgaaaatggtctgctgctgctgaacggcaagccgttgct
gattcgaggcgttaaccgtcacgagcatcatcctctgcatggtcaggtcatggatgagcagacgatggtgca
ggatgtaagtttaaactattcgttactaactaactttaaacatttaaattttcagatcctgctgatgaagca
gaacaactttaacgccgtgcgctgttcgcattatccgaaccatccgctgtggtacacgctgtgcgaccgcta
cggcctgtatgtggtggatgaagccaatattgaaacccacggcatggtgccaatgaatcgtctgaccgatga
tccgcgctggctaccggcgatgagcgaacgcgtaacgcgaatggtgcagcgcgatcgtaatcacccgagtgt
gatcatctggtcgctggggaatggtaagtttaaacagttgaatactaactaacggagatctttgaaattttc
agaatcaggccacggcgctaatcacgacgcgctgtatcgctggatcaaatctgtcgatccttcccgcccggt
gcagtatgaaggcggcggagccgacaccacggccaccgatattatttgcccgatgtacgcgcgcgtggatga
agaccagcccttcccggctgtgccgaaatggtccatcaaaaaatggctttcgctacctggagagacgcgccc
gctgattctttgcgaggtaagtttaaacagaactctactaactaacacattagatcctaattttcagtacgc
tcacgcgatgggcaacagtcttggcggtttcgctaaatactggcaggcgtttcgtcagtatccccgtttaca
gggcggcttcgtctgggactgggtggatcagtcgctgattaaatatgatgaaaacggcaacccgtggtcggc
ttacggcggtgattttggcgatacgccgaacgatcgccagttctgtatgaacggtctggtctttgccgaccg
cacgccgcatccagcgtaagtttaaacaataacctactaactaacgtagataatttaaattttcaggctgac
ggaagcaaaacaccagcagcagttttttccagttccgtttatccgggcaaaccatcgaagtgaccagcgaata
cctgttccgtcatagcgataacgagctcctgcactggatggtggcgctggatggtaagccgctggcaagcgg
tgaagtgcctctggatgtcgctccacaaggtaaacagttgattgaactgcctgaactaccgcagccggagag
cgccgggcaactctggctcacagtacgcgtagtgcaaccgaacgcgaccgcatggtcagaagccgggcacat
cagcgcatggcagcagtggaggtaagtttaaacaagatcctactaactaactctacattgatgaattttcag
actggcggaaaacctcagtgtgacgctccccgccgcgtcccacgccatcccgcatctgaccaccagcgaaat
ggattttgcatcgagctgggtaataagcgttggcaatttaaccgccagtcaggctttctttcacagatgtg
gattggcgataaaaaacaactgctgacgccgctgcgcgatcagttcacccgtgcaccgctggataacgacat
tggcgtaagtgaagcgacccgcattgaccctaacgcctgggtcggtaagtttaaacaaagttgtactaacta
acgaagatcttgataattttcagaacgctggaaggcggcggggccattaccaggccgaagcagcgttgttgca
gtgcacggcagatacacttgctgatgcggtgctgattacgaccgctcacgcgtggcagcatcaggggaaaac
cttatttatcagccggaaaacctaccggattgatggtagtggtcaaatggcgattaccgttgatgttgaagt
```

FIG. 4 (CONTINUED).

```
ggcgagcgatacaccgcatccggcgcggattggcctgaactgccagctggcgcaggtagcagagcgggtaaa
ctggctcggattagggccgcaagaaaactatcccgaccgcccttactgccgcctgttttgaccgctgggatct
gccattgtcagacatgtagtaagtttaaacttgatagtactaactaacatgtttcatttaaattttcagtac
cccgtacgtcttcccgagcgaaaacggtctgcgctgcgggacgcgcgaattgaattatggcccacaccagtg
gcgcggcgacttccagttcaacatcagccgctacagtcaacagcaactgatggaaaccagccatcgccatct
gctgcacgcggaagaaggcacatggctgaatatcgacggtttccatatggggattggtggcgacgactcctg
gagcccgtcagtatcggcggaattccaactgagcgccggtcgctaccattaccaacttgtctggtgtcaaaa
ataataggggccgctgtcatcagagtaagtttaaactgagttctactaactaacgagtaatatttaaatttt
cagcatctcgcgccgtgcctctgacttctaagtccaattactcttcaacatccctacatgctctttctccc
tgtgctcccaccccctattttgttattatcaaaaaaacttcttcttaatttctttgttttttagcttcttt
taagtcacctctaacaatgaaattgtgtagattcaaaaatagaattaattcgtaataaaaagtcgaaaaaaa
ttgtgctccctcccccccattaataataattctatcccaaaatctacacaatgttctgtgtacacttcttatg
tttttttttacttctgataaatttttttttgaaacatcatagaaaaaaccgcacacaaaataccttatcatatg
ttacgtttcagtttatgaccgcaatttttatttcttcgcacgtctgggcctctcatgacgtcaaatcatgct
catcgtgaaaaagttttggagtatttttggaattttttcaatcaagtgaaagtttatgaaattaattttcctg
cttttgcttttttgggggtttcccctattgtttgtcaagagtttcgaggacgcgttttttcttgctaaaatca
caagtattgatgagcacgatgcaagaaagatcggaagaaggtttgggtttgaggctcagtggaaggtgagta
gaagttgataatttgaaagtggagtagtgtctatggggtttttgccttaaatgacagaatacattcccaata
taccaaacataactgtttcctactagtcggccgtacgggccctttcgtctcgcgcgtttcggtgatgacggt
gaaaacctctgacacatgcagctcccggagacggtcacagcttgtctgtaagcggatgccgggagcagacaa
gcccgtcagggcgcgtcagcgggtgttggcgggtgtcggggctggcttaactatgcggcatcagagcagatt
gtactgagagtgcaccatatgcggtgtgaaataccgcacagatgcgtaaggagaaaataccgcatcaggcgg
ccttaagggcctcgtgatacgcctatttttataggttaatgtcatgataataatggtttcttagacgtcagg
tggcacttttcggggaaatgtgcgcggaacccctatttgtttattttttctaaatacattcaaatatgtatcc
gctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacattt
ccgtgtcgcccttattccctttttttgcggcattttgccttcctgttttttgctcacccagaaacgctggtgaa
agtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagat
ccttgagagttttcgccccgaagaacgtttttccaatgatgagcactttttaaagttctgctatgtggcgcggt
attatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttga
gtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataac
catgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttt
gcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaacga
cgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttac
tctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggc
ccttccggctggctggtttattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagc
actggggccagatggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatga
acgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttactc
atatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataa
tctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaagg
atcttcttgagatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggt
ggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagatacc
aaatactgtccttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacct
cgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaag
acgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttggagcg
aacgacctacaccgaactgagatacctacagcgtgagcattgagaaagcgccacgcttcccgaagggagaaa
ggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccaggggggaaacgc
ctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcagg
ggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgc
tcacatgttctttcctgcgttatcccctgattctgtggataaccgtattaccgcctttgagtgagctgatac
cgctcgccgcagccgaacgaccgagcgcagcgagtcagtgagcgaggaagcggaagagcgcccaatacgcaa
accgcctctccccgcgcgttggccgattcattaatgcagctggcacgacaggtttcccgactggaaagcggg

cagtgagcgcaacgcaattaatgtgagttagctcactcattaggcaccccaggctttacactttatgcttcc
ggctcgtatgttgtgtggaattgtgagcggataacaatttcacacaggaaacagctatgaccatgattacgc
ca
```

12/27

FIG. 5. Nucleotide sequence of pGQ3

```
CGCGCCATGA GTAAAGGAGA AGAACTTTTC ACTGGAGTTG TCCCAATTCT
TGTTGAATTA GATGGTGATG TTAATGGGCA CAAATTTTCT GTCAGTGGAG
AGGGTGAAGG TGATGCAACA TACGGAAAAC TTACCCTTAA ATTTATTTGC
ACTACTGGAA AACTACCTGT TCCATGGGTA AGTTTAAACA TATATATACT
AACTAACCCT GATTATTTAA ATTTTCAGCC AACACTTGTC ACTACTTTCT
GTTATGGTGT TCAATGCTTC TCGAGATACC CAGATCATAT GAAACGGCAT
GACTTTTTCA AGAGTGCCAT GCCCGAAGGT TATGTACAGG AAAGAACTAT
ATTTTTCAAA GATGACGGGA ACTACAAGAC ACGTAAGTTT AAACAGTTCG
GTACTAACTA ACCATACATA TTTAAATTTT CAGGTGCTGA AGTCAAGTTT
GAAGGTGATA CCCTTGTTAA TAGAATCGAG TTAAAGGTA TTGATTTTAA
AGAAGATGGA AACATTCTTG GACACAAATT GGAATACAAC TATAACTCAC
ACAATGTATA CATCATGGCA GACAAACAAA AGAATGGAAT CAAAGTTGTA
AGTTTAAACT TGGACTTACT AACTAACGGA TTATATTTAA ATTTTCAGAA
CTTCAAAATT AGACACAACA TTGAAGATGG AAGCGTTCAA CTAGCAGACC
ATTATCAACA AAATACTCCA ATTGGCGATG GCCCTGTCCT TTTACCAGAC
AACCATTACC TGTCCACACA ATCTGCCCTT TCGAAAGATC CCAACGAAAA
GAGAGACCAC ATGGTCCTTC TTGAGTTTGT AACAGCTGCT GGGATTACAC
ATGGCATGGA TGAACTATAC AAATAGGGCC GGCCGAGCTC CGCATCGGCC
GCTGTCATCA GATCGCCATC TCGCGCCCGT GCCTCTGACT TCTAAGTCCA
ATTACTCTTC AACATCCCTA CATGCTCTTT CTCCCTGTGC TCCCACCCCC
TATTTTTGTT ATTATCAAAA AAACTTCTTC TTAATTTCTT TGTTTTTTAG
CTTCTTTTAA GTCACCTCTA ACAATGAAAT TGTGTAGATT CAAAAATAGA
ATTAATTCGT AATAAAAAGT CGAAAAAAAT TGTGCTCCCT CCCCCCATTA
ATAATAATTC TATCCCAAAA TCTACACAAT GTTCTGTGTA CACTTCTTAT
GTTTTTTTTA CTTCTGATAA ATTTTTTTTG AAACATCATA GAAAAAACCG
CACACAAAAT ACCTTATCAT ATGTTACGTT TCAGTTTATG ACCGCAATTT
TTATTTCTTC GCACGTCTGG GCCTCTCATG ACGTCAAATC ATGCTCATCG
TGAAAAAGTT TTGGAGTATT TTTGGAATTT TTCAATCAAG TGAAAGTTTA
TGAAATTAAT TTTCCTGCTT TTGCTTTTTG GGGGTTTCCC CTATTGTTTG
TCAAGAGTTT CGAGGACGGC GTTTTTCTTG CTAAAATCAC AAGTATTGAT
GAGCACGATG CAAGAAAGAT CGGAAGAAGG TTTGGGTTTG AGGCTCAGTG
GAAGGTGAGT AGAAGTTGAT AATTTGAAAG TGGAGTAGTG TCTATGGGGT
TTTTGCCTTA AATGACAGAA TACATTCCCA ATATACCAAA CATAACTGTT
TCCTACTAGT CGGCCGTACG GGCCCTTTCG TCTCGCGCGT TTCGGTGATG
ACGGTGAAAA CCTCTGACAC ATGCAGCTCC CGGAGACGGT CACAGCTTGT
CTGTAAGCGG ATGCCGGGAG CAGACAAGCC CGTCAGGGCG CGTCAGCGGG
TGTTGGCGGG TGTCGGGGCT GGCTTAACTA TGCGGCATCA GAGCAGATTG
TACTGAGAGT GCACCATATG CGGTGTGAAA TACCGCACAG ATGCGTAAGG
AGAAAATACC GCATCAGGCG GCCTTAAGGG CCTCGTGATA CGCCTATTTT
TATAGGTTAA TGTCATGATA ATAATGGTTT CTTAGACGTC AGGTGGCACT
TTTCGGGGAA ATGTGCGCGG AACCCCTATT TGTTTATTTT TCTAAATACA
TTCAAATATG TATCCGCTCA TGAGACAATA ACCCTGATAA ATGCTTCAAT
AATATTGAAA AAGGAAGAGT ATGAGTATTC AACATTTCCG TGTCGCCCTT
ATTCCCTTTT TTGCGGCATT TTGCCTTCCT GTTTTTGCTC ACCCAGAAAC
GCTGGTGAAA GTAAAAGATG CTGAAGATCA GTTGGGTGCA CGAGTGGGTT
ACATCGAACT GGATCTCAAC AGCGGTAAGA TCCTTGAGAG TTTTCGCCCC
GAAGAACGTT TTCCAATGAT GAGCACTTTT AAAGTTCTGC TATGTGGCGC
GGTATTATCC CGTATTGACG CCGGGCAAGA GCAACTCGGT CGCCGCATAC
ACTATTCTCA GAATGACTTG GTTGAGTACT CACCAGTCAC AGAAAAGCAT
```

FIG.5(CONTINUED 1).

```
CTTACGGATG GCATGACAGT AAGAGAATTA TGCAGTGCTG CCATAACCAT
GAGTGATAAC ACTGCGGCCA ACTTACTTCT GACAACGATC GGAGGACCGA
AGGAGCTAAC CGCTTTTTTG CACAACATGG GGGATCATGT AACTCGCCTT
GATCGTTGGG AACCGGAGCT GAATGAAGCC ATACCAAACG ACGAGCGTGA
CACCACGATG CCTGTAGCAA TGGCAACAAC GTTGCGCAAA CTATTAACTG
GCGAACTACT TACTCTAGCT TCCCGGCAAC AATTAATAGA CTGGATGGAG
GCGGATAAAG TTGCAGGACC ACTTCTGCGC TCGGCCCTTC CGGCTGGCTG
GTTTATTGCT GATAAATCTG GAGCCGGTGA GCGTGGGTCT CGCGGTATCA
TTGCAGCACT GGGGCCAGAT GGTAAGCCCT CCCGTATCGT AGTTATCTAC
ACGACGGGGA GTCAGGCAAC TATGGATGAA CGAAATAGAC AGATCGCTGA
GATAGGTGCC TCACTGATTA AGCATTGGTA ACTGTCAGAC CAAGTTTACT
CATATATACT TTAGATTGAT TTAAAACTTC ATTTTTAATT TAAAAGGATC
TAGGTGAAGA TCCTTTTTGA TAATCTCATG ACCAAAATCC CTTAACGTGA
GTTTTCGTTC CACTGAGCGT CAGACCCCGT AGAAAAGATC AAAGGATCTT
CTTGAGATCC TTTTTTTCTG CGCGTAATCT GCTGCTTGCA AACAAAAAAA
CCACCGCTAC CAGCGGTGGT TTGTTTGCCG GATCAAGAGC TACCAACTCT
TTTTCCGAAG GTAACTGGCT TCAGCAGAGC GCAGATACCA AATACTGTCC
TTCTAGTGTA GCCGTAGTTA GGCCACCACT TCAAGAACTC TGTAGCACCG
CCTACATACC TCGCTCTGCT AATCCTGTTA CCAGTGGCTG CTGCCAGTGG
CGATAAGTCG TGTCTTACCG GGTTGGACTC AAGACGATAG TTACCGGATA
AGGCGCAGCG GTCGGGCTGA ACGGGGGGTT CGTGCACACA GCCCAGCTTG
GAGCGAACGA CCTACACCGA ACTGAGATAC CTACAGCGTG AGCATTGAGA
AAGCGCCACG CTTCCCGAAG GGAGAAAGGC GGACAGGTAT CCGGTAAGCG
GCAGGGTCGG AACAGGAGAG CGCACGAGGG AGCTTCCAGG GGGAAACGCC
TGGTATCTTT ATAGTCCTGT CGGGTTTCGC CACCTCTGAC TTGAGCGTCG
ATTTTTGTGA TGCTCGTCAG GGGGGCGGAG CCTATGGAAA AACGCCAGCA
ACGCGGCCTT TTTACGGTTC CTGGCCTTTT GCTGGCCTTT TGCTCACATG
TTCTTTCCTG CGTTATCCCC TGATTCTGTG GATAACCGTA TTACCGCCTT
TGAGTGAGCT GATACCGCTC GCCGCAGCCG AACGACCGAG CGCAGCGAGT
CAGTGAGCGA GGAAGCGGAA GAGCGCCCAA TACGCAAACC GCCTCTCCCC
GCGCGTTGGC CGATTCATTA ATGCAGCTGG CACGACAGGT TTCCCGACTG
GAAAGCGGGC AGTGAGCGCA ACGCAATTAA TGTGAGTTAG CTCACTCATT
AGGCACCCCA GGCTTTACAC TTTATGCTTC CGGCTCGTAT GTTGTGTGGA
ATTGTGAGCG GATAACAATT TCACACAGGA AACAGCTATG ACCATGATTA
CGCCAAGCTT GCATGCCTGC AGTGATTCAG AGAGGTTGAG AATTATTTTC
AAAAACATTC AATGTTTCC CTTGGAGTGA CTATGCAAAT ATGAAAATGT
TTTCCAAAAA TATTTGGATG CCCTGATAAA AAGTAGGTGA AATTTCGCAG
GGGAACATCA TATTAAAATG TTGAATTTTT AGAAGAAATG GAAATGTTTG
TCGGTGGTAT GCTCGAATAT TTGAGATATT ATATATTTAC TGTTAAATCC
GAAATTTTTG ACAAACGGAA AAAATTTGTG TCGAAATACT ACATTTTCGA
TAACACAAAG GTACTTCCAT AACACTTATA AAAACTGTTT GACTATCTTA
ATTGTGTTTC CATGAAGGTA TTGTGAATAT TTTTGACAAA CTGATAGAAT
TTTCAGGAAA AAAAAATCCA AGAATAAACA TTTTTCAGAA TTTGAACTTT
CTAATGGCTG ATTAATAAAA CAAAGTTATA CAACTATTCA AAGCAGTTGC
TCAATCTGGC ATTTTCTTGT GTTTTTTTTT GAATATTTCA TCAGCAAGAT
GTTGATAATT TTGTGTTAAT TCTAATTGTT TTCTACAATT TTTCAAACCG
AAAATTGACC TTTGACTTTG TTTACTTTGT TCTCGTGGGT TAACTGTTCA
CTGATTCTTA TTGCTGTTGA TGAGGTCTTT GATCAAATTT GTATTGTTTT
TATACTGCAT ATTGCTTCAA TTCTAAATCA TCTAATATAT TGTCAAACAA
CTTCTTGTTT TTTTTTTCAT TCAAAACTTC TGCAAAAACG TTCTCTTAAC
AAAGGTTCAC ACAACAACTC TCCTCTCCAT CTCTTTCTCT CAACAACAAT
```

FIG. 5 (CONTINUED 2).

```
GTGCTGGCCT TGCATGTTTG CCAGTGCGGG TTGTTTACGC GTTTTCAAGA
TTTTTGGTCT CCTATCTAAC GTCCCGAAAT GCATTTTTTC CTTTCATTTG
GTTTTTTTCT GTTCGAGAAA AGTGACCGTT TGTCAAATCT TCTAATTTTC
AGTGAATAAA ATGCTGCAAT CTACTGCTCG CACTGCTTCA AAGCTTGTTC
AACCGGTTGC GGGGTAAGTC AAAATGAAAT TTTCGTTTAA AAAATTGGTTT
TTTTTGGTAT TATAGATAAA ACTTATACCA AAACAAAACA TATTTAGAAA
AACTTTAATA GAGAATAATT GTTTAATAAT TAATTTTTGC AAGCTCCTTT
TAAATTAAGA CATCTAAAAC AGTTTTCAGC TTGATTGTTT TAATGGTTTA
GAAAGCAATA TTTGTATTTT GTGTTAAACT GAAAATATCT AGGAAATACT
ACTTTTAAAA TATTTGAAAC TTGAAATTTT AAAATTCCAA ATAATTTTAC
TCATTTCCTA AAGTGTTTGA GTATTTGTAT CCTGTGCTGA CACCGAAATG
TTCTCAATTT TGGAAAAAAA AGATTTTTAT CCGTATCTTC AGTCTTACAA
TTTTTTTCAC CTTTTTTTTC ATTTCAGAGT TCTCGCCGTC CGCTCCAAGC
ACACTCTCCC AGATCTCCCA TTCGACTATG CAGATTTGGA ACCTGTAATC
AGCCATGAAA TCATGCAGCT TCATCATCAA AAGCATCATG CCACCTACGT
GAACAATCTC AATCAGATCG AGGAGAAACT TCACGAGGCT GTTTCGAAAG
GTTTTTTAAT CAGAAGATTT TGAAATGAAT TTTTTTTTTG GTATATAGGG
AATCTAAAAG AAGCAATTGC TCTCCAACCA GCGCTGAAAT TCAATGGTGG
TGGACACATC AATCATTCTA TCTTCTGGAC CAACTTGGCT AAGGATGGTG
GAGAACCTTC AAAGGAGCTG ATGGACACTA TTAAGGCTTG G
```

FIG. 6. Nucleotide sequence of pGQ4

```
GTGATTCAGA GAGGTTGAGA ATTATTTTCA AAAACATTCA ATGTTTTCCC
TTGGAGTGAC TATGCAAATA TGAAAATGTT TTCCAAAAAT ATTTGGATGC
TGAATTTTTA GAAGAAATGG AAATGTTTGT CGGTGGTATG CTCGAATATT
TGAGATATTA TATATTTACT GTTAAATCCG AAATTTTTGA CAAACGGAAA
AAATTTGTGT CGAAATACTA CATTTTCGAT AACACAAAGG TACTTCCATA
TTTAAACACA GCTTTATGAT GTAAAAGCTA TTGTGTTTCC ATGAAGGTAT
ACACTTATAA AAACTGTTTG ACTATCTTAT TTCAGGAAAA AAAAATCCAA
GAATAAACAT TTTTCAGAAT TTGAACTTTC TAATGGCTGA TTAATAAAAC
AAAGTTATAC AACTATTCAA AGCAGTTGCT CAATCTGGCA TTTTCTTGTG
TTTTTTTTTG AATATTTCAT CAGCAAGATG TTGATAATTT TGTGTTAATT
CTAATTGTTT TCTACAATTT TTCAAACCGA AAATTGACCT TTGACTTTGT
TTACTTTGTT CTCGTGGGTT AACTGTTCAC TGATTTCTAT TGCTGTTGAT
GAGGTCTTTG ATCAAATTTG TATTGTTTTT ATACTGCATA TTGCTTCAAT
TCTAAATCAT CTAATATATT GTCAAACAAC TTCTTGTTTT TTTTTTCATT
CAAAACTTCT GCAAAAACGT TCTCTTAACA AAGGTTCACA CAACAACTCT
CCTCTCCATC TCTTTCTCTC AACAACAATG TGCTGGCCTT GCATGTTTGC
CAGTGCGGGT TGTTTACGCG TTTTCAAGAT TTTTGGTCTC CTATCTAACG
TCCCGAAATG CATTTTTTCC TTTCATTTGG TTTTTTTCTG TTCGAGAAAA
GTGACCGTTT GTCAAATCTT CTAATTTTCA GTGAATAAAA TGCTGCAATC
TACTGCTCGC ACTGCTTCAA AGCTTGTTCA ACCGGTTGCG GGGTAAGTCA
AAATGAAATT TTCGTTTAAA AATTGGTTTT TTTTGGTATT ATAGATAAAA
CTTATACCAA AACAAAACAT ATTTAGAAAA ACTTTAATAG AGAATAATTG
TTTAATAATT AATTTTTGCA AGCTCCTTTT AAATTAAGAC ATCTAAAACA
GTTTTCAGCT TGATTGTTTT AATGGTTTAG AAAGCAATAT TTGTATTTTG
TGTTAAACTG AAAATATCTA GGAAATACTA CTTTTAAAAT ATTTGAAACT
TGAAATTTTA AAATTCCAAA TAATTTTACT CATTTCCTAA AGTGTTTGAG
TATTTGTATC CTGTGCTGAC ACCGAAATGT TCTCAATTTT GGAAAAAAAA
GATTTTTATC CGTATCTTCA GTCTTACAAT TTTTTTCACC TTTTTTTTCA
TTTCAGAGTT CTCGCCGTCC GCTCCAAGCA CACTCTCCCA GATCTCCCAT
TCGACTATGC AGATTTGGAA CCTGTAATCA GCCATGAAAT CATGCAGCTT
CATCATCAAA AGCATCATGC CACCTACGTG AACAATCTCA ATCAGATCGA
GGAGAAACTT CACGAGGCTG TTTCGAAAGG TTTTTTAATC AGAAGATTTT
GAAATGAATT TTTTTTTTGG TATATAGGGA ATCTAAAAGA AGCAATTGCT
CTCCAACCAG CGCTGAAATT CAATGGTGGT GGACACATCA ATCATTCTAT
CTTCTGGACC AACTTGGCTA AGGATGGTGG AGAACTTCA AAGGAGCTGA
TGGACACTAT TAAGCCGAGC TCAGAAAAAA TGACTGCTCC AAAGAAGAAG
CGTAAGGTAC CGGTAGAAAA AATGGAAGAC GCCAAAAACA TAAAGAAAGG
CCCGGCGCCA TTCTATCCGC TGGAAGATGG AACCGCTGGA GAGCAACTGC
ATAAGGCTAT GAAGAGATAC GCCCTGGTTC CTGGAACAAT TGCTTTTACA
GATGCACATA TCGAGGTGGA CATCACTTAC GCTGAGTACT TCGAAATGTC
CGTTCGGTTG GCAGAAGCTA TGAAACGATA TGGGCTGAAT ACAAATCACA
GAATCGTCGT ATGCAGTGAA AACTCTCTTC AATTCTTTAT GCCGGTGTTG
GGCGCGTTAT TTATCGGAGT TGCAGTTGCG CCCGCGAACG ACATTTATAA
TGAACGTGAA TTGCTCAACA GTATGGGCAT TTCGCAGCCT ACCGTGGTGT
TCGTTTCCAA AAAGGGGTTG CAAAAAATTT TGAACGTGCA AAAAAAGCTC
CCAATCATCC AAAAAATTAT TATCATGGAT TCTAAAACGG ATTACCAGGG
ATTTCAGTCG ATGTACACGT TCGTCACATC TCATCTACCT CCCGGTTTTA
ATGAATACGA TTTTGTGCCA GAGTCCTTCG ATAGGGACAA GACAATTGCA
```

FIG. 6 (CONTINUED 1).

```
CTGATCATGA ACTCCTCTGG ATCTACTGGT CTGCCTAAAG GTGTCGCTCT
GCCTCATAGA ACTGCCTGCG TGAGATTCTC GCATGCCAGA GATCCTATTT
TTGGCAATCA AATCATTCCG GATACTGCGA TTTTAAGTGT TGTTCCATTC
CATCACGGTT TTGGAATGTT TACTACACTC GGATATTTGA TATGTGGATT
TCGAGTCGTC TTAATGTATA GATTTGAAGA AGAGCTGTTT CTGAGGAGCC
TTCAGGATTA CAAGATTCAA AGTGCGCTGC TGGTGCCAAC CCTATTCTCC
TTCTTCGCCA AAAGCACTCT GATTGACAAA TACGATTTAT CTAATTTACA
CGAAATTGCT TCTGGTGGCG CTCCCCTCTC TAAGGAAGTC GGGGAAGCGG
TTGCCAAGAG GTTCCATCTG CCAGGTATCA GGCAAGGATA TGGGCTCACT
GAGACTACAT CAGCTATTCT GATTACACCC GAGGGGGATG ATAAACCGGG
CGCGGTCGGT AAAGTTGTTC CATTTTTTGA AGCGAAGGTT GTGGATCTGG
ATACCGGGAA AACGCTGGGC GTTAATCAAA GAGGCGAACT GTGTGTGAGA
GGTCCTATGA TTATGTCCGG TTATGTAAAC AATCCGGAAG CGACCAACGC
CTTGATTGAC AAGGATGGAT GGCTACATTC TGGAGACATA GCTTACTGGG
ACGAAGACGA ACACTTCTTC ATCGTTGACC GCCTGAAGTC TCTGATTAAG
TACAAAGGCT ATCAGGTGGC TCCCGCTGAA TTGGAATCCA TCTTGCTCCA
ACACCCCAAC ATCTTCGACG CAGGTGTCGC AGGTCTTCCC GACGATGACG
CCGGTGAACT TCCCGCCGCC GTTGTTGTTT TGGAGCACGG AAAGACGATG
ACGGAAAAAG AGATCGTGGA TTACGTCGCC AGTCAAGTAA CAACCGCGAA
AAAGTTGCGC GGAGGAGTTG TGTTTGTGGA CGAAGTACCG AAAGGTCTTA
CCGGAAAACT CGACGCAAGA AAAATCAGAG AGATCCTCAT AAAGGCCAAG
AAGGGCGGAA AGATCGCCGT GTAATTCTAG GAATCCAAC TGAGCGCCGG
TCGCTACCAT TACCAACTTG TCTGGTGTCA AAAATAATAG GGGCCGCTGT
CATCAGAGTA AGTTTAAACT GAGTTCTACT AACTAACGAG TAATATTTAA
ATTTTCAGCA TCTCGCGCCC GTGCCTCTGA CTTCTAAGTC CAATTACTCT
TCAACATCCC TACATGCTCT TTCTCCCTGT GCTCCCACCC CCTATTTTTG
TTATTATCAA AAAAACTTCT TCTTAATTTC TTTGTTTTTT AGCTTCTTTT
AAGTCACCTC TAACAATGAA ATTGTGTAGA TTCAAAAATA GAATTAATTC
GTAATAAAAA GTCGAAAAAA ATTGTGCTCC CTCCCCCCAT TAATAATAAT
TCTATCCCAA AATCTACACA ATGTTCTGTG TACACTTCTT ATGTTTTTTT
TACTTCTGAT AAATTTTTTT TGAAACATCA TAGAAAAAAC CGCACACAAA
ATACCTTATC ATATGTTACG TTTCAGTTTA TGACCGCAAT TTTTATTTCT
TCGCACGTCT GGGCCTCTCA TGACGTCAAA TCATGCTCAT CGTGAAAAAG
TTTTGGAGTA TTTTTGGAAT TTTTCAATCA AGTGAAAGTT TATGAAATTA
ATTTTCCTGC TTTTGCTTTT TGGGGGTTTC CCCTATTGTT TGTCAAGAGT
TTCGAGGACG GCGTTTTTCT TGCTAAAATC ACAAGTATTG ATGAGCACGA
TGCAAGAAAG ATCGGAAGAA GGTTTGGGTT TGAGGCTCAG TGGAAGGTGA
GTAGAAGTTG ATAATTTGAA AGTGGAGTAG TGTCTATGGG GTTTTTGCCT
TAAATGACAG AATACATTCC CAATATACCA AACATAACTG TTTCCTACTA
GTCGGCCGTA CGGGCCCTTT CGTCTCGCGC GTTTCGGTGA TGACGGTGAA
AACCTCTGAC ACATGCAGCT CCCGGAGACG GTCACAGCTT GTCTGTAAGC
GGATGCCGGG AGCAGACAAG CCCGTCAGGG CGCGTCAGCG GGTGTTGGCG
GGTGTCGGGG CTGGCTTAAC TATGCGGCAT CAGAGCAGAT TGTACTGAGA
GTGCACCATA TGCGGTGTGA AATACCGCAC AGATGCGTAA GGAGAAAATA
CCGCATCAGG CGGCCTTAAG GGCCTCGTGA TACGCCTATT TTTATAGGTT
AATGTCATGA TAATAATGGT TTCTTAGACG TCAGGTGGCA CTTTTCGGGG
AAATGTGCGC GGAACCCCTA TTTGTTTATT TTTCTAAATA CATTCAAATA
TGTATCCGCT CATGAGACAA TAACCCTGAT AAATGCTTCA ATAATATTGA
AAAAGGAAGA GTATGAGTAT TCAACATTTC CGTGTCGCCC TTATTCCCTT
TTTTGCGGCA TTTTGCCTTC CTGTTTTTGC TCACCCAGAA ACGCTGGTGA
AAGTAAAAGA TGCTGAAGAT CAGTTGGGTG CACGAGTGGG TTACATCGAA
```

FIG. 6 (CONTINUED 2).

```
CTGGATCTCA ACAGCGGTAA GATCCTTGAG AGTTTTCGCC CCGAAGAACG
TTTTCCAATG ATGAGCACTT TTAAAGTTCT GCTATGTGGC GCGGTATTAT
CCCGTATTGA CGCCGGGCAA GAGCAACTCG GTCGCCGCAT ACACTATTCT
CAGAATGACT TGGTTGAGTA CTCACCAGTC ACAGAAAAGC ATCTTACGGA
TGGCATGACA GTAAGAGAAT TATGCAGTGC TGCCATAACC ATGAGTGATA
ACACTGCGGC CAACTTACTT CTGACAACGA TCGGAGGACC GAAGGAGCTA
ACCGCTTTTT TGCACAACAT GGGGGATCAT GTAACTCGCC TTGATCGTTG
GGAACCGGAG CTGAATGAAG CCATACCAAA CGACGAGCGT GACACCACGA
TGCCTGTAGC AATGGCAACA ACGTTGCGCA AACTATTAAC TGGCGAACTA
CTTACTCTAG CTTCCCGGCA ACAATTAATA GACTGGATGG AGGCGGATAA
AGTTGCAGGA CCACTTCTGC GCTCGGCCCT TCCGGCTGGC TGGTTTATTG
CTGATAAATC TGGAGCCGGT GAGCGTGGGT CTCGCGGTAT CATTGCAGCA
CTGGGGCCAG ATGGTAAGCC CTCCCGTATC GTAGTTATCT ACACGACGGG
GAGTCAGGCA ACTATGGATG AACGAAATAG ACAGATCGCT GAGATAGGTG
CCTCACTGAT TAAGCATTGG TAACTGTCAG ACCAAGTTTA CTCATATATA
CTTTAGATTG ATTTAAAACT TCATTTTTAA TTTAAAAGGA TCTAGGTGAA
GATCCTTTTT GATAATCTCA TGACCAAAAT CCCTTAACGT GAGTTTTCGT
TCCACTGAGC GTCAGACCCC GTAGAAAAGA TCAAAGGATC TTCTTGAGAT
CCTTTTTTTC TGCGCGTAAT CTGCTGCTTG CAAACAAAAA AACCACCGCT
ACCAGCGGTG GTTTGTTTGC CGGATCAAGA GCTACCAACT CTTTTTCCGA
AGGTAACTGG CTTCAGCAGA GCGCAGATAC CAAATACTGT CCTTCTAGTG
TAGCCGTAGT TAGGCCACCA CTTCAAGAAC TCTGTAGCAC CGCCTACATA
CCTCGCTCTG CTAATCCTGT TACCAGTGGC TGCTGCCAGT GGCGATAAGT
CGTGTCTTAC CGGGTTGGAC TCAAGACGAT AGTTACCGGA TAAGGCGCAG
CGGTCGGGCT GAACGGGGGG TTCGTGCACA CAGCCCAGCT TGGAGCGAAC
GACCTACACC GAACTGAGAT ACCTACAGCG TGAGCATTGA GAAAGCGCCA
CGCTTCCCGA AGGGAGAAAG GCGGACAGGT ATCCGGTAAG CGGCAGGGTC
GGAACAGGAG AGCGCACGAG GGAGCTTCCA GGGGGAAACG CCTGGTATCT
TTATAGTCCT GTCGGGTTTC GCCACCTCTG ACTTGAGCGT CGATTTTTGT
GATGCTCGTC AGGGGGGCGG AGCCTATGGA AAAACGCCAG CAACGCGGCC
TTTTTACGGT TCCTGGCCTT TTGCTGGCCT TTTGCTCACA TGTTCTTTCC
TGCGTTATCC CCTGATTCTG TGGATAACCG TATTACCGCC TTTGAGTGAG
CTGATACCGC TCGCCGCAGC CGAACGACCG AGCGCAGCGA GTCAGTGAGC
GAGGAAGCGG AAGAGCGCCC AATACGCAAA CCGCCTCTCC CCGCGCGTTG
GCCGATTCAT TAATGCAGCT GGCACGACAG GTTTCCCGAC TGGAAAGCGG
GCAGTGAGCG CAACGCAATT AATGTGAGTT AGCTCACTCA TTAGGCACCC
CAGGCTTTAC ACTTTATGCT TCCGGCTCGT ATGTTGTGTG GAATTGTGAG
CGGATAACAA TTTCACACAG GAAACAGCTA TGACCATGAT TACGCCAAGC
TGTAAGTTTA AACATGATCT TACTAACTAA CTATTCTCAT TTAAATTTTC
AGAGCTTAAA AATGGCTGAA ATCACTCACA ACGATGGATA CGCTAACAAC
TTGGAAATGA AATAAGCTTG CATGCCTGCA
```

FIG. 7. Nucleotide sequence of the vit-2 promoter/NLS

```
ATGTTTAGAA CCCCTCATTC AAAATTAATA GACAGGGCTC TCACCGAATG TTGCAATTTG
TTTCTGATAA GGGTCACAAA GCGGAGCGAA TGCTTGAATG TGTCCATCAA TGAGCTTATC
AATGCGCTAA AACGCTATAA CTTCCATATG AAGTCAATCG AACATATGTC AATCTTTAGC
CGTATATAAA GGTGCACTGA AAACAGTCCA ATCACGGTTC AGCCATGAGG TCGATCCCCG
GCCGGGATTG GCCAAAGGAC CCAAAGGTAT GTTTCGAATG ATACTAACAT AACATAGAAC
ATTTTCAGGA GGACCCTTGG AGGGTACCGG GGATTGGCCA AAGGACCCAA AGGTATGTTT
CGAATGATAC TAACATAACA TAGAACATTT TCAGGAGGAC CCTTGCTTGG AGGGTACCGA
GCTCAGAAAA AATGACTGCT CCAAAGAAGA AGCGTAAGGT ACCGGTAGAA AAA
```

FIG. 8. Schematic drawing of pGN156

FIG. 9. Schematic drawing of pGQ1

- *Pst* I
- o-GQ1
- Exon 1
- ctl-1 promoter + coding region
- Exon 2
- Exon 3 partial
- o-GQ2bis
- *Bam* H I
- synth. intron A
- GFPI
- GFPII
- GFPIII
- GFPIV
- Fsel
- unc-54 3 UTR
- amp

pGQ1
5442 bp

FIG. 10. Schematic drawing of pGQ2

FIG. 11. Schematic drawing of pCLUC6

FIG. 12. Schematic drawing of pGQ3

FIG. 13. Schematic drawing of pGQ4

FIG. 14.

Stage specific LacZ expression
measured 1 h after adding probe

Stage specific LacZ expression
measured 2 h after adding probe

FIG. 15.

FIG. 16.

Stage specific LacZ expression
measured 5 h after adding probe

FIG. 17.

Fluorescence in function of number of vit-2::lacZ worms per well, lysed with 15% MeOH, C12 FDG probe

$y = 13224x + 97902$
$R^2 = 0.8801$

FIG. 18.

Flat bottom 3,5h

FIG. 19.

U-shape 18h washed1x

1

SEQUENCE LISTING

<110> DEVGEN NV

<120> VIT-2 PROMOTER CONSTRUCTS

<130> SCB/57946/001

<140>
<141>

<160> 7

<170> PatentIn Ver. 2.0

<210> 1
<211> 5442
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Plasmid pGQ1

<400> 1
atgaccatga ttacgccaag cttgcatgcc tgcagccaat gcattggaag agatattttg 60
cgcgtcaaat atgttttgtg tccccgtaat atttttttaa atcaaatttc acattttaac 120
cataaaaaac tctttcaaaa gtgtaatttt ctacgcaaaa atgccgttcg gatgaaaaat 180
tacttttgaa aaacaaactc gaaactacgg tacgcaaaaa agtacatcgg tgtttgcaca 240
taagtgaaaa caatgttgtt ttttttgtaat taaaatcgat taattttttt tcccggaaaa 300
caaaaacgtt ttcagcgtgg atttctattg tttcttgcgt aaaaaaaaat tatttaccaa 360
ttttaaacga taatttccac gaattttcgc cattaatctc tcgattttgt tgattcttga 420
ctccgagcaa tctctccggt tttcgcaaac gattatatta tttatttgtt ttccttttca 480
gtgccgattc tcggaaattc aacagtaaat cttcaaaatg ccaatgcttc cccacatggt 540
caatctaagt gagtttcttt gttacaaaat acacgtgatg tcagattgtc tcatttcggt 600
ttgatctacg tagatctaca aaaaatgcgg gaattgagcc gcagagttct caactgcttt 660
cgcatggtta agaacgtgcg gacgtcaaat tgttttgggc aaaaattccc gcattttttg 720
tagatcaaac cgtaatggga cagtctggca ccacgtgact atatattttt agcggtcaac 780
gacacaaaac ccggaccaat ggctgaggat cagctgaaag cttatagaga tagaaatcag 840
gtgagaaaaa tcaatttcag cgatttttctt cgcaatttat ataaaaactg attttttccag 900
gaaccccacc tgctcaccac atccaatgga gctccgatct actcgaagac cgccgtgctc 960
accgccggac gacgtggtcc aatgctaatg caggacatcg tttatatgga cgagatggct 1020
catttcgatc gtgaacgcat cccggagcgt gtcgtccatg ccaaaggtgg tggtgctcat 1080
ggatacttcg aggtcaccca tgacatcacc aagtactgta aggccgatat gttcaacaag 1140
gtcggaaaac agacaccact tctcgttcgt ttttcaacgg tcgctggaga atcggccgga 1200
tccccgggat tggccaaagg acccaaaggt atgtttcgaa tgatactaac ataacataga 1260
acattttcag gaggaccctt ggctagcgtc gacggtacca tggggcgcgc catgagtaaa 1320
ggagaagaac ttttcactgg agttgtccca attcttgttg aattagatgg tgatgttaat 1380
gggcacaaat tttctgtcag tggagagggt gaaggtgatg caacatacgg aaaacttacc 1440
cttaaattta tttgcactac tggaaaacta cctgttccat gggtaagttt aaacatatat 1500
atactaacta accctgatta tttaaatttt cagccaacac ttgtcactac tttctgttat 1560
ggtgttcaat gcttctcgag atacccagat catatgaaac ggcatgactt tttcaagagt 1620
gccatgcccg aaggttatgt acaggaaaga actatatttt caaagatga cgggaactac 1680
aagacacgta agtttaaaca gttcggtact aactaaccat acatatttaa attttcaggt 1740
gctgaagtca agtttgaagg tgatacccct gttaatagaa tcgagttaaa aggtattgat 1800
tttaaagaag atggaaacat tcttggacac aaattggaat acaactataa ctcacacaat 1860
gtatacatca tggcagacaa acaaaagaat ggaatcaaag ttgtaagttt aaacttggac 1920
ttactaacta acggattata tttaaatttt cagaacttca aaattagaca caacattgaa 1980

```
gatggaagcg ttcaactagc agaccattat caacaaaata ctccaattgg cgatggccct 2040
gtccttttac cagacaacca ttacctgtcc acacaatctg ccctttcgaa agatcccaac 2100
gaaaagagag accacatggt ccttcttgag tttgtaacag ctgctgggat tacacatggc 2160
atggatgaac tatacaaata gggccggccg agctccgcat cggccgctgt catcagatcg 2220
ccatctcgcg cccgtgcctc tgacttctaa gtccaattac tcttcaacat ccctacatgc 2280
tctttctccc tgtgctccca cccctatttt ttgttattat caaaaaaact tcttcttaat 2340
ttctttgttt tttagcttct tttaagtcac ctctaacaat gaaattgtgt agattcaaaa 2400
atagaattaa ttcgtaataa aaagtcgaaa aaaattgtgc tccctccccc cattaataat 2460
aattctatcc caaaatctac acaatgttct gtgtacactt cttatgtttt ttttacttct 2520
gataaatttt ttttgaaaca tcatagaaaa aaccgcacac aaaatacctt atcatatgtt 2580
acgtttcagt ttatgaccgc aatttttatt tcttcgcacg tctgggcctc tcatgacgtc 2640
aaatcatgct catcgtgaaa aagtttttgga gtattttttgg aattttttcaa tcaagtgaaa 2700
gtttatgaaa ttaattttcc tgcttttgct ttttgggggt ttccctattt gtttgtcaag 2760
agtttcgagg acggcgtttt tcttgctaaa atcacaagta ttgatgagca cgatgcaaga 2820
aagatcggaa gaaggtttgg gtttgaggct cagtggaagg tgagtagaag ttgataattt 2880
gaaagtggag tagtgtctat ggggtttttg ccttaaatga cagaatacat tcccaatata 2940
ccaaacataa ctgtttccta ctagtcggcc gtacgggccc tttcgtctcg cgcgtttcgg 3000
tgatgacggt gaaaacctct gacacgtgca gctcccggag acggtcacag cttgtctgta 3060
agcggatgcc gggagcagac aagcccgtca gggcgcgtca gcgggtgttg gcgggtgtcg 3120
gggctggctt aactatgcgg catcagagca gattgtactg agagtgcacc atatgcggtg 3180
tgaaataccg cacagatgcg taaggagaaa ataccgcatc aggcggcctt aagggcctcg 3240
tgatacgcct attttttatag gttaatgtca tgataataat ggtttcttag acgtcaggtg 3300
gcactttctcg gggaaatgtg cgcggaaccc ctatttgttt attttttctaa atacattcaa 3360
atatgtatcc gctcatgaga caataaccct gataaatgct tcaataatat tgaaaaagga 3420
agagtatgag tattcaacat ttccgtgtcg cccttattcc cttttttgcg gcattttgcc 3480
ttcctgtttt tgctcaccca gaaacgctgg tgaaagtaaa agatgctgaa gatcagttgg 3540
gtgcacgagt gggttacatc gaactggatc tcaacagcgg taagatcctt gagagttttc 3600
gccccgaaga acgttttcca atgatgagca cttttaaagt tctgctatgt ggcgcggtat 3660
tatcccgtat tgacgccggg caagagcaac tcggtcgccg catacactat tctcagaatg 3720
acttggttga gtactcacca gtcacagaaa agcatcttac ggatggcatg acagtaagag 3780
aattatgcag tgctgccata accatgagtg ataacactgc ggccaactta cttctgacaa 3840
cgatcggagg accgaaggag ctaaccgctt ttttgcacaa catgggggat catgtaactc 3900
gccttgatcg ttgggaaccg gagctgaatg aagccatacc aaacgacgag cgtgacacca 3960
cgatgcctgt agcaatggca acaacgttgc gcaaactatt aactggcgaa ctacttactc 4020
tagcttcccg gcaacaatta atagactgga tggaggcgga taaagttgca ggaccacttc 4080
tgcgctcggc ccttccggct ggctggttta ttgctgataa atctggagcc ggtgagcgtg 4140
ggtctcgcgg tatcattgca gcactggggc cagatggtaa gccctcccgt atcgtagtta 4200
tctacacgac ggggagtcag gcaactatgg atgaacgaaa tagacagatc gctgagatag 4260
gtgcctcact gattaagcat tggtaactgt cagaccaagt ttactcatat atactttaga 4320
ttgatttaaa acttcatttt taatttaaaa ggatctaggt gaagatcctt tttgataatc 4380
tcatgaccaa aatcccttaa cgtgagtttt cgttccactg agcgtcagac cccgtagaaa 4440
agatcaaagg atcttcttga gatccttttt ttctgcgcgt aatctgctgc ttgcaaacaa 4500
aaaaaccacc gctaccagcg gtggtttgtt tgccggatca gagctacca actctttttc 4560
cgaaggtaac tggcttcagc agagcgcaga taccaaatac tgtccttcta gtgtagccgt 4620
agttaggcca ccacttcaag aactctgtag caccgcctac atacctcgct ctgctaatcc 4680
tgttaccagt ggctgctgcc agtggcgata agtcgtgtct taccgggttg gactcaagac 4740
gatagttacc ggataaggcg cagcggtcgg gctgaacggg gggttcgtgc acacagccca 4800
gcttggagcg aacgacctac accgaactga gatacctaca gcgtgagcat tgagaaagcg 4860
ccacgcttcc cgaagggaga aaggcggaca ggtatccggt aagcggcagg tcggaacag 4920
gagagcgcac gagggagctt ccaggggga acgcctggta tctttatagt cctgtcgggt 4980
ttcgccacct ctgacttgag cgtcgatttt tgtgatgctc gtcaggggg cggagcctat 5040
ggaaaaacgc cagcaacgcg gcctttttac ggttcctggc cttttgctgg ccttttgctc 5100
acatgttctt cctgcgtta tcccctgatt ctgtggataa ccgtattacc gcctttgagt 5160
gagctgatac cgctcgccgc agccgaacga ccgagcgcag cgagtcagtg agcgaggaag 5220
cggaagagcg cccaatacgc aaaccgcctc tccccgcgcg ttggccgatt cattaatgca 5280
gctggcacga caggtttccc gactggaaag cgggcagtga gcgcaacgca attaatgtga 5340
gttagctcac tcattaggca ccccaggctt tacactttat gcttccggct cgtatgttgt 5400
```

```
gtggaattgt gagcggataa caatttcaca caggaaacag ct                      5442

<210> 2
<211> 5686
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Plasmid pcLUC6

<400> 2
atgactgctc caaagaagaa gcgtaaggta ccggtagaaa aaatggaaga cgccaaaaac 60
ataaagaaag gcccggcgcc attctatccg ctggaagatg gaaccgctgg agagcaactg 120
cataaggcta tgaagagata cgccctggtt cctggaacaa ttgcttttac agatgcacat 180
atcgaggtgg acatcactta cgctgagtac ttcgaaatgt ccgttcggtt ggcagaagct 240
atgaaacgat atgggctgaa tacaaatcac agaatcgtcg tatgcagtga aaactctctt 300
caattcttta tgccggtgtt gggcgcgtta tttatcggag ttgcagttgc gcccgcgaac 360
gacatttata tgaacgtga attgctcaac agtatgggca tttcgcagcc taccgtggtg 420
ttcgtttcca aaaaggggtt gcaaaaaatt ttgaacgtgc aaaaaaagct cccaatcatc 480
caaaaaatta ttatcatgga ttctaaaacg gattaccagg gatttcagtc gatgtacacg 540
ttcgtcacat ctcatctacc tcccggtttt aatgaatacg attttgtgcc agagtccttc 600
gatagggaca agacaattgc actgatcatg aactcctctg gatctactgg tctgcctaaa 660
ggtgtcgctc tgcctcatag aactgcctgc gtgagattct cgcatgccag agatcctatt 720
tttggcaatc aaatcattcc ggatactgcg attttaagtg ttgttccatt ccatcacggt 780
tttggaatgt ttactacact cggatatttg atatgtggat ttcgagtcgt cttaatgtat 840
agatttgaag aagagctgtt tctgaggagc cttcaggatt acaagattca aagtgcgctg 900
ctggtgccaa ccctattctc cttcttcgcc aaaagcactc tgattgacaa atacgattta 960
tctaatttac acgaaattgc ttctggtggc gctcccctct ctaaggaagt cggggaagcg 1020
gttgccaaga ggttccatct gccaggtatc aggcaaggat atgggctcac tgagactaca 1080
tcagctattc tgattacacc cgagggggat gataaaccgg gcgcggtcgg taaagttgtt 1140
ccatttttg aagcgaaggt tgtggatctg gataccggga aaacgctggg cgttaatcaa 1200
agaggcgaac tgtgtgtgag aggtcctatg attatgtccg gttatgtaaa caatccggaa 1260
gcgaccaacg ccttgattga caaggatgga tggctacatt ctggagacat agcttactgg 1320
gacgaagacg aacacttctt catcgttgac cgcctgaagt ctctgattaa gtacaaaggc 1380
tatcaggtgg ctcccgctga attggaatcc atcttgctcc aacaccccaa catcttcgac 1440
gcaggtgtcg caggtcttcc cgacgatgac gccggtgaac ttcccgccgc cgttgttgtt 1500
ttggagcacg gaaagacgat gacggaaaaa gagatcgtgg attacgtcgc cagtcaagta 1560
acaaccgcga aaaagttgcg cggaggagtt gtgtttgtgg acgaagtacc gaaaggtctt 1620
accggaaaac tcgacgcaag aaaaatcaga gagatcctca taaaggccaa gaagggcgga 1680
aagatcgccg tgtaattcta ggaattccaa ctgagcgccg gtcgctacca ttaccaactt 1740
gtctggtgtc aaaaataata ggggccgctg tcatcagagt aagtttaaac tgagttctac 1800
taactaacga gtaatattta aattttcagc atctcgcgcc cgtgcctctg acttctaagt 1860
ccaattactc ttcaacatcc ctacatgctc tttctccctg tgctcccacc ccctattttt 1920
gttattatca aaaaaacttc ttcttaattt ctttgttttt tagcttcttt taagtcacct 1980
ctaacaatga aattgtgtag attcaaaaat agaattaatt cgtaataaaa agtcgaaaaa 2040
aattgtgctc cctccccca ttaataataa ttctatccca aaatctacac aatgttctgt 2100
gtacacttct tatgtttttt ttacttctga taaatttttt ttgaaacatc atagaaaaaa 2160
ccgcacacaa aataccttat catatgttac gtttcagttt atgaccgcaa ttttttattc 2220
ttcgcacgtc tgggcctctc atgacgtcaa atcatgctca tcgtgaaaaa gttttggagt 2280
attttggaa ttttcaatc aagtgaaagt ttatgaaatt aattttcctg cttttgcttt 2340
ttggggggttt cccctattgt ttgtcaagag tttcgaggac ggcgttttc ttgctaaaat 2400
cacaagtatt gatgagcacg atgcaagaaa gatcggaaga aggtttgggt ttgaggctca 2460
gtggaaggtg agtagaagtt gataatttga aagtggagta gtgtctatgg ggttttttgcc 2520
ttaaatgaca gaatacattc ccaatatacc aaacataact gtttcctact agtcggccgt 2580
acgggccctt tcgtctcgcg cgtttcggtg atgacggtga aaacctctga cacatgcagc 2640
tcccggagac ggtcacagct tgtctgtaag cggatgccgg gagcagacaa gcccgtcagg 2700
gcgcgtcagc gggtgttggc gggtgtcggg gctggcttaa ctatgcggca tcagagcaga 2760
```

4

```
ttgtactgag agtgcaccat atgcggtgtg aaataccgca cagatgcgta aggagaaaat 2820
accgcatcag gcggccttaa gggcctcgtg atacgcctat ttttataggt taatgtcatg 2880
ataataatgg tttcttagac gtcaggtggc acttttcggg gaaatgtgcg cggaacccct 2940
atttgtttat ttttctaaat acattcaaat atgtatccgc tcatgagaca ataaccctga 3000
taaatgcttc aataatattg aaaaaggaag agtatgagta ttcaacattt ccgtgtcgcc 3060
cttattccct tttttgcggc attttgcctt cctgtttttg ctcacccaga aacgctggtg 3120
aaagtaaaag atgctgaaga tcagttgggt gcacgagtgg gttacatcga actggatctc 3180
aacagcggta agatccttga gagttttcgc cccgaagaac gtttttccaat gatgagcact 3240
tttaaagttc tgctatgtgg cgcggtatta tcccgtattg acgccgggca agagcaactc 3300
ggtcgccgca tacactattc tcagaatgac ttggttgagt actcaccagt cacagaaaag 3360
catcttacgg atggcatgac agtaagagaa ttatgcagtg ctgccataac catgagtgat 3420
aacactgcgg ccaacttact tctgacaacg atcggaggac cgaaggagct aaccgctttt 3480
ttgcacaaca tgggggatca tgtaactcgc cttgatcgtt gggaaccgga gctgaatgaa 3540
gccataccaa acgacgagcg tgacaccacg atgcctgtag caatggcaac aacgttgcgc 3600
aaactattaa ctggcgaact acttactcta gcttcccggc aacaattaat agactggatg 3660
gaggcggata aagttgcagg accacttctg cgctcggccc ttccggctgg ctggtttatt 3720
gctgataaat ctggagccgg tgagcgtggg tctcgcggta tcattgcagc actggggcca 3780
gatggtaagc cctcccgtat cgtagttatc tacacgacgg ggagtcaggc aactatggat 3840
gaacgaaata gacagatcgc tgagataggt gcctcactga ttaagcattg gtaactgtca 3900
gaccaagttt actcatatat actttagatt gatttaaaac ttcattttta atttaaaagg 3960
atctaggtga agatcctttt tgataatctc atgaccaaaa tcccttaacg tgagttttcg 4020
ttccactgag cgtcagaccc cgtagaaaag atcaaaggat cttcttgaga tccttttttt 4080
ctgcgcgtaa tctgctgctt gcaaacaaaa aaaccaccgc taccagcggt ggtttgtttg 4140
ccggatcaag agctaccaac tctttttccg aaggtaactg gcttcagcag agcgcagata 4200
ccaaatactg tccttctagt gtagccgtag ttaggccacc acttcaagaa ctctgtagca 4260
ccgcctacat acctcgctct gctaatcctg ttaccagtgg ctgctgccag tggcgataag 4320
tcgtgtctta ccgggttgga ctcaagacga tagttaccgg ataaggcgca gcggtcgggc 4380
tgaacggggg gttcgtgcac acagcccagc ttggagcgaa cgacctacac cgaactgaga 4440
tacctacagc gtgagcattg agaaagcgcc acgcttcccg aagggagaaa ggcggacagg 4500
tatccggtaa gcggcaggt cggaacagga gagcgcacga gggagcttcc agggggaaac 4560
gcctggtatc tttatagtcc tgtcgggttt cgccacctct gacttgagcg tcgattttg 4620
tgatgctcgt caggggggcg gagcctatgg aaaaacgcca gcaacgcggc cttttacgg 4680
ttcctggcct tttgctcac atgttctttc ctgcgttatc ccctgattct 4740
gtggataacc gtattaccgc ctttgagtga gctgataccg ctcgccgcag ccgaacgacc 4800
gagcgcagcg agtcagtgag cgaggaagcg gaagagcgcc caatacgcaa accgcctctc 4860
cccgcgcgtt ggccgattca ttaatgcagc tggcacgaca ggtttcccga ctggaaagcg 4920
ggcagtgagc gcaacgcaat taatgtgagt tagctcactc attaggcacc ccaggcttta 4980
cactttatgc ttccggctcg tatgttgtgt ggaattgtga gcggataaca atttcacaca 5040
ggaaacagct atgaccatga ttacgccaag ctgtaagttt aaacatgatc ttactaacta 5100
actattctca tttaaatttt cagagcttaa aaatggctga atcactcac aacgatggat 5160
acgctaacaa cttggaaatg aaataagctt gcatgcctgc aggccttggt cgactctaga 5220
ggatcaaact gtattacttg aaacaattta gttatatgtt tagaacccct cattcaaaat 5280
taatagacag ggctctcacc gaatgttgca atttgtttct gataagggtc acaaagcgga 5340
gcgaatgctt gaatgtgtcc atcaatgagc ttatcaatgc gctaaaacgc tataacttcc 5400
atatgaagtc aatcgaacat atgtcaatct ttagccgtat ataaaggtgc actgaaaaca 5460
gtccaatcac ggttcagcca tgaggtcgat ccccggccgg gattggccaa aggacccaaa 5520
ggtatgtttc gaatgatact aacataacat agaacatttt caggaggacc cttggagggt 5580
accgggatt ggccaaagga cccaaaggta tgtttcgaat gatactaaca taacatagaa 5640
cattttcagg aggacccttg cttggagggt accgagctca gaaaaa       5686
```

<210> 3
<211> 6099
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Plasmid pGQ2

5

<400> 3
```
atgactgctc caaagaagaa gcgtaaggta ccggtagaaa aaatggaaga cgccaaaaac 60
ataaagaaag gcccggcgcc attctatccg ctggaagatg gaaccgctgg agagcaactg 120
cataaggcta tgaagagata cgccctggtt cctggaacaa ttgcttttac agatgcacat 180
atcgaggtgg acatcactta cgctgagtac ttcgaaatgt ccgttcggtt ggcagaagct 240
atgaaacgat atgggctgaa tacaaatcac agaatcgtcg tatgcagtga aaactctctt 300
caattcttta tgccggtgtt gggcgcgtta tttatcggag ttgcagttgc gcccgcgaac 360
gacatttata tgaacgtga attgctcaac agtatgggca tttcgcagcc.taccgtggtg 420
ttcgtttcca aaaagggctt gcaaaaaatt ttgaacgtgc aaaaaaagct cccaatcatc 480
caaaaaatta ttatcatgga ttctaaaacg gattaccagg gatttcagtc gatgtacacg 540
ttcgtcacat ttcatctacc tcccggtttt aatgaatacg attttgtgcc agagtccttc 600
gatagggaca agacaattgc actgatcatg aactcctctg gatctactgg tctgcctaaa 660
ggtgtcgctc tgcctcatag aactgcctgc gtgagattct cgcatgccag agatcctatt 720
tttggcaatc aaatcattcc ggatactgcg attttaagtg ttgttccatt ccatcacggt 780
tttggaatgt ttactacact cggatatttg atatgtggat ttcgagtcgt cttaatgtat 840
agatttgaag aagagctgtt tctgaggagc cttcaggatt acaagattca aagtgcgctg 900
ctggtgccaa ccctattctc cttcttcgcc aaaagcactc tgattgacaa atacgattta 960
tctaatttac acgaaattgc ttctggtggc gctcccctct ctaaggaagt cggggaagcg 1020
gttgccaaga ggttccatct gccaggtatc aggcaaggat atgggctcac tgagactaca 1080
tcagctattc tgattacacc cgaggggat gataaaccgg gcgcggtcgg taaagttgtt 1140
ccattttttg aagcgaaggt tgtggatctg gataccggga aaacgctggg cgttaatcaa 1200
agaggcgaac tgtgtgtgag aggtcctatg attatgtccg gttatgtaaa caatccggaa 1260
gcgaccaacg ccttgattga caagtatgga tggctacatt ctggagacat agcttactgg 1320
gacgaagacg aacacttctt catcgttgac cgcctgaagt ctctgattaa gtacaaaggc 1380
tatcaggtgg ctcccgctga attggaatcc atcttgctcc aacaccccaa catcttcgac.1440
gcaggtgtcg caggtcttcc cgacgatgac gccggtgaac ttcccgccgc cgttgttgtt 1500
ttggagcacg gaaagacgat gacggaaaaa gagatcgtgg attacgtcgc cagtcaagta 1560
acaaccgcga aaaagttgcg cggaggagtt gtgtttgtgg acgaagtacc gaaaggtctt 1620
accggaaaac tcgacgcaag aaaaatcaga gagatcctca taaaggccaa gaagggcgga 1680
aagatcgccg tgtaattcta ggaattccaa ctgagcgccg gtcgctacca ttaccaactt 1740
gtctggtgtc aaaaataata ggggccgctg tcatcagagt aagtttaaac tgagttctac 1800
taactaacga gtaatattta aattttcagc atctcgcgcc cgtgcctctg acttctaagt 1860
ccaattactc ttcaacatcc ctacatgctc tttctccctg tgctcccacc cctatttttt 1920
gttattatca aaaaaacttc ttcttaattt ctttgttttt tagcttcttt taagtcacct 1980
ctaacaatga aattgtgtag attcaaaaat agaattaatt cgtaataaaa agtcgaaaaa 2040
aattgtgctc cctccccccca ttaataataa ttctatccca aaatctacac aatgttctgt 2100
gtacacttct tatgtttttt ttacttctga taaattttttt ttgaaacatc atagaaaaaa 2160
ccgcacacaa aataccttat catatgttac gtttcagttt atgaccgcaa tttttatttc 2220
ttcgcacgtc tgggcctctc atgacgtcaa atcatgctca tcgtgaaaaa gttttggagt 2280
attttggaa tttttcaatc aagtgaaagt ttatgaaatt aatttttcctg cttttgcttt 2340
ttgggggttt cccctattgt ttgtcaagag tttcgaggac ggcgtttttc ttgctaaaat 2400
cacaagtatt gatgagcacg atgcaagaaa gatcggaaga aggtttgggt ttgaggctca 2460
gtggaaggtg agtagaagtt gataatttga aagtggagta gtgtctatgg ggttttttgcc 2520
ttaaatgaca gaatacattc ccaatatacc aaacataact gtttcctact agtcggccgt 2580
acgggccctt tcgtctcgcg cgtttcggtg atgacggtga aacctctga cacatgcagc 2640
tcccggagac ggtcacagct tgtctgtaag cggatgccgg gagcagacaa gcccgtcagg 2700
gcgcgtcagc gggtgttggc gggtgtcggg gctggcttaa ctatgcggca tcagagcaga 2760
ttgtactgag agtgcaccat atgcggtgtg aaataccgca cagatgcgta aggagaaaat 2820
accgcatcag gcggccttaa gggcctcgtg atacgcctat ttttataggt taatgtcatg 2880
ataataatgg tttcttagac gtcaggtggc.acttttcggg gaaatgtgcg cggaacccct 2940
atttgtttat ttttctaaat acattcaaat atgtatccgc tcatgagaca ataaccctga 3000
taaatgcttc aataatattg aaaaggaag agtatgagta ttcaacattt.ccgtgtcgcc 3060
cttattccct tttttgcggc attttgcctt cctgttttttg ctcacccaga aacgctggtg 3120
aaagtaaaag atgctgaaga tcagttgggt gcacgagtgg gttacatcga actggatctc 3180
aacagcggta agatccttga gagttttcgc cccgaagaac gttttccaat gatgagcact 3240
tttaaagttc tgctatgtgg cgcggtatta tcccgtattg acgccgggca agagcaactc 3300
```

6

```
ggtcgccgca tacactattc tcagaatgac ttggttgagt actcaccagt cacagaaaag 3360
catcttacgg atggcatgac agtaagagaa ttatgcagtg ctgccataac catgagtgat 3420
aacactgcgg ccaacttact tctgacaacg atcggaggac cgaaggagct aaccgctttt 3480
ttgcacaaca tggggggatca tgtaactcgc cttgatcgtt gggaaccgga gctgaatgaa 3540
gccataccaa acgacgagcg tgacaccacg atgcctgtag caatggcaac aacgttgcgc 3600
aaactattaa ctggcgaact acttactcta gcttcccggc aacaattaat agactggatg 3660
gaggcggata aagttgcagg accacttctg cgctcggccc ttccggctgg ctggtttatt 3720
gctgataaat ctggagccgg tgagcgtggg tctcgcggta tcattgcagc actggggcca 3780
gatggtaagc cctcccgtat cgtagttatc tacacgacgg ggagtcaggc aactatggat 3840
gaacgaaata gacagatcgc tgagataggt gcctcactga ttaagcattg gtaactgtca 3900
gaccaagttt actcatatat actttagatt gatttaaaac ttcattttta atttaaaagg 3960
atctaggtga agatcctttt tgataatctc atgaccaaaa tcccttaacg tgagttttcg 4020
ttccactgag cgtcagaccc cgtagaaaag atcaaaggat cttcttgaga tcctttttttt 4080
ctgcgcgtaa tctgctgctt gcaaacaaaa aaaccaccgc taccagcggt ggtttgtttg 4140
ccggatcaag agctaccaac tctttttccg aaggtaactg gcttcagcag agcgcagata 4200
ccaaatactg tccttctagt gtagccgtag ttaggccacc acttcaagaa ctctgtagca 4260
ccgcctacat acctcgctct gctaatcctg ttaccagtgg ctgctgccag tggcgataag 4320
tcgtgtctta ccgggttgga ctcaagacga tagttaccgg ataaggcgca gcggtcgggc 4380
tgaacggggg gttcgtgcac acagcccagc ttggagcgaa cgacctacac cgaactgaga 4440
tacctacagc gtgagcattg agaaagcgcc acgcttcccg aagggagaaa ggcggacagg 4500
tatccggtaa gcggcagggt cggaacagga gagcgcacga gggagcttcc aggggggaaac 4560
gcctggtatc tttatagtcc tgtcgggttt cgccacctct gacttgagcg tcgatttttg 4620
tgatgctcgt caggggggcg gagcctatgg aaaaacgcca gcaacgcggc ctttttacgg 4680
ttcctggcct tttgctcac atgttctttc ctgcgttatc ccctgattct 4740
gtggataacc gtattaccgc ctttgagtga gctgataccg ctcgccgcag ccgaacgacc 4800
gagcgcagcg agtcagtgag cgaggaagcg gaagagcgcc caatacgcaa accgcctctc 4860
cccgcgcgtt ggccgattca ttaatgcagc tggcacgaca ggtttcccga ctggaaagcg 4920
ggcagtgagc gcaacgcaat taatgtgagt tagctcactc attaggcacc ccaggcttta 4980
cacttatgc ttccggctcg tatgttgtgt ggaattgtga gcggataaca atttcacaca 5040
ggaaacagct atgaccatga ttacgccaag ctgtaagttt aaacatgatc ttactaacta 5100
actattctca tttaaatttt cagagcttaa aaatggctga atcactcac aacgatggat 5160
acgctaacaa cttggaaatg aaataagctt gcatgcctgc aggcctgaga tattttgcgc 5220
gtcaaatatg ttttgtgtcc ccgtaatatt tttaaatc aaatttcaca tttaaccat 5280
aaaaaactct ttcaaaagtg taattttcta cgcaaaaatg ccgttcggat gaaaaattac 5340
ttttgaaaaa caaactcgaa actacggtac gcaaaaaagt acatcggtgt ttgcacataa 5400
gtgaaaacaa tgttgttttt ttgtaattaa aatcgattaa ttttttttcc cggaaaacaa 5460
aaacgttttc agcgtggatt tctattgttt cttgcgtaaa aaaaattat ttaccaattt 5520
taaacgataa tttccacgaa ttttcgccat taatctctcg attttgttga ttcttgactc 5580
cgagcaatct ctccggtttt cgcaaacgat tatattattt atttgttttc cttttcagtg 5640
ccgattctcg gaaattcaac agtaaatctt caaaatgcca atgcttcccc acatggtcaa 5700
tctaagtgag tttctttgtt acaaaataca cgtgatgtca gattgtctca tttcggtttg 5760
atctacgtag atctacaaaa aatgcgggaa ttgagccgca gagttctcaa ctgctttcgc 5820
atggttaaga acgtgcggac gtcaaattgt tttgggcaaa aattcccgca ttttttgtag 5880
atcaaaccgt aatgggacag tctggcacca cgtgactata tattttagc ggtcaacgac 5940
acaaacccg gaccaatggc tgaggatcag ctgaaagctt atagagatag aaatcaggtg 6000
agaaaaatca atttcagcga ttttcttcgc aatttatata aaaactgatt tttccaggaa 6060
ccccacctgc tcaccacatc caatcggagc tcagaaaaa                        6099
```

```
<210> 4
<211> 7346
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Plasmid pGN156

<400> 4
```

```
agcttgcatg cctgcagggt cgactctaga ggatcaaact gtattacttg aaacaattta 60
gttatatgtt tagaacccct cattcaaaat taatagacag ggctctcacc gaatgttgca 120
atttgtttct gataagggtc acaaagcgga gcgaatgctt gaatgtgtcc atcaatgagc 180
ttatcaatgc gctaaaacgc tataacttcc atatgaagtc aatcgaacat atgtcaatct 240
ttagccgtat ataaaggtgc actgaaaaca gtccaatcac ggttcagcca tgaggtcgat 300
ccccggccgg gattggccaa aggacccaaa ggtatgtttc gaatgatact aacataacat 360
agaacatttt caggaggacc cttggagggt accggtgggt gaagaccaga aacagcacct 420
cgaactgagc cgcgatattg cccagcgttt caacgcgctg tatggcgaga tcgatcccgt 480
cgttttacaa cgtcgtgact gggaaaaccc tggcgttacc caacttaatc gccttgcagc 540
acatccccct ttcgccagct ggcgtaatag cgaagaggcc cgcaccgatc gcccttccca 600
acagttgcga aggtaagttt aaacagatcc atactaacta acttgttctg acataatttt 660
cagcttgaat ggcgaatggc gctttgcctg gtttccggca ccagaagcgg tgccggaaag 720
ctggctggag tgcgatcttc ctgaggccga tactgtcgtc gtcccctcaa actggcagat 780
gcacggttac gatgcgccca tctacaccaa cgtaacctat cccattacgg tcaatccgcc 840
gtttgttccc acggagaatc cgacgggttg ttactcgctc acatttaatg ttgatgaaag 900
ctggctacag gaaggccaga cgcgaattat ttttgatggc gttaactcgg cgtttcatct 960
gtggtgcaac gggcgctggg tcggttacgg ccaggtaagt ttaattaagt tgatactaac 1020
taacaaagat ctgattaatt ttcaggacag tcgtttgccg tctgaatttg acctgagcgc 1080
attttttacgc gccggagaaa accgcctcgc ggtgatggtg ctgcgttgga gtgacggcag 1140
ttatctggaa gatcaggata tgtggcggat gagcggcatt ttccgtgacg tctcgttgct 1200
gcataaaccg actacacaaa tcagcgattt ccatgttgcc actcgcttta atgatgattt 1260
ctcccgcgct gtactggagg ctgaagtcca ggtaagttta acaggatct tactaactaa 1320
catgctaaca ctgaatttc agatgtgcgg cgagttgcgt gactacctac gggtaacagt 1380
ttctttatgg cagggtgaaa cgcaggtcgc cagcggcacc gcgcctttcg gcggtgaaat 1440
tatcgatgag cgtggtggtt atgccgatcg cgtcacacta cgtctgaacg tcgaaaaccc 1500
gaaactgtgg agcgccgaaa tcccgaatct ctatcgtgcg gtggttgaac tgcacaccgc 1560
cgacggcacg ctgattgaag cagaagcctg cgatgtcggt ttccgcgagg tgcggattga 1620
aaatggtctg ctgctgctga acggcaagcc gttgctgatt cgaggcgtta accgtcacga 1680
gcatcatcct ctgcatggtc aggtcatgga tgagcagacg atggtgcagg atgtaagttt 1740
aaactattcg ttactaacta actttaaaca tttaaatttt cagatcctgc tgatgaagca 1800
gaacaacttt aacgccgtgc gctgttcgca ttatccgaac catccgctgt ggtacacgct 1860
gtgcgaccgc tacggcctgt atgtggtgga tgaagccaat attgaaaccc acggcatggt 1920
gccaatgaat cgtctgaccg atgatccgcg ctggctaccg gcgatgagcg aacgcgtaac 1980
gcgaatggtg cagcgcgatc gtaatcaccc gagtgtgatc atctggtcgc tggggaatgg 2040
taagtttaaa cagttgaata ctaactaacg gagatctttg aaattttcag aatcaggcca 2100
cggcgctaat cacgacgcgc tgtatcgctg gatcaaatct gtcgatcctt cccgcccggt 2160
gcagtatgaa ggcggcggag ccgacaccac ggccaccgat attatttgcc cgatgtacgc 2220
gcgcgtggat gaagaccagc ccttcccggc tgtgccgaaa tggtccatca aaaatggct 2280
ttcgctacct ggagagacgc gcccgctgat tctttgcgag gtaagtttaa acagaactct 2340
actaactaac acattagatc ctaattttca gtacgctcac gcgatgggca acagtcttgg 2400
cggtttcgct aaatactggc aggcgtttcg tcagtatccc cgtttacagg cggcttcgt 2460
ctgggactgg gtggatcagt cgctgattaa atatgatgaa aacggcaacc cgtggtcggc 2520
ttacggcggt gattttggcg atacgccgaa cgatcgccag ttctgtatga cggtctggt 2580
ctttgccgac cgcacgccgc atccagcgta agtttaaaca ataacctact aactaacgta 2640
gataattaa attttcaggc tgacggaagc aaaacaccag cagcagtttt ccagttccg 2700
tttatccggg caaaccatcg aagtgaccag cgaatacctg ttccgtcata gcgataacga 2760
gctcctgcac tggatggtgg cgctggatgg taagccgctg gcaagcggtg aagtgcctct 2820
ggatgtcgct ccacaaggta aacagttgat tgaactgcct gaactaccgc agccggagag 2880
cgccgggcaa ctctggctca cagtacgcgt agtgcaaccg aacgcgaccg catggtcaga 2940
gccgggcac atcagcgcat ggcagcagtg gaggtaagtt taaacaagat cctactaact 3000
aactctacat tgatgaattt tcagactggc ggaaaacctc agtgtgacgc tccccgccgc 3060
gtcccacgcc atcccgcatc tgaccaccag cgaaatggat ttttgcatcg agctgggtaa 3120
taagcgttgg caatttaacc gccagtcagg ctttctttca gatgtgga ttggcgataa 3180
aaaacaactg ctgacgccgc tgcgcgatca gttcacccgt gcaccgctgg ataacgacat 3240
tggcgtaagt gaagcgaccc gcattgaccc taacgcctgg gtcggtaagt ttaaacaaag 3300
ttgtactaac taacgaagat cttgataatt ttcagaacgc tggaaggcgg cgggccatta 3360
ccaggccgaa gcagcgttgt tgcagtgcac ggcagataca cttgctgatg cggtgctgat 3420
```

8

```
tacgaccgct cacgcgtggc agcatcaggg gaaaacctta tttatcagcc ggaaaaccta 3480
ccggattgat ggtagtggtc aaatggcgat taccgttgat gttgaagtgg cgagcgatac 3540
accgcatccg gcgcggattg gcctgaactg ccagctggcg caggtagcag agcgggtaaa 3600
ctggctcgga ttagggccgc aagaaaacta tcccgaccgc cttactgccg cctgtttttga 3660
ccgctgggat ctgccattgt cagacatgta gtaagtttaa acttgatagt actaactaac 3720
atgtttcatt taaattttca gtaccccgta cgtcttcccg agcgaaaacg gtctgcgctg 3780
cgggacgcgc gaattgaatt atggcccaca ccagtggcgc ggcgacttcc agttcaacat 3840
cagccgctac agtcaacagc aactgatgga aaccagccat cgccatctgc tgcacgcgga 3900
agaaggcaca tggctgaata tcgacggttt ccatatgggg attggtggcg acgactcctg 3960
gagcccgtca gtatcggcgg aattccaact gagcgccggt cgctaccatt accaacttgt 4020
ctggtgtcaa aaataatagg ggccgctgtc atcagagtaa gtttaaactg agttctacta 4080
actaacgagt aatatttaaa ttttcagcat ctcgcgcccg tgcctctgac ttctaagtcc 4140
aattactctt caacatccct acatgctctt tctccctgtg ctcccacccc ctattttgt 4200
tattatcaaa aaaacttctt cttaatttct ttgttttta gcttctttta agtcacctct 4260
aacaatgaaa ttgtgtagat tcaaaaatag aattaattcg taataaaaag tcgaaaaaaa 4320
ttgtgctccc tccccccatt aataataatt ctatcccaaa atctacacaa tgttctgtgt 4380
acacttctta tgttttttt acttctgata aattttttt gaaacatcat agaaaaaacc 4440
gcacacaaaa taccttatca tatgttacgt ttcagtttat gaccgcaatt tttatttctt 4500
cgcacgtctg ggcctctcat gacgtcaaat catgctcatc gtgaaaaagt tttggagtat 4560
ttttggaatt tttcaatcaa gtgaaagttt atgaaattaa ttttcctgct tttgcttttt 4620
gggggtttcc cctattgttt gtcaagagtt tcgaggacgg cgtttttctt gctaaaatca 4680
caagtattga tgagcacgat gcaagaaaga tcggaagaag gtttgggttt gaggctcagt 4740
ggaaggtgag tagaagttga taatttgaaa gtggagtagt gtctatgggg ttttttgcctt 4800
aaatgacaga atacattccc aatataccaa acataactgt ttcctactag tcggccgtac 4860
gggccctttc gtctcgcgcg tttcggtgat gacggtgaaa acctctgaca catgcagctc 4920
ccggagacgg tcacagcttg tctgtaagcg gatgccggga gcagacaagc ccgtcagggc 4980
gcgtcagcgg gtgttggcgg gtgtcggggc tggcttaact atgcggcatc agagcagatt 5040
gtactgagag tgcaccatat gcggtgtgaa ataccgcaca gatgcgtaag gagaaaatac 5100
cgcatcaggc ggccttaagg gcctcgtgat acgcctattt ttataggtta atgtcatgat 5160
aataatggtt tcttagacgt caggtggcac ttttcgggga aatgtgcgcg gaaccccctat 5220
ttgtttattt ttctaaatac attcaaatat gtatccgctc atgagacaat aaccctgata 5280
aatgcttcaa taatattgaa aaaggaagag tatgagtatt caacatttcc gtgtcgccct 5340
tattccctttt tttgcggcat tttgccttcc tgtttttgct cacccagaaa cgctggtgaa 5400
agtaaaagat gctgaagatc agttgggtgc acgagtgggt tacatcgaac tggatctcaa 5460
cagcggtaag atccttgaga gttttcgccc cgaagaacgt tttccaatga tgagcacttt 5520
taaagttctg ctatgtggcg cggtattatc ccgtattgac gccgggcaag agcaactcgg 5580
tcgccgcata cactattctc agaatgactt ggttgagtac tcaccagtca cagaaaagca 5640
tcttacggat ggcatgacag taagagaatt atgcagtgct gccataacca tgagtgataa 5700
cactgcggcc aacttacttc tgacaacgat cggaggaccg aaggagctaa ccgcttttttt 5760
gcacaacatg ggggatcatg taactcgcct tgatcgttgg gaaccggagc tgaatgaagc 5820
cataccaaac gacgagcgtg acaccacgat gcctgtagca atggcaacaa cgttgcgcaa 5880
actattaact ggcgaactac ttactctagc ttcccggcaa caattaatag actggatgga 5940
ggcggataaa gttgcaggac cacttctgcg ctcggccctt ccggctggct ggtttattgc 6000
tgataaatct ggagccggtg agcgtgggtc tcgcggtatc attgcagcac tggggccaga 6060
tggtaagccc tcccgtatcg tagttatcta cacgacgggg agtcaggcaa ctatggatga 6120
acgaaataga cagatcgctg agataggtgc ctcactgatt aagcattggt aactgtcaga 6180
ccaagtttac tcatatatac tttagattga tttaaaactt catttttaat ttaaaaggat 6240
ctaggtgaag atcctttttg ataatctcat gaccaaaatc ccttaacgtg agttttcgtt 6300
ccactgagcg tcagaccccg tagaaaagat caaaggatct tcttgagatc cttttttttct 6360
gcgcgtaatc tgctgcttgc aaacaaaaaa accaccgcta ccagcggtgg tttgtttgcc 6420
ggatcaagag ctaccaactc tttttccgaa ggtaactggc ttcagcagag cgcagatacc 6480
aaatactgtc cttctagtgt agccgtagtt aggccaccac ttcaagaact ctgtagcacc 6540
gcctacatac ctcgctctgc taatcctgtt accagtggct gctgccagtg cgataagtc 6600
gtgtcttacc gggttggact caagacgata gttaccggat aaggcgcagc ggtcgggctg 6660
aacggggggt tcgtgcacac agcccagctt ggagcgaacg acctacaccg aactgagata 6720
cctacagcgt gagcattgag aaagcgccac gcttcccgaa gggagaaagg cggacaggta 6780
tccggtaagc ggcagggtcg aacaggaga gcgcacgagg gagcttccag ggggaaacgc 6840
```

9

```
ctggtatctt tatagtcctg tcgggtttcg ccacctctga cttgagcgtc gatttttgtg 6900
atgctcgtca ggggggcgga gcctatggaa aaacgccagc aacgcggcct ttttacggtt 6960
cctggccttt tgctggcctt ttgctcacat gttctttcct gcgttatccc ctgattctgt 7020
ggataaccgt attaccgcct ttgagtgagc tgataccgct cgccgcagcc gaacgaccga 7080
gcgcagcgag tcagtgagcg aggaagcgga agagcgccca atacgcaaac cgcctctccc 7140
cgcgcgttgg ccgattcatt aatgcagctg gcacgacagg tttcccgact ggaaagcggg 7200
cagtgagcgc aacgcaatta atgtgagtta gctcactcat taggcacccc aggctttaca 7260
ctttatgctt ccggctcgta tgttgtgtgg aattgtgagc ggataacaat ttcacacagg 7320
aaacagctat gaccatgatt acgcca                                         7346
```

<210> 5
<211> 5991
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Plasmid pGQ3

<400> 5
```
cgcgccatga gtaaaggaga agaactttc actggagttg tcccaattct tgttgaatta 60
gatggtgatg ttaatgggca caaattttct gtcagtggag agggtgaagg tgatgcaaca 120
tacggaaaac ttaccctaa atttatttgc actactggaa aactacctgt tccatgggta 180
agtttaaaca tatatatact aactaaccct gattatttaa attttcagcc aacacttgtc 240
actactttct gttatggtgt tcaatgcttc tcgagatacc cagatcatat gaaacggcat 300
gacttttca agagtgccat gcccgaaggt tatgtacagg aaagaactat attttttcaaa 360
gatgacggga actacaagac acgtaagttt aaacagttcg gtactaacta accatacata 420
tttaaatttt caggtgctga agtcaagttt gaaggtgata cccttgttaa tagaatcgag 480
ttaaaggta ttgattttaa agaagatgga aacattcttg gacacaaatt ggaatacaac 540
tataactcac acaatgtata catcatggca gacaaacaaa agaatggaat caaagttgta 600
agtttaaact tggacttact aactaacgga ttatatttaa attttcagaa cttcaaaatt 660
agacacaaca ttgaagatgg aagcgttcaa ctagcagacc attatcaaca aaatactcca 720
attggcgatg gccctgtcct tttaccagac aaccattacc tgtccacaca atctgccctt 780
tcgaaagatc ccaacgaaaa gagagaccac atggtccttc ttgagtttgt aacagctgct 840
gggattacac atggcatgga tgaactatac aaatagggcc ggccgagctc cgcatcggcc 900
gctgtcatca gatcgccatc tcgcgccgt gcctctgact tctaagtcca attactcttc 960
aacatcccta catgctcttt ctccctgtgc tcccaccccc tattttgtt attatcaaaa 1020
aaacttcttc ttaatttctt tgttttttag cttcttttaa gtcacctcta acaatgaaat 1080
tgtgtagatt caaaaataga attaattcgt aataaaaagt cgaaaaaaat tgtgctccct 1140
cccccatta ataataattc tatcccaaaa tctacacaat gttctgtgta cacttcttat 1200
gtttttttta cttctgataa atttttttttg aaacatcata gaaaaaaccg cacacaaaat 1260
accttatcat atgttacgtt tcagtttatg accgcaattt ttatttcttc gcacgtctgg 1320
gcctctcatg acgtcaaatc atgctcatcg tgaaaaagtt ttggagtatt tttggaattt 1380
ttcaatcaag tgaaagttta tgaaattaat tttcctgctt ttgcttttttg ggggtttccc 1440
ctattgtttg tcaagagttt cgaggacggc gttttttcttg ctaaaatcac aagtattgat 1500
gagcacgatg caagaaagat cggaagaagg tttgggtttg aggctcagtg gaaggtgagt 1560
agaagttgat aatttgaaag tggagtagtg tctatggggt ttttgcctta aatgacagaa 1620
tacattccca atataccaaa cataactgtt tcctactagt cggccgtacg ggccctttcg 1680
tctcgcgcgt ttcggtgatg acggtgaaaa cctctgacac atgcagctcc cggagacggt 1740
cacagcttgt ctgtaagcgg atgccgggag cagacaagcc cgtcagggcg cgtcagcggg 1800
tgttggcggg tgtcggggct ggcttaacta tgcggcatca gagcagattg tactgagagt 1860
gcaccatatg cggtgtgaaa taccgcacag atgcgtaagg agaaaatacc gcatcaggcg 1920
gccttaaggg cctcgtgata cgcctatttt tataggttaa tgtcatgata ataatggttt 1980
cttagacgtc aggtggcact tttcggggaa atgtgcgcgg aacccctatt tgtttatttt 2040
tctaaataca ttcaaatatg tatccgctca tgagacaata accctgataa atgcttcaat 2100
aatattgaaa aaggaagagt atgagtattc aacatttccg tgtcgccctt attccctttt 2160
ttgcggcatt ttgccttcct gttttttgctc acccagaaac gctggtgaaa gtaaaagatg 2220
ctgaagatca gttgggtgca cgagtgggtt acatcgaact ggatctcaac agcggtaaga 2280
```

10

```
tccttgagag ttttcgcccc gaagaacgtt ttccaatgat gagcactttt aaagttctgc 2340
tatgtggcgc ggtattatcc cgtattgacg ccgggcaaga gcaactcggt cgccgcatac 2400
actattctca gaatgacttg gttgagtact caccagtcac agaaaagcat cttacggatg 2460
gcatgacagt aagagaatta tgcagtgctg ccataaccat gagtgataac actgcggcca 2520
acttacttct gacaacgatc ggaggaccga aggagagct gaatgaagcc ataccaaacg 2580
gggatcatgt aactcgcctt gatcgttggg aaccggagct gaatgaagcc ataccaaacg 2640
acgagcgtga caccacgatg cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg 2700
gcgaactact tactctagct tcccggcaac aattaataga ctggatggag gcggataaag 2760
ttgcaggacc acttctgcgc tcggcccttc cggctggctg gtttattgct gataaatctg 2820
gagccggtga gcgtgggtct cgcggtatca ttgcagcact ggggccagat ggtaagccct 2880
cccgtatcgt agttatctac acgacgggga gtcaggcaac tatggatgaa cgaaatagac 2940
agatcgctga gataggtgcc tcactgatta agcattggta actgtcagac caagtttact 3000
catatatact ttagattgat ttaaaacttc attttttaatt taaaaggatc taggtgaaga 3060
tcctttttga taatctcatg accaaaatcc cttaacgtga gttttcgttc cactgagcgt 3120
cagaccccgt agaaaagatc aaaggatctt cttgagatcc ttttttttctg cgcgtaatct 3180
gctgcttgca aacaaaaaaa ccaccgctac cagcggtggt ttgtttgccg gatcaagagc 3240
taccaactct ttttccgaag gtaactggct tcagcagagc gcagatacca aatactgtcc 3300
ttctagtgta gccgtagtta ggccaccact tcaagaactc tgtagcaccg cctacatacc 3360
tcgctctgct aatcctgtta ccagtggctg ctgccagtgg cgataagtcg tgtcttaccg 3420
ggttggactc aagacgatag ttaccggata aggcgcagcg gtcgggctga acggggggtt 3480
cgtgcacaca gcccagcttg gagcgaacga cctacaccga actgagatac ctacagcgtg 3540
agcattgaga aagcgccacg cttcccgaag ggagaaaggc ggacaggtat ccggtaagcg 3600
gcagggtcgg aacaggagag cgcacgaggg agcttccagg gggaaacgcc tggtatcttt 3660
atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg attttttgtga tgctcgtcag 3720
ggggggcggag cctatggaaa aacgccagca acgcggcctt tttacggttc ctggcctttt 3780
gctggccttt tgctcacatg ttctttcctg cgttatcccc tgattctgtg ataaccgta 3840
ttaccgcctt tgagtgagct gataccgctc gccgcagccg aacgaccgag cgcagcgagt 3900
cagtgagcga ggaagcggaa gagcgcccaa tacgcaaacc gcctctcccc gcgcgttggc 3960
cgattcatta atgcagctgg cacgacaggt ttcccgactg gaaagcgggc agtgagcgca 4020
acgcaattaa tgtgagttag ctcactcatt aggcacccca ggctttacac tttatgcttc 4080
cggctcgtat gttgtgtgga attgtgagcg gataacaatt tcacacagga aacagctatg 4140
accatgatta cgccaagctt gcatgcctgc agtgattcag agaggttgag aattattttc 4200
aaaaacattc aatgttttcc cttggagtga ctatgcaaat atgaaaatgt tttccaaaaa 4260
tatttggatg ccctgataaa aagtaggtga aatttcgcag gggaacatca tattaaaatg 4320
ttgaattttt agaagaaatg gaaatgtttg tcggtggtat gctcgaatat ttgagatatt 4380
atatatttac tgttaaatcc gaaattttca acaaacggaa aaaatttgtg tcgaaatact 4440
acattttcga taacacaaag gtacttccat aaaactgttt gactatctta 4500
attgtgtttc catgaaggta ttgtgaatat tttttgacaaa ctgatagaat tttcaggaaa 4560
aaaaaatcca agaataaaca ttttttcagaa tttgaacttt ctaatggctg attaataaaa 4620
caaagttata caactattca aagcagttgc tcaatctggc attttcttgt gttttttttt 4680
gaatatttca tcagcaagat gttgataatt ttgtgttaat tctaattgtt ttctacaatt 4740
tttcaaaccg aaaattgacc tttgactttg tttactttgt tctcgtgggt taactgttca 4800
ctgatttcta ttgctgttga tgaggtcttt gatcaaattt gtattgtttt tatactgcat 4860
attgcttcaa ttctaaatca tctaatatat tgtcaaacaa cttcttgttt ttttttcat 4920
tcaaaacttc tgcaaaaacg ttctcttaac aaaggttcac acaacaactc tcctctccat 4980
ctctttctct caacaacaat gtgctggcct tgcatgtttg ccagtgcggg ttgtttacgc 5040
gttttcaaga tttttggtct cctatctaac gtcccgaaat gcattttttc ctttcatttg 5100
gttttttttct gttcgagaaa agtgaccgtt tgtcaaatct tctaattttc agtgaataaa 5160
atgctgcaat ctactgctcg cactgcttca tttttggtat tatagataaa acttatacca 5220
aaaatgaaat tttcgtttaa aaattggttt ttttggtat tatagataaa acttatacca 5280
aaacaaaaca tatttagaaa aactttaata gagaataatt gtttaataat taattttttgc 5340
aagctccttt taaattaaga catctaaaac agttttcagc ttgattgttt taatggttta 5400
gaaagcaata tttgtatttt gtgttaaact gaaaatatct aggaaatact acttttaaaa 5460
tatttgaaac ttgaaatttt aaaattccaa ataattttac tcatttccta aagtgtttga 5520
gtatttgtat cctgtgctga caccgaaatg ttctcaattt tggaaaaaaa agatttttat 5580
ccgtatcttc agtcttacaa tttttttcac ctttttttc atttcagagt tctcgccgtc 5640
cgctccaagc acactctccc agatctccca ttcgactatg cagatttgga acctgtaatc 5700
```

11

```
agccatgaaa tcatgcagct tcatcatcaa aagcatcatg ccacctacgt gaacaatctc 5760
aatcagatcg aggagaaact tcacgaggct gtttcgaaag gttttttaat cagaagattt 5820
tgaaatgaat ttttttttg gtatataggg aatctaaaag aagcaattgc tctccaacca 5880
gcgctgaaat tcaatggtgg tggacacatc aatcattcta tcttctggac caacttggct 5940
aaggatggtg gagaaccttc aaaggagctg atggacacta ttaaggcttg g          5991
```

```
<210> 6
<211> 6980
<212> DNA
<213> Artificial Sequence
```

```
<220>
<223> Description of Artificial Sequence: Plasmid pGQ4
```

```
<400> 6
gtgattcaga gaggttgaga attattttca aaaacattca atgttttccc ttggagtgac 60
tatgcaaata tgaaatgtt ttccaaaaat atttggatgc tgaatttta gaagaaatgg 120
aaatgtttgt cggtggtatg ctcgaatatt tgagatatta tatatttact gttaaatccg 180
aaatttttga caaacggaaa aaatttgtgt cgaaatacta cattttcgat aacacaaagg 240
tacttccata tttaaacaca gctttatgat gtaaaagcta ttgtgtttcc atgaaggtat 300
acacttataa aaactgtttg actatcttat ttcaggaaaa aaaaatccaa gaataaacat 360
ttttcagaat ttgaactttc taatggctga ttaataaaac aaagttatac aactattcaa 420
agcagttgct caatctggca ttttcttgtg ttttttttg aatatttcat cagcaagatg 480
ttgataattt tgtgttaatt ctaattgttt ctacaatttt tcaaaccga aaattgacct 540
ttgactttgt ttactttgtt ctcgtgggtt aactgttcac tgatttctat tgctgttgat 600
gaggtctttg atcaaatttg tattgttttt atactgcata ttgcttcaat tctaaatcat 660
ctaatatatt gtcaaacaac ttcttgtttt tttttcatt caaaacttct gcaaaaacgt 720
tctcttaaca aaggttcaca caacaactct cctctccatc tctttctctc aacaacaatg 780
tgctggcctt gcatgtttgc cagtgcgggt tgtttacgcg tttttcaagat ttttggtctc 840
ctatctaacg tcccgaaatg cattttttcc tttcatttgg ttttttttctg ttcgagaaaa 900
gtgaccgttt gtcaaatctt ctaattttca gtgaataaaa tgctgcaatc tactgctcgc 960
actgcttcaa agcttgttca accggttgcg gggtaagtca aaatgaaatt ttcgtttaaa 1020
aattggtttt ttttggtatt atagataaaa cttataccaa aacaaaacat atttagaaaa 1080
actttaatag agaataattg tttaataatt aattttttgca agctcctttt aaattaagac 1140
atctaaaaca gtttttcagct tgattgtttt aatggtttag aaagcaatat ttgtattttg 1200
tgttaaactg aaaatatcta ggaaatacta cttttaaaat atttgaaact gaaattttta 1260
aaattccaaa taattttact catttcctaa agtgtttgag tatttgtatc ctgtgctgac 1320
accgaaatgt tctcaatttt ggaaaaaaaa gatttttatc cgtatcttca gtcttacaat 1380
tttttttcacc ttttttttttca tttcagagtt ctcgccgtcc gctccaagca cactctccca 1440
gatctcccat tcgactatgc agatttggaa cctgtaatca gccatgaaat catgcagctt 1500
catcatcaaa agcatcatgc cacctacgtg aacaatctca tcagatcga ggagaaactt 1560
cacgaggctg tttcgaaagg tttttttaatc agaagatttt gaaatgaatt ttttttttgg 1620
tatatatggga atctaaaaga agcaattgct ctccaaccag cgctgaaatt caatggtggt 1680
ggacacatca atcattctat cttctggacc aacttggcta aggatggtgg agaaccttca 1740
aaggagctga tggacactat taagccgagc tcagaaaaaa tgactgctcc aaagaagaag 1800
cgtaaggtac cggtagaaaa aatggaagac gccaaaaaca taagaaagg cccggcgcca 1860
ttctatccgc tggaagatgg aaccgctgga gagcaactgc ataaggctat gaagagatac 1920
gccctggttc ctggaacaat tgcttttaca gatgcacata tcgaggtgga catcacttac 1980
gctgagtact tcgaaatgtc cgttcggttg cagaagcta tgaaacgata tgggctgaat 2040
acaaatcaca gaatcgtcgt atgcagtgaa aactctcttc aattctttat gccggtgttg 2100
ggcgcgttat ttatcggagt tgcagttgcg cccgcgaacg acatttataa tgaacgtgaa 2160
ttgctcaaca gtatgggcat ttcgcagcct accgtggtgt cgtttccaa aaagggttg 2220
caaaaaattt gaacgtgca aaaaagctc ccaatcatcc aaaaaattat tatcatggat 2280
tctaaaacgg attaccaggg atttcagtcg atgtacacgt cgtcacatc tcatctacct 2340
cccggtttta atgaatacga ttttgtgcca gagtccttcg ataggggacaa gacaattgca 2400
ctgatcatga actcctctgg atctactggt ctgcctaaag gtgtcgctct gcctcataga 2460
actgcctgcg tgagattctc gcatgccaga gatcctattt ttggcaatca aatcattccg 2520
```

```
gatactgcga  ttttaagtgt  tgttccattc  catcacggtt  ttggaatgtt  tactacactc 2580
ggatatttga  tatgtggatt  tcgagtcgtc  ttaatgtata  gatttgaaga  agagctgttt 2640
ctgaggagcc  ttcaggatta  caagattcaa  agtgcgctgc  tggtgccaac  cctattctcc 2700
ttcttcgcca  aaagcactct  gattgacaaa  tacgatttat  ctaatttaca  cgaaattgct 2760
tctggtggcg  ctcccctctc  taaggaagtc  ggggaagcgg  ttgccaagag  gttccatctg 2820
ccaggtatca  ggcaaggata  tgggctcact  gagactacat  cagctattct  gattacaccc 2880
gaggggatg   ataaaccggg  cgcggtcggt  aaagttgttc  cattttttga  agcgaaggtt 2940
gtggatctgg  ataccgggaa  aacgctgggc  gttaatcaaa  gaggcgaact  gtgtgtgaga 3000
ggtcctatga  ttatgtccgg  ttatgtaaac  aatcttactg  gg  acgaagacga  acacttcttc 3120
aaggatggat  ggctacattc  tggagacata  gcttactggg  acgaagacga  acacttcttc 3120
atcgttgacc  gcctgaagtc  tctgattaag  tacaaaggct  atcaggtggc  tcccgctgaa 3180
ttggaatcca  tcttgctcca  acaccccaac  atctgttgtt  tggagcacgg  aaagacgatg 3300
gacgatgacg  ccggtgaact  tcccgccgcc  gttgttgtaa  caaccgcgaa  aaagttgcgc 3360
acggaaaaag  agatcgtgga  ttacgtcgcc  agtcaagtaa  caaccgcgaa  aaagttgcgc 3360
acggaaaaag  agatcgtgga  ttacgtcgcc  agtcaagtaa  ccggaaaact  cgacgcaaga 3420
ggaggagttg  tgtttgtgga  cgaagtaccg  aaaggtctta  ccggaaaact  cgacgcaaga 3420
aaaatcagag  agatcctcat  aaaggccaag  aagggcggaa  agatcgccgt  gtaattctag 3480
gaattccaac  tgagcgccgg  tcgctaccat  taccaacttg  tctggtgtca  aaaataatag 3540
gggccgctgt  catcagagta  agtttaaact  gagttctact  aactaacgag  taatatttaa 3600
attttcagca  tctcgcgccc  gtgcctctga  cttctaagtc  caattactct  tcaacatccc 3660
tacatgctct  ttctccctgt  gctcccaccc  cctatttttg  ttattatcaa  aaaaacttct 3720
tcttaatttc  tttgtttttt  agcttctttt  aagtcacctc  taacaatgaa  attgtgtaga 3780
ttcaaaaata  gaattaattc  gtaataaaaa  gtcgaaaaaa  attgtgctcc  ctccccccat 3840
taataataat  tctatcccaa  aatctacaca  atgttctgtg  tacacttctt  atgtttttt  3900
tacttctgat  aaatttttt   tgaaacatat  tagaaaaaac  cgcacacaaa  ataccttatc 3960
atatgttacg  tttcagttta  tgaccgcaat  ttttatttct  tcgcacgtct  gggcctctca 4020
tgacgtcaaa  tcatgctcat  cgtgaaaaag  ttttggagta  tttttggaat  ttttcaatca 4080
agtgaaagtt  tatgaaatta  attttcctgc  ttttgctttt  tggggtttc   cctattgtt  4140
tgtcaagagt  ttcgaggacg  gcgttttttct  tgctaaaatc  acaagtattg  atgagcacga 4200
tgcaagaaag  atcggaagaa  ggtttgggtt  tgaggctcag  tggaaggtga  gtagaagttg 4260
ataatttgaa  agtggagtag  tgtcctacta  gtcggccgta  cgggcccttt  cgtctcgcgc 4320
caatatacca  aacataactg  tttcctacta  gtcggccgta  cgggcccttt  cgtctcgcgc 4380
gtttcggtga  tgacggtgaa  aacctctgac  acatgcagct  cccggagacg  gtcacagctt 4440
gtctgtaagc  ggatgccggg  agcagacaag  cccgtcaggg  cgcgtcagcg  ggtgttggcg 4500
ggtgtcgggg  ctggcttaac  tatgcggcat  cagagcagat  tgtactgaga  gtgcaccata 4560
tgcggtgtga  aataccgcac  agatgcgtaa  ggagaaaata  ccgcatcagg  cggccttaag 4620
ggcctcgtga  tacgcctatt  tttataggtt  aatgtcatga  taataatggt  ttcttagacg 4680
tcaggtggca  ctttttcgggg  aaatgtgcgc  ggaacccta   tttgtttatt  tttctaaata 4740
cattcaaata  tgtatccgct  catgagacaa  taaccctgat  aaatgcttca  ataatattga 4800
aaaaggaaga  gtatgagtat  tcaacatttc  cgtgtcgccc  ttattccctt  ttttgcggca 4860
ttttgccttc  ctgtttttgc  tcacccagaa  acgctggtga  aagtaaaaga  tgctgaagat 4920
cagttgggtg  cacgagtggg  ttacatcgaa  ctggatctca  acagcggtaa  gatccttgag 4980
agttttcgcc  ccgaagaacg  ttttccaatg  atgagcactt  ttaaagttct  gctatgtggc 5040
gcggtattat  cccgtattga  cgccgggcaa  gagcaactcg  gtcgccgcat  acactattct 5100
cagaatgact  tggttgagta  ctcaccagtc  acagaaaagc  atcttacgga  tggcatgaca 5160
gtaagagaat  tatgcagtgc  tgccataacc  atgagtgata  acactgcggc  caacttactt 5220
ctgacaacga  tcggaggacc  gaaggagcta  accgcttttt  tgcacaacat  ggggggatcat 5280
gtaactcgcc  ttgatcgttg  ggaaccggag  ctgaatgaag  ccataccaaa  cgacgagcgt 5340
gacaccacga  tgcctgtagc  aatggcaaca  acgttgcgca  aactattaac  tggcgaacta 5400
cttactctag  cttcccggca  acaattaata  gactggatgg  aggcggataa  agttgcagga 5460
ccacttctgc  gctcggccct  tccggctggc  tggtttattg  ctgataaatc  tggagccggt 5520
gagcgtgggt  ctcgcggtat  cattgcagca  ctggggccag  atggtaagcc  ctcccgtatc 5580
gtagttatct  acacgacggg  gagtcaggca  actatggatg  aacgaaatag  acagatcgct 5640
gagataggtg  cctcactgat  taagcattgg  taactgtcag  accaagttta  ctcatatata 5700
ctttagattg  atttaaaact  tcattttaa   tttaaaagga  tctaggtgaa  gatccttttt 5760
gataatctca  tgaccaaaat  cccttaacgt  gagttttcgt  tccactgagc  gtcagacccc 5820
gtagaaaaga  tcaaaggatc  ttcttgagat  ccttttttttc  tgcgcgtaat  ctgctgcttg 5880
caaacaaaaa  aaccaccgct  accagcggtg  gtttgtttgc  cggatcaaga  gctaccaact 5940
```

13

```
cttttttccga aggtaactgg cttcagcaga gcgcagatac caaatactgt ccttctagtg 6000
tagccgtagt taggccacca cttcaagaac tctgtagcac cgcctacata cctcgctctg 6060
ctaatcctgt taccagtggc tgctgccagt ggcgataagt cgtgtcttac cgggttggac 6120
tcaagacgat agttaccgga taaggcgcag cggtcgggct gaacggggggg ttcgtgcaca 6180
cagcccagct tggagcgaac gacctacacc gaactgagat acctacagcg tgagcattga 6240
gaaagcgcca cgcttcccga agggagaaag gcggacaggt atccggtaag cggcagggtc 6300
ggaacaggag agcgcacgag ggagcttcca gggggaaacg cctggtatct ttatagtcct 6360
gtcgggtttc gccacctctg acttgagcgt cgattttgt gatgctcgtc aggggggcgg 6420
agcctatgga aaaacgccag caacgcggcc ttttttacggt tcctggcctt ttgctggcct 6480
tttgctcaca tgttctttcc tgcgttatcc cctgattctg tggataaccg tattaccgcc 6540
tttgagtgag ctgataccgc tcgccgcagc cgaacgaccg agcgcagcga gtcagtgagc 6600
gaggaagcgg aagagcgccc aatacgcaaa ccgcctctcc ccgcgcgttg gccgattcat 6660
taatgcagct ggcacgacag gtttcccgac tggaaagcgg gcagtgagcg caacgcaatt 6720
aatgtgagtt agctcactca ttaggcaccc caggctttac actttatgct ccggctcgt 6780
atgttgtgtg gaattgtgag cggataacaa tttcacacag gaaacagcta tgaccatgat 6840
tacgccaagc tgtaagttta aacatgatct tactaactaa ctattctcat ttaaattttc 6900
agagcttaaa aatggctgaa atcactcaca acgatggata cgctaacaac ttggaaatga 6960
aataagcttg catgcctgca                                              6980
```

```
<210> 7
<211> 473
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Vit-2
      promoter/NLS fragment

<400> 7
atgtttagaa cccctcattc aaaattaata gacagggctc tcaccgaatg ttgcaatttg 60
tttctgataa gggtcacaaa gcggagcgaa tgcttgaatg tgtccatcaa tgagcttatc 120
aatgcgctaa aacgctataa cttccatatg aagtcaatcg aacatatgtc aatctttagc 180
cgtatataaa ggtgcactga aaacagtcca atcacggttc agccatgagg tcgatccccg 240
gccgggattg gccaaaggac ccaaaggtat gtttcgaatg atactaacat aacatagaac 300
attttcagga ggaccttgg agggtaccgg ggattggcca aaggacccaa aggtatgttt 360
cgaatgatac taacataaca tagaacattt tcaggaggac ccttgcttgg agggtaccga 420
gctcagaaaa aatgactgct ccaaagaaga agcgtaaggt accggtagaa aaa         473
```

INDICATIONS RELATING TO DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on page ____21____ , line ____6-11____

B. IDENTIFICATION OF DEPOSIT   Further deposits are identified on an additional sheet ☐

Name of depositary institution

BELGIAN COORDINATED COLLECTION OF MICROORGANISMS

Address of depositary institution *(including postal code and country)*

Belgian Coordinated Collection of Microorganisms
Laboratorium Voor Molecular Biology - Plasmidencollectie
University of Ghent
K.L. Ledeganckstaat
9000 Ghent, BELGIUM

Date of deposit	Accession Number
01 JUNE 2001	IMBP 5719CB

C. ADDITIONAL INDICATIONS *(leave blank if not applicable)*   This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *(if the indications are not for all designated States)*

E. SEPARATE FURNISHING OF INDICATIONS *(leave blank if not applicable)*

The indications listed below will be submitted to the International Bureau later *(specify the general nature of the indications e.g. "Accession Number of Deposit")*

For receiving Office use only	For International Bureau use only
☐ This sheet was received with the international application	☒ This sheet was received by the International Bureau on: **1 0 AUG 2001**
Authorized officer	Authorized officer Sylvaine DESCLOUX,

Form PCT/RO/134 (July 1998)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 December 2001 (13.12.2001)

PCT

(10) International Publication Number
WO 01/094627 A3

(51) International Patent Classification[7]: G01N 33/50

(21) International Application Number: PCT/IB01/01213

(22) International Filing Date: 8 June 2001 (08.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0014009.5   8 June 2000 (08.06.2000)   GB

(71) Applicant *(for all designated States except US)*: DEV-GEN NV [BE/BE]; Technologiepark 9, B-9052 Zwijnaarde (BE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: VERWAERDE, Philippe [FR/FR]; 72, résidence Du Château D'Eau, F-59960 Neuville En Ferrain (FR). BOGAERT, Thierry [BE/BE]; Wolvendreef 26g, B-8500 Kortrijk (BE).

(74) Agents: BALDOCK, Sharon, Claire et al.; Boult Wade Tennant, Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)
— of inventorship (Rule 4.17(iv)) for US only

Published:
— with international search report
— with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description

(88) Date of publication of the international search report:
3 October 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ASSAY TECHNIQUES BASED ON GROWTH STAGE DEPENDENT EXPRESSION IN C. *ELEGANS*

(57) Abstract: This invention is directed to new methods to perform assays with nematodes, and more particularly with microscopic nematodes such as C. *elegans*. In particular, the invention provides methods based on the use of growth-stage specific promoters to drive growth-stage specific gene expression.

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7   G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7   G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, EPO-Internal, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 51351 A (GEN HOSPITAL CORP) 19 November 1998 (1998-11-19) cited in the application the whole document	
A	LIU ZHONGCHI ET AL: "The Caenorhabditis elegans heterochronic gene pathway controls stage-specific transcription of collagen genes." DEVELOPMENT (CAMBRIDGE), vol. 121, no. 8, 1995, pages 2471-2478, XP002191574 ISSN: 0950-1991 abstract	
A	WO 99 01552 A (HESCHELER JUERGEN) 14 January 1999 (1999-01-14) claims 1,11-13	

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
27 February 2002	15/03/2002

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Authorized officer Niemann, F

INTERNATIONAL SEARCH REPORT

.nformation on patent family members

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9851351	A	19-11-1998	US	6225120 B1	01-05-2001
			AU	7494198 A	08-12-1998
			EP	1019092 A1	19-07-2000
			PL	336858 A1	17-07-2000
			WO	9851351 A1	19-11-1998
			HU	0002199 A2	28-09-2000
WO 9901552	A	14-01-1999	DE	19727962 A1	14-01-1999
			WO	9901552 A1	14-01-1999
			EP	1002080 A1	24-05-2000

THIS PAGE BLANK (USPTO)